WO2019165105A1 - Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer - Google Patents
Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer Download PDFInfo
- Publication number
- WO2019165105A1 WO2019165105A1 PCT/US2019/019003 US2019019003W WO2019165105A1 WO 2019165105 A1 WO2019165105 A1 WO 2019165105A1 US 2019019003 W US2019019003 W US 2019019003W WO 2019165105 A1 WO2019165105 A1 WO 2019165105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligand
- urokinase receptor
- agent
- patient
- cancer
- Prior art date
Links
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims abstract description 276
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title claims abstract description 274
- 239000003446 ligand Substances 0.000 title claims abstract description 256
- 229960005356 urokinase Drugs 0.000 title claims abstract description 253
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 184
- 201000011510 cancer Diseases 0.000 title claims abstract description 101
- 238000003384 imaging method Methods 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 162
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 104
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 104
- 101800004225 Somatomedin-B Proteins 0.000 claims abstract description 103
- 239000012216 imaging agent Substances 0.000 claims abstract description 77
- 102100035140 Vitronectin Human genes 0.000 claims abstract description 55
- 108010031318 Vitronectin Proteins 0.000 claims abstract description 44
- 239000002872 contrast media Substances 0.000 claims abstract description 24
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 23
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 22
- 238000002059 diagnostic imaging Methods 0.000 claims abstract description 12
- 239000003102 growth factor Substances 0.000 claims abstract description 11
- 239000000906 photoactive agent Substances 0.000 claims abstract description 7
- 102000005962 receptors Human genes 0.000 claims description 150
- 108020003175 receptors Proteins 0.000 claims description 150
- 238000009739 binding Methods 0.000 claims description 141
- 230000027455 binding Effects 0.000 claims description 128
- 150000001413 amino acids Chemical group 0.000 claims description 85
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 63
- 230000035772 mutation Effects 0.000 claims description 59
- 102000040430 polynucleotide Human genes 0.000 claims description 47
- 108091033319 polynucleotide Proteins 0.000 claims description 47
- 239000002157 polynucleotide Substances 0.000 claims description 47
- -1 18F Chemical compound 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 39
- 238000006467 substitution reaction Methods 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 34
- 238000002560 therapeutic procedure Methods 0.000 claims description 31
- 239000013598 vector Substances 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 23
- 230000001965 increasing effect Effects 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 238000002591 computed tomography Methods 0.000 claims description 18
- 238000000799 fluorescence microscopy Methods 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 239000007850 fluorescent dye Substances 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 241001529936 Murinae Species 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 11
- 238000012285 ultrasound imaging Methods 0.000 claims description 11
- 238000005415 bioluminescence Methods 0.000 claims description 10
- 230000029918 bioluminescence Effects 0.000 claims description 10
- 238000012634 optical imaging Methods 0.000 claims description 10
- 230000036961 partial effect Effects 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000005298 paramagnetic effect Effects 0.000 claims description 8
- 108010054624 red fluorescent protein Proteins 0.000 claims description 8
- 239000002961 echo contrast media Substances 0.000 claims description 7
- 238000009169 immunotherapy Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000000155 isotopic effect Effects 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 108700012359 toxins Proteins 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 102220591322 Hemoglobin subunit beta_K18E_mutation Human genes 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 102220612026 Tyrosine-protein kinase Fer_K37R_mutation Human genes 0.000 claims description 6
- 238000001815 biotherapy Methods 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 102200052311 rs3218772 Human genes 0.000 claims description 6
- 102200082926 rs35973315 Human genes 0.000 claims description 6
- 102220023090 rs387907458 Human genes 0.000 claims description 6
- 102220076182 rs749750052 Human genes 0.000 claims description 6
- 102200015540 rs75295839 Human genes 0.000 claims description 6
- 102220020916 rs80357276 Human genes 0.000 claims description 6
- 230000005284 excitation Effects 0.000 claims description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- 238000002600 positron emission tomography Methods 0.000 claims description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 5
- 102220062249 rs786203938 Human genes 0.000 claims description 5
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 238000002073 fluorescence micrograph Methods 0.000 claims description 4
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 4
- 102200015464 rs121912302 Human genes 0.000 claims description 4
- 102220073972 rs796052053 Human genes 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- IHXWECHPYNPJRR-UHFFFAOYSA-N 3-hydroxycyclobut-2-en-1-one Chemical class OC1=CC(=O)C1 IHXWECHPYNPJRR-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 3
- 150000001454 anthracenes Chemical class 0.000 claims description 3
- 150000001639 boron compounds Chemical class 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 150000002790 naphthalenes Chemical class 0.000 claims description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical class C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000004893 oxazines Chemical class 0.000 claims description 3
- 150000003220 pyrenes Chemical class 0.000 claims description 3
- 102220234440 rs572685299 Human genes 0.000 claims description 3
- 102220122845 rs767335346 Human genes 0.000 claims description 3
- 102220223994 rs772197667 Human genes 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 2
- 229910052691 Erbium Inorganic materials 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 2
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229910052771 Terbium Inorganic materials 0.000 claims description 2
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 2
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims description 2
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 102220204631 rs769160861 Human genes 0.000 claims description 2
- 102220018673 rs80358415 Human genes 0.000 claims description 2
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004065 semiconductor Substances 0.000 claims description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 2
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940027941 immunoglobulin g Drugs 0.000 claims 2
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 claims 1
- 102220005331 rs281865555 Human genes 0.000 claims 1
- 102220135761 rs61731517 Human genes 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims 1
- 230000021615 conjugation Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 128
- 210000004027 cell Anatomy 0.000 description 119
- 108090000765 processed proteins & peptides Proteins 0.000 description 107
- 102000004169 proteins and genes Human genes 0.000 description 107
- 235000001014 amino acid Nutrition 0.000 description 106
- 235000018102 proteins Nutrition 0.000 description 105
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 98
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 98
- 102400000099 Somatomedin-B Human genes 0.000 description 91
- 229940024606 amino acid Drugs 0.000 description 91
- 102000004196 processed proteins & peptides Human genes 0.000 description 79
- 229920001184 polypeptide Polymers 0.000 description 62
- 125000005647 linker group Chemical group 0.000 description 57
- 101000760331 Mus musculus Urokinase plasminogen activator surface receptor Proteins 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 41
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 40
- 150000007523 nucleic acids Chemical class 0.000 description 39
- 102000039446 nucleic acids Human genes 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 20
- 108091026890 Coding region Proteins 0.000 description 19
- 206010027476 Metastases Diseases 0.000 description 19
- 230000009401 metastasis Effects 0.000 description 19
- 230000003993 interaction Effects 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 239000005557 antagonist Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 238000002864 sequence alignment Methods 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000004448 titration Methods 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000036438 mutation frequency Effects 0.000 description 10
- 238000010647 peptide synthesis reaction Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000000562 conjugate Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000009826 neoplastic cell growth Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000700618 Vaccinia virus Species 0.000 description 8
- 206010046865 Vaccinia virus infection Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001476 gene delivery Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 208000007089 vaccinia Diseases 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 229960004065 perflutren Drugs 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 230000004797 therapeutic response Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 108091005461 Nucleic proteins Chemical group 0.000 description 6
- 102220482235 Serine/threonine-protein kinase Nek7_Y28A_mutation Human genes 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin-C1 Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 6
- 229960000909 sulfur hexafluoride Drugs 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 102220477610 Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical]_Y27A_mutation Human genes 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 108091006020 Fc-tagged proteins Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000006830 Luminescent Proteins Human genes 0.000 description 5
- 108010047357 Luminescent Proteins Proteins 0.000 description 5
- 101000638885 Mus musculus Urokinase-type plasminogen activator Proteins 0.000 description 5
- 108010043958 Peptoids Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 241000700663 Avipoxvirus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010006654 Bleomycin Proteins 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000710960 Sindbis virus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- OOUACICUAVTCEC-LZHWUUGESA-N aezs-108 Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OOUACICUAVTCEC-LZHWUUGESA-N 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229960002436 cladribine Drugs 0.000 description 4
- 229960002465 dabrafenib Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 229960002584 gefitinib Drugs 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 4
- 108700003825 lysine(6)-doxorubicin LHRH Proteins 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 4
- 229960003171 plicamycin Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- 229960004066 trametinib Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229960003862 vemurafenib Drugs 0.000 description 4
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- GSVQIUGOUKJHRC-YFKPBYRVSA-N (2s)-3-(n-acetyl-3-amino-2,4,6-triiodoanilino)-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](C)CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I GSVQIUGOUKJHRC-YFKPBYRVSA-N 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical class [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- PCZHWPSNPWAQNF-LMOVPXPDSA-K 2-[[(2s)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron Chemical compound [Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)N(CC(O)=O)CC([O-])=O)C=C1 PCZHWPSNPWAQNF-LMOVPXPDSA-K 0.000 description 3
- QPHJQCAPTXSDDP-UHFFFAOYSA-N 2-phenyl-2,7-diazaspiro[4.4]nonane Chemical compound C1NCCC11CN(C=2C=CC=CC=2)CC1 QPHJQCAPTXSDDP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GNOGSFBXBWBTIG-UHFFFAOYSA-N Acetrizoic acid Chemical compound CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I GNOGSFBXBWBTIG-UHFFFAOYSA-N 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010008908 FS 069 Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101150002754 HGS gene Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- FJYJNLIEGUTPIJ-UHFFFAOYSA-N Iobenzamic acid Chemical compound NC1=C(I)C=C(I)C(C(=O)N(CCC(O)=O)C=2C=CC=CC=2)=C1I FJYJNLIEGUTPIJ-UHFFFAOYSA-N 0.000 description 3
- SMQYOVYWPWASGU-UHFFFAOYSA-N Iocarmic acid Chemical compound OC(=O)C1=C(I)C(C(=O)NC)=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(=O)NC)C(I)=C(C(O)=O)C=2I)I)=C1I SMQYOVYWPWASGU-UHFFFAOYSA-N 0.000 description 3
- WWVAPFRKZMUPHZ-UHFFFAOYSA-N Iodoxamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I WWVAPFRKZMUPHZ-UHFFFAOYSA-N 0.000 description 3
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 3
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 3
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 3
- ZFHZUGUCWJVEQC-FPUQOWELSA-M Ipodate Sodium Chemical compound [Na+].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I ZFHZUGUCWJVEQC-FPUQOWELSA-M 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 3
- 102220580206 Non-receptor tyrosine-protein kinase TYK2_K17E_mutation Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 229960005216 acetrizoic acid Drugs 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 3
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- RERHJVNYJKZHLJ-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;2-(3,5-diiodo-4-oxopyridin-1-yl)acetate Chemical compound OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1 RERHJVNYJKZHLJ-UHFFFAOYSA-N 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229940005375 calcium iopodate Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- HVZGHKKROPCBDE-HZIJXFFPSA-L chembl2068725 Chemical compound [Ca+2].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I.CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I HVZGHKKROPCBDE-HZIJXFFPSA-L 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229960005223 diatrizoic acid Drugs 0.000 description 3
- 229960001845 diodone Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 3
- 229960004455 gadobenic acid Drugs 0.000 description 3
- 229960003935 gadofosveset Drugs 0.000 description 3
- PIZALBORPSCYJU-QSQMUHTISA-H gadofosveset Chemical compound O.[Na+].[Na+].[Na+].[Gd+3].C1CC(OP([O-])(=O)OC[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC(=O)[O-])N(CC([O-])=O)CC([O-])=O)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 PIZALBORPSCYJU-QSQMUHTISA-H 0.000 description 3
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 3
- 229960003460 gadopentetic acid Drugs 0.000 description 3
- 229960005451 gadoteridol Drugs 0.000 description 3
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 3
- 229960002059 gadoversetamide Drugs 0.000 description 3
- 229960001547 gadoxetic acid Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229960000963 iobenzamic acid Drugs 0.000 description 3
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 3
- 229960004108 iobitridol Drugs 0.000 description 3
- 229960002517 iocarmic acid Drugs 0.000 description 3
- 229960001943 iocetamic acid Drugs 0.000 description 3
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 3
- 229960004901 iodamide Drugs 0.000 description 3
- 229940029355 iodipamide Drugs 0.000 description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 3
- 229960004359 iodixanol Drugs 0.000 description 3
- 229960002487 iodoxamic acid Drugs 0.000 description 3
- HHFIATHHSBFCBY-UHFFFAOYSA-N ioglicic acid Chemical compound CNC(=O)CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I HHFIATHHSBFCBY-UHFFFAOYSA-N 0.000 description 3
- 229960004877 ioglicic acid Drugs 0.000 description 3
- 229960004876 ioglycamic acid Drugs 0.000 description 3
- FZDZULUFHNDEDJ-UHFFFAOYSA-N ioglycamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)COCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FZDZULUFHNDEDJ-UHFFFAOYSA-N 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 229960001025 iohexol Drugs 0.000 description 3
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 3
- 229960000780 iomeprol Drugs 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- OLAOYPRJVHUHCF-UHFFFAOYSA-N iooxitalamic acid Chemical compound CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I OLAOYPRJVHUHCF-UHFFFAOYSA-N 0.000 description 3
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 3
- 229960004647 iopamidol Drugs 0.000 description 3
- 229960002979 iopanoic acid Drugs 0.000 description 3
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 3
- 229960000824 iopentol Drugs 0.000 description 3
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 3
- 229960002603 iopromide Drugs 0.000 description 3
- 229960000929 iotalamic acid Drugs 0.000 description 3
- 229960003182 iotrolan Drugs 0.000 description 3
- 229960000506 iotroxic acid Drugs 0.000 description 3
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 3
- 229960001707 ioxaglic acid Drugs 0.000 description 3
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 3
- 229960002611 ioxilan Drugs 0.000 description 3
- 229960003781 ioxitalamic acid Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960003695 methiodal Drugs 0.000 description 3
- RDFJFVXMRYVOAC-UHFFFAOYSA-N methiodal Chemical compound OS(=O)(=O)CI RDFJFVXMRYVOAC-UHFFFAOYSA-N 0.000 description 3
- 229960000554 metrizamide Drugs 0.000 description 3
- 229960004712 metrizoic acid Drugs 0.000 description 3
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- DRKHJSDSSUXYTE-UHFFFAOYSA-L oxidanium;2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [OH3+].[Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC DRKHJSDSSUXYTE-UHFFFAOYSA-L 0.000 description 3
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960003175 sodium iopodate Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- YMOXVLQZFAUUKI-UHFFFAOYSA-N tyropanoate Chemical compound CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I YMOXVLQZFAUUKI-UHFFFAOYSA-N 0.000 description 3
- 229940005396 tyropanoic acid Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 2
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108090000363 Bacterial Luciferases Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 108010049175 N-substituted Glycines Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 101150038998 PLAUR gene Proteins 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229910018503 SF6 Inorganic materials 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 2
- 239000004189 Salinomycin Substances 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- CBPNZQVSJQDFBE-SREVRWKESA-N [(1S,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32R,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound C[C@@H]1CC[C@@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC CBPNZQVSJQDFBE-SREVRWKESA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000001251 acridines Chemical class 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229940064305 adrucil Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 2
- 229960003982 apatinib Drugs 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940108502 bicnu Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940088547 cosmegen Drugs 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940087477 ellence Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- 229960005304 fludarabine phosphate Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000012395 formulation development Methods 0.000 description 2
- 229960005063 gadodiamide Drugs 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 229930000755 gossypol Natural products 0.000 description 2
- 229950005277 gossypol Drugs 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 229940088013 hycamtin Drugs 0.000 description 2
- 229940096120 hydrea Drugs 0.000 description 2
- 229940099279 idamycin Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229940090411 ifex Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 238000002675 image-guided surgery Methods 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229950002133 iniparib Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960004537 ioversol Drugs 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 108010034897 lentil lectin Proteins 0.000 description 2
- 229940063725 leukeran Drugs 0.000 description 2
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 230000007434 lytic lesion Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940087732 matulane Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229940083118 mekinist Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940090009 myleran Drugs 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229940086322 navelbine Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- 229940109551 nipent Drugs 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 229950006584 obatoclax Drugs 0.000 description 2
- 229960000572 olaparib Drugs 0.000 description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
- 229950010632 perifosine Drugs 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229940063179 platinol Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000026447 protein localization Effects 0.000 description 2
- 229940117820 purinethol Drugs 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229950003687 ribociclib Drugs 0.000 description 2
- 102220080600 rs797046116 Human genes 0.000 description 2
- 229960001548 salinomycin Drugs 0.000 description 2
- 235000019378 salinomycin Nutrition 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 229940068117 sprycel Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 229940069905 tasigna Drugs 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960000653 valrubicin Drugs 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 2
- 229960002360 vintafolide Drugs 0.000 description 2
- KUZYSQSABONDME-QRLOMCMNSA-N vintafolide Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C=4C=CC(NCC=5N=C6C(=O)NC(N)=NC6=NC=5)=CC=4)C(O)=O)C(O)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KUZYSQSABONDME-QRLOMCMNSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 229940034727 zelboraf Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- CZWUESRDTYLNDE-UHFFFAOYSA-N (2z)-2-[(2e,4e,6e)-7-[1-(5-carboxypentyl)-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]hepta-2,4,6-trienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate Chemical compound CC1(C)C2=CC(S([O-])(=O)=O)=CC=C2N(CC)\C1=C/C=C/C=C/C=C/C1=[N+](CCCCCC(O)=O)C2=CC=C(S(O)(=O)=O)C=C2C1(C)C CZWUESRDTYLNDE-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FQQREHKSHAYSMG-UHFFFAOYSA-N 1,2-dimethylacridine Chemical compound C1=CC=CC2=CC3=C(C)C(C)=CC=C3N=C21 FQQREHKSHAYSMG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 244000003363 Allium ursinum Species 0.000 description 1
- 235000005336 Allium ursinum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108091005943 CyPet Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000191830 Enterobacteria phage L Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000027294 Fusi Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102220474002 Gamma-secretase subunit PEN-2_F25A_mutation Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010024405 HER2 peptide (369-377) Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 101000657849 Mus musculus Small nuclear ribonucleoprotein-associated protein B Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001532689 Narcissus pseudonarcissus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000000890 Somatomedin B domains Human genes 0.000 description 1
- 108050007913 Somatomedin B domains Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229940125666 actinium-225 Drugs 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000005082 bioluminescent agent Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- ADRVRLIZHFZKFE-UHFFFAOYSA-N ethanediperoxoic acid Chemical compound OOC(=O)C(=O)OO ADRVRLIZHFZKFE-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- IIPNDONTVPDUFZ-UHFFFAOYSA-N ethyl 2-methyl-1-oxido-3,4-dihydropyrrol-1-ium-2-carboxylate Chemical compound CCOC(=O)C1(C)CCC=[N+]1[O-] IIPNDONTVPDUFZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- NOOCUACGACDJSK-UHFFFAOYSA-N gold;pyrrole-2,5-dione Chemical compound [Au].O=C1NC(=O)C=C1 NOOCUACGACDJSK-UHFFFAOYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical group NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002078 nanoshell Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108091000699 pea lectin Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940034049 polysaccharide-k Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960005562 radium-223 Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 102200012888 rs121918644 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000000878 small molecule-drug conjugate Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940081616 tafinlar Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention pertains generally to anti-cancer therapeutics and cancer diagnostic agents and methods of treating, detecting, and imaging cancer.
- the invention relates to engineered ligands that bind to the urokinase receptor and methods of treating, detecting, and imaging cancer using such ligands.
- the invention relates to engineered ligands that bind to the urokinase receptor and methods of treating, detecting, and imaging cancer using such ligands.
- the invention includes a ligand of a urokinase receptor (uPAR) comprising a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin.
- uPAR urokinase receptor
- GFD growth factor domain
- SMB somatomedin B
- the ligand further comprises a linker connecting the GFD to the SMB domain.
- the linker is about 40 to about 50 angstroms in length.
- the linker comprises a sequence selected from the group consisting of SEQ ID NO: l 1, SEQ ID NO: 14, and SEQ ID NO: 15, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence i dentity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor.
- the linker comprises at least one amino acid substitution selected from the group consisting of S5N, S10G,
- the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of R30W, K37G, K37R,
- the GFD comprises the R30W, K37R, Q39R, E41R, and H42Y amino acid substitutions.
- the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R, and wherein positions of the amino acids are numbered relative to the reference human GFD sequence of SEQ ID NO:3.
- the GFD comprises the L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R amino acid
- the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DIN, E3G, MT4V, and K17E, and wherein positions of the amino acids are numbered relative to the reference murine SMB domain sequence of SEQ ID NO:5.
- the SMB domain comprises the DIN, E3G, M14V, and K17E amino acid substitutions.
- the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DI G, E3G, K18E, and P41S, and wherein positions of the amino acids are numbered relative to the reference human SMB domain sequence of SEQ ID NO:7.
- the SMB domain comprises the DIG, E3G, K18E, and P41 S amino acid substitutions.
- the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12 and SEQ ID NO: 13, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding and/or inhibiting the urokinase receptor.
- the ligand further comprises an immunoglobulin Fc domain covalently linked to the fusion protein.
- the immunoglobulin Fc domain may be derived from an IgG (e.g., IgGl, IgG2, IgG3, or lgG4), IgM, IgE, IgA or IgD, or a combination or hybrid thereof.
- the Fc fragment is derived from an IgG2a immunoglobulin.
- the Fc domain is derived from a human IgGl isotype.
- the immunoglobulin Fc domain may be linked for example, to the N- terminal or C -terminal end of the fusion protein.
- the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-20; or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor.
- the ligand further comprises an anti-cancer therapeutic agent conjugated to the fusion protein.
- the anti-cancer therapeutic agent may include, but is not limited to, a cytotoxic agent, a drug, a toxin, a nuclease, a hormone, an anti-cancer therapeutic agent conjugated to the fusion protein.
- the anti-cancer therapeutic agent may include, but is not limited to, a cytotoxic agent,
- a composition for use in the treatment of cancer comprising the ligand, wherein the anti-cancer therapeutic agent is conjugated to the fusion protein.
- the fusion protein further comprises a signal peptide (e.g., a urokinase signal peptide).
- a signal peptide e.g., a urokinase signal peptide
- the fusion protein further comprises a tag or detectable label.
- the invention includes a composition for use in the treatment of cancer comprising a ligand of a urokinase receptor described herein.
- the composition further comprises a pharmaceutically acceptable excipient.
- the composition further comprises one or more other anti-cancer therapeutic agents, such as, but not limited to, ch emotherapeuti c,
- the invention includes a method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a ligand of a urokinase receptor described herein. Multiple cycles of treatment may be administered to a subj ect.
- the ligand is admini stered according to a daily dosing regimen or intermittently.
- the ligand is administered for a time period sufficient to efFect at least a partial tumor response, and more preferably a complete tumor response in the subject.
- a ligand of a urokinase receptor may be administered by any suitable mode of administration.
- the ligand is administered intravenously, subcutaneously, or intralesionally to a subject.
- the ligand is administered locally at a site of a tumor or cancerous cells in the subject.
- the method further comprises performing surgery, radiation therapy, chemotherapy, immunotherapy, or biologic therapy, or a combination thereof.
- the invention includes a kit comprising a pharmaceutical composition compri sing a ligand of a urokinase receptor and instructions for treating cancer.
- the kit may further comprise means for delivering the composition to a subject.
- the invention includes a urokinase receptor-targeted imaging agent comprising a ligand of the urokinase receptor described herein conjugated to a diagnostic agent.
- the diagnostic agent can be, for example, an isotopic label, a fluorescent label, a chemiluminescent label, a bioluminescent label, a paramagnetic ion, an enzyme, a contrast agent (e.g., ultrasound contrast agent, a magnetic resonance imaging (MRI) contrast agent, or a radiocontrast agent), or a photoactive agent.
- MRI magnetic resonance imaging
- Exemplary' fluorescent labels include fluorescein derivatives, rhodamine derivatives, coumarin derivatives, cyanine derivatives, acridine derivatives, squaraine derivatives, naphthalene derivatives, oxadiazol derivatives, anthracene derivatives, pyrene derivatives, oxazine derivatives, arylmethine derivatives, and tetrapyrrole derivatives.
- the fluorescent label may comprise a fluorescent protein, such as, but not limited to, a green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, rsCherry, and rsCherryRev.
- GFP green fluorescent protein
- EGFP enhanced green fluorescent protein
- YFP yellow fluorescent protein
- EYFP enhanced yellow fluorescent protein
- BFP blue fluorescent protein
- RFP red fluorescent protein
- TagRFP TagRFP
- Isotopic labels may comprise radioactive isotopes (e.g., gamma-emitters, beta- emitters, and positron-emitters) or non-radioactive isotopes (e.g., stable trace isotopes), such as, but not limited to, 3 ⁇ 4, 2 H, 1 20 I, 123 I, 124 I, l25 I, 131 I, 35 S, n C, 13 C, 14 C, 32 P , 15 N, 13 N, 1 10 In, m In, 177 LU, 18 F, 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 90 Y, 89 Zr, 94m Tc, 94 Tc, 99m Tc, 154 Gd, 155 Gd, 156 Gd, 1S7 Gd, 1 58 Gd, ls O, 186 Re, 188 Re, 51 M, 52m Mn, 55 Co, 72 As, 75 Br,
- Exemplary paramagnetic ions include chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (ill), dysprosium (III), holmium (ill) and erbium (IP).
- the invention includes a urokinase receptor-targeted imaging agent comprising a ligand of a urokinase receptor, described herein, conjugated to a contrast agent.
- the contrast agent may be an ultrasound contrast agent (e.g., a microbubble), a magnetic resonance imaging (MRI) contrast agent, or a radi ocontrast agent.
- the invention includes a method of detecting cancer, the method comprising: a) administering a detectably effective amount of a urokinase receptor- targeted imaging agent, described herein, to a patient suspected of having cancer, under conditions wherein the urokinase receptor-targeted imaging agent binds to urokinase receptors present on tumors or cancerous cells, if present, in the patient; and b) detecting the urokinase receptor-targeted imaging agent bound to the tumors or cancerous cells, if present, by imaging tissue of the patient.
- a urokinase receptor- targeted imaging agent described herein
- imaging of tissue is performed using a method selected from the group consisting of ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), and fluorescence imaging.
- UI ultrasound imaging
- PET positron emission tomography
- SPECT single photon emission computed tomography
- MRI magnetic resonance imaging
- CT computed tomography
- OI optical imaging
- PI photoacoustic imaging
- fluorescence imaging fluorescence imaging
- the methods of the invention can be used for determining the prognosis of the patient. Detection of a precan cerous lesion indicates the patient is at risk of developing cancer. Detection of increased levels of the urokinase receptor on the surface of tumors or cancerous cells is associated with tumor growth and cancer progression.
- the invention includes a method of imaging tissue of a patient suspected of having cancer, the method comprising: a) contacting tissue of the patient with a detectably effective amount of a urokinase receptor-targeted imaging agent described herein under conditions wherein the urokinase receptor-targeted imaging agent binds to urokinase receptors present on tumors and cancerous cells, if present in the tissue; and b) imaging the tissue of the patient, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient compared to a control indicates that the patient has cancer.
- the tissue may he contacted with the urokinase receptor-targeted imaging agent either in vivo or in vitro.
- imaging of tissue is performed using a method selected from the group consisting of ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), and fluorescence imaging.
- UI ultrasound imaging
- PET positron emission tomography
- SPECT single photon emission computed tomography
- MRI magnetic resonance imaging
- CT computed tomography
- OI optical imaging
- PI photoacoustic imaging
- fluorescence imaging fluorescence imaging
- the invention includes a method of monitoring progression of cancer in a patient, the method comprising: imaging tissue of the patient according to a method described herein, wherein a first image is obtained at a first time point and a second image is obtained later at a second time point, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is worsening, and detecti on of decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is improving.
- Increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient may be caused, for example, by growth of a tumor or the presence of more tumors or cancerous cells at the second time point, which can be determined by inspection of the images.
- decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient may be caused, for example, by tumor shrinkage or the presence of fewer tumors or cancerous cells.
- the invention includes a method for evaluating the effect of an agent for treating cancer in a patient, the method comprising: imaging tissue of the patient according to a method described herein before and after the patient is treated with the agent, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from tumor growth or increase in number of tumors or cancer cells) after the patient is treated with the agent compared to before the patient is treated with the agent indicates that the patient is worsening, and decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from reduction in tumor size or reduction in the number of cancer cells) after the subject is treated with the agent compared to before the patient is treated with the agent indicates that the patient is improving.
- the urokinase receptor-targeted imaging agent e.g., from tumor growth or increase in number of tumors or cancer cells
- a method for monitoring the efficacy of a therapy for treating cancer in a patient comprising: imaging tissue of the patient according to a method described herein before and after the subject undergoes said therapy, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from tumor growth or increase in number of tumors or cancer cells) after the patient undergoes said therapy compared to before the patient undergoes said therapy indicates that the patient is worsening, and decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from reduction in tumor size or reduction in the number of cancer cells) after the patient undergoes said therapy compared to before the patient undergoes said therapy indicates that the patient is improving.
- the urokinase receptor-targeted imaging agent e.g., from tumor growth or increase in number of tumors or cancer cells
- the invention includes a method of treating a patient suspected of having cancer, the method comprising: a) receiving information regarding whether or not cancer was detected in the patient using a urokinase receptor-targeted imaging agent according to a method described herein; and b) administering anti-cancer therapy to the subject if cancer was detected in the patient.
- the anti -cancer therapy comprises surgery, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy, or any combination thereof.
- the invention includes a method of using a urokinase receptor-targeted imaging agent comprising a fluorescent label for fluorescence imaging of cancerous cells, the method comprising: a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the fluorescent label, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor-targeted imaging agent; b) illuminating the cell with light at a fluorescence excitation wavelength of the fluorescent label; and c) recording a fluorescence image of the cancerous cells by detecting fluorescence emitted by the fluorescent label of the urokinase receptor-targeted imaging agent.
- Fluorescence images may be visualized, for example, with a fluorescence microscope, a fiber-optic fluorescence imaging system, or a medical fluorescence imaging device, such as a miniaturized medical imaging system (e.g., a handheld microscope, a laparoscope, an endoscope, or a microendoscope).
- a fluorescence microscope e.g., a fluorescence microscope, a fiber-optic fluorescence imaging system
- a medical fluorescence imaging device such as a miniaturized medical imaging system (e.g., a handheld microscope, a laparoscope, an endoscope, or a microendoscope).
- the invention includes a method of using a urokinase receptor-targeted imaging agent comprising a bioluminescent label for bioluminescence imaging of cancerous cells, the method comprising: a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the bioluminescent label, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor- targeted imaging agent; b) contacting the cancerous cells with a chemiluminescent substrate; and c) recording a bioluminescence image of the cancerous cells by detecting bioluminescence emitted from the bioluminescent label of the urokinase receptor-targeted imaging agent.
- the invention includes a kit comprising an imaging agent comprising a ligand of a urokinase receptor and instructions for imaging cancer.
- the kit may further comprise means for delivering the composition to a subject.
- the invention includes a recombinant polynucleotide compri sing a promoter operably linked to a polynucl eotide encoding a ligand of a urokinase receptor described herein.
- the recombinant polynucleotide is provided by a vector such as a bacterial plasmid vector or a viral expression vector.
- Exemplary viral vectors include adenovirus, retrovirus (e.g., g- retrovirus and lenti virus), poxvirus, adeno-associated virus, baculovirus, or herpes simplex virus vectors.
- the invention includes a host cell or host subject comprising the recombinant polynucleotide.
- the invention includes a method for producing a ligand of a urokinase receptor, the method comprising: a) transforming a host cell with a recombinant polynucleotide comprising a promoter operably linked to a polynucleotide encoding a ligand of a urokinase receptor described herein; b) culturing the transformed host cell under conditions whereby the ligand of the urokinase receptor is expressed; and c) isolating the ligand of the urokinase receptor from the host cell.
- the invention includes a method for producing a ligand of a urokinase receptor in a host subject, the method comprising introducing into the host subject a recombinant polynucleotide comprising a promoter operably linked to a nucleotide sequence encoding the ligand of the urokinase receptor, wherein the ligand of the urokinase receptor is expressed in the host subj ect in an amount sufficient to inhibit the urokinase receptor and/or have anti-tumor activity in the subject.
- the invention includes a method for treating cancer compri sing administering to a subject in need thereof a therapeutically effective amount of a recombinant polynucleotide comprising a promoter operably linked to a nucleotide sequence encoding the ligand of the urokinase receptor.
- FIGS. 1A and IB show the strategy for developing a bispecific (i.e., biepitopic) ligand that binds different domains of uPAR.
- FIG. 1 A shows that uPAR is a key regulator of numerous biological processes that drive cancer growth and metastasis. Binding of the soluble ligand uPA to uPAR localizes ECM degradation at the cell surface and uPAR- driven cancer growth and metastasis via pathways 1 -7. uPAR also binds vitronectin in the absence of uPA (pathway 8), facilitating migration and metastasis.
- FIG. 1 A shows that uPAR is a key regulator of numerous biological processes that drive cancer growth and metastasis. Binding of the soluble ligand uPA to uPAR localizes ECM degradation at the cell surface and uPAR- driven cancer growth and metastasis via pathways 1 -7. uPAR also binds vitronectin in the absence of u
- 1B shows our approach to target uPAR-driven cancer growth and metastasis: i) The growth factor domain (GFD) of uPA binds uPAR and blocks localized ECM degradation and pathways 3, 5, and 6 in panel A, but not pathways 2, 4, 7, and 8. ii) SMB binds uPAR and blocks pathways 4, 7, and 8, and is expected to block 2, but not 3, 5, and 6, and ECM
- GFD and SMB simultaneously bind uPAR, and will be linked together to form a high affinity bispecific ligand that simultaneously blocks multiple uPAR-mediated processes driving cancer growth and metastasis.
- FIG. 2 shows modeling the GDF-SMB fusion protein with a 4x(GGGGS) amino acid linker.
- the GFD domain of uPA and the SMB domain of vitronectin are shown genetically fused by a 20-amino acid linker comprising four GGGGS (SEQ ID NO: 9) repeats (black), and simultaneously bound to uPAR.
- Three different possible orientations of the l inker are shown from multiple views of the complex to indicate the presence or absence of potential steric clash between the linker and proteins.
- the figures were generated by editing data from PDB 3BT1 (Huai et al (2008) Nat. Struct. Mol Biol. 15, 422-423) using IJCSF chimera molecular viewing software (Pettersen et al. (2004) J. Comput. Chem. 25, 1605-1612).
- FIG. 3 shows modeling the GDF-SMB fusion protein with a 5x(GGGGS) amino acid linker (SEQ ID NO: 11).
- the GFD domain of uPA and the SMB domain of vitronectin are shown genetically fused by a 25-amino acid linker comprising four GGGGS repeats (black), and simultaneously bound to uPAR.
- Three different possible orientations of the linker are shown from multiple views of the complex to indicate the presence or absence of potential steric clash between the linker and proteins.
- the figures were generated by editing data from PDB 3BT1 (Huai et al., supra) using UCSF chimera molecular viewing software (Pettersen et al., supra).
- FIG. 4 shows equilibrium binding titrations of three different yeast-displayed mGFD-mSMB fusion protein designs to soluble muPAR.
- Three different mGFD-mSMB designs containing either a 3x, 4x, or 5x GGGGS linker (SEQ ID NO: 11) bridging the GFD and SMB domains were displayed on the surface of yeast and their binding affinities for uPAR were compared. Binding reactions were incubated at room
- mGFD-mSMB fusion protein with the 5x(GGGGS) linker (henceforth simply referred to as "mGFD-mSMB) had the highest affinity for muPAR, indicating the 5x(GGGGS) linker is the most optimal of the three tested.
- FIG. 5 shows equilibrium binding titrations of yeast-displayed mGFD and mGFD-mSMB to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The K d values are 1.83 nM and 0.22 nM for mGFD and mGFD-mSMB, respectively. These data indicate the bispecific mGFD- mSMB fusion protein has approximately 8.3-fold higher affinity for muPAR compared to the wild type mGFD ligand.
- FIGS. 6A and 6B show analyses of specific amino acids driving the enhanced affinity of the mGFD-mSMB fusion protein for muPAR.
- FIG. 6A shows a structural representation of the binding interaction between the SMB domain of mGFD-mSMB and muPAR.
- the mouse SMB structure has not been solved; therefore, the human proteins are shown here as an example.
- Amino acids Y27 and Y28 (grey sticks) in SMB form the specific binding interaction with uPAR (Deng, et al. (1996) J. Biol. Chem. 271 , 12716- 12723; Deng et al. (1996) J. Cell Biol. 134, 1563-1571; and Okumura et al. (2002) J.
- FIG. 6B shows amino acid mutations Y27A and Y28A in SMB abolishes its affinity for uPAR. As expected, these mutations effectively render the affinity of mGFD-mSMB
- FIG. 7 shows a structural alignment of the mouse GFD -uPAR complex with the human GFD-uPAR-SMB complex.
- the structure of human uPAR bound to hGFD and hSMB is shown aligned to the structure of mouse uPAR bound by mGFD.
- the figure was generated using data from PDB files 3BT1 (Huai et al., supra) and 3LAQ (Lin et al. (2010) J. Biol. Chem. 285, 10982-1092) and UCSF chimera molecular viewing software (Pettersen et al., supra).
- FIG. 8 shows equilibrium binding titrations of yeast-displayed hGFD and the hGFD-hSMB fusion protein to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The K d values are 1.04 nM and 0.12 nM for hGFD and hGFD-hSMB, respectively. These data indicate the bispecific hGFD-hSMB fusion protein has approximately 8.7-fold higher affinity for huPAR compared to the wild type hGFD ligand.
- FIGS. 9A and 9B show analyses of specific amino acids driving the enhanced affinity of the hGFD-hSMB fusion protein for uPAR.
- FIG. 9 A shows a structural representation of the binding interaction between the SMB domain of hGFD-hSMB and huPAR. Amino acids Y27 and Y28 (grey sticks) in SMB form the specific binding interaction with huPAR. The linker fusing hGFD and hSMB is shown in black.
- FIG. 9B shows that amino acid mutations Y27A and Y28A in SMB abolish its affinity for uPAR. As expected, these mutations effectively render the affinity of hGFD-hSMB equal to that of hGFD for huPAR.
- FIGS. 10 A and 10B show the purification of soluble recombinant uPAR proteins.
- FIG. 10A shows chromatograms of huPAR, muPAR, and muPAR-FLAG purified by FPLC on a Superdex 75, 10/300 GL column. Proteins were diluted and run in PBS, pH 7.4 buffer at 0.4 mL/min. Collected fractions are highlighted in gray.
- FIG. 10B shows an analysi s of proteins collected after FPLC. Proteins were analyzed by 4-12%
- Lanes contain, from left to right: huPAR, muPAR, muPAR-FLAG, and Kaleidoscope protein ladder.
- FIG. 11 shows amino acid sequence alignment of mGFD variants from 5 separate DNA libraries. 10 sequences from each of 5 separate mGFD DNA libraries are shown arranged by library from high-to-low mutation frequency. The wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 12 shows sort progression of mGFD library 1.
- Four rounds of FACS were used to isolate high affinity variants from the first mGFD library.
- Equilibrium binding screens were used to perform all sorts. Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 2 and 3, and by collecting a smaller percentage of the top binding variants in each successive sort. The gates used to select variants are shown, along with the percentage of the expressing population collected.
- FIGS. 13A and 13B show analyses of mGFD library 1 after sort 4.
- FIG. 13A shows an amino acid sequence alignment of 20 mGFD variants after sort 4. The wild- type mGFD sequence is highlighted in light gray, and mutations are highlighted with colored squares.
- FIG. I3B shows equilibrium binding titrations of yeast-displayed mGFD and the bulk mGFD library after sort 4 to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The K d of mGFD is 3.89 nM, and the apparent K d of the library is 1.52 nM. These data indicate the first round of directed evolution generated marginally improved mGFD variants.
- FIG. 13A shows an amino acid sequence alignment of 20 mGFD variants after sort 4. The wild- type mGFD sequence is highlighted in light gray, and mutations are highlighted with colored squares.
- FIG. I3B shows equilibrium binding titrations of yeast-displa
- FIG. 14 shows amino acid sequence alignment of mGFD library 2 variants.
- DNA from the mGFD library 1 variants remaining after the 4 th sort was mutagenized using error-prone PCR for a subsequent round of directed evolution.
- Five separate DNA libraries were generated with varying mutation frequency, and 10 sequences from three of the libraries are shown here aligned to the wild-type mGFD sequence. Sequences are arranged by library (1, 3, and 5) from top to bottom, with libraries 1 and 5 having the highest and lowest mutation frequency, respectively.
- the wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 15 shows sort progression of mGFD library 2.
- Sorts 1 -2 were performed using equilibrium binding screens with the indicated concentrations of soluble muPAR, and sorts 3-6 were performed using kinetic off rate screens.
- Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 1 and 2, or by increasing the‘off" time in sorts 3-6, and by collecting a smaller percentage of the top binding variants in successive sorts.
- the gates used to select variants are shown, along with the percentage of the expressing population collected.
- FIGS. 16A and 16B show sequence analyses of mGFD library 2 after sorts 5 and 6. Amino acid sequence alignment of (FIG. 16A) 35 mGFD variants isolated after sort 5, and (FIG. 16B) 10 mGFD variants isolated after sort 6. The wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIGS. 17A and 17B show analyses of the engineered *mGFD protein generated by directed evolution .
- FIG. 17A shows equilibrium binding titrations of yeast-displayed wild-type mGFD and the engineered *mGFD protein to soluble muPAR. Binding reactions were incubated at room temperature for 48 hours and analyzed by flow cytometry. The K d values of mGFD and *mGFD are 2.11 nM and 0 009 nM, respectively. These data indicate directed evolution of the mGFD protein successfully generated a variant with 235 -fold higher affinity for muPAR.
- FIG 17B shows amino acid mutations in *mGFD mapped onto the wild-type mGFD-muPAR complex.
- mGFD and muPAR are shown in green and blue ribbon, respectively. Side chains of the five amino acids mutated in *mGFD are show as red spheres. The figure was generated using data from PDB file 3LAQ 28 and UCSF chimera molecular viewing software (Pettersen et al., supra).
- FIG. 18 shows amino acid sequence alignment of hGFD variants from 5 separate DNA libraries.10 sequences from each of 5 separate hGFD DNA libraries with varying levels of mutation frequency are shown arrange from high to low mutation frequency.
- the wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 19 shows sort progression of hGFD library 1.
- Four rounds of FACS were used to isolate high affinity variants from the first hGFD library.
- Equilibrium binding screens were used to perform all sorts. Selective pressure for improved variants was increased by reducing the concentration of huPAR incubated with the library between sorts, and by collecting a smaller percentage of the top binding variants in each successive sort. The gates used to select variants are shown, along with the percentage of the expressing population collected.
- FIGS. 20A and 20B show analyses of hGFD library 1 variants remaining after the 4 th sort.
- FIG. 20A shows an amino acid sequence alignment of 20 hGFD library 1 variants isolated after the 4 th sort. The wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 20B shows equilibrium binding titrations of yeast-displayed hGFD variants and wt hGFD to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
- FIG. 21 shows sort progression of hGFD library 2.
- Six rounds of FACS were used to isolate high affinity variants from the second hGFD library.
- Sorts 1 -4 were performed using equilibrium binding screens with the indicated concentrations of soluble huPAR, and sorts 5-6 were performed using kinetic off rate screens.
- Selective pressure for improved variants was increased by reducing the concentration of huPAR incubated with the library between sorts, or by increasing the "off time in sorts 5-6, and by collecting a smaller percentage of the top binding variants in successive sorts.
- the gates used to select variants are shown, along with the percentage of the expressing population collected.
- FIGS. 22A and 22B show sequence analyses of the hGFD library 2 after sorts 4 and 6. Amino acid sequence alignments of (FIG. 22A) 10 hGFD variants isolated after sort 4, and (FIG. 22B) 40 hGFD variants isolated after sort 6. The wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIGS. 23 A and 23B show analyses of hGFD Library 2 variants after sort 6.
- FIG. 23 A shows an amino acid sequence alignment of seven hGFD variants isolated after sort 6 to wild type hGFD.
- FIG. 23B shows kinetic dissociation of soluble huPAR from the yeast-displayed hGFD library 2 variants listed in panel A as a function of incubation time. Samples were incubated at room temperature for the indicated time and analyzed by flow cytometry.
- the hGFD L2.S6.15 variant (henceforth referred to as *hGFD, FIG. 45) displayed marginally slower dissociation kinetics than all other variants.
- FIGS. 24 A and 24B show an analysis of the engineered *hGFD protein generated by directed evolution.
- FIG. 24A show equilibrium binding titrations of yeast-displayed wild-type hGFD and the engineered *hGFD protein to soluble huPAR. Binding reactions were incubated at room temperature for 48 hours and analyzed by flow cytometry. The K d values of hGFD and *hGFD are 0.843 nM and 0.028 nM, respectively. These data indicate directed evolution of the hGFD protein successfully generated a variant with 30- fold higher affinity for huPAR.
- FIG. 24B shows amino acid mutations in *hGFD mapped onto the w r i ld-type hGFD-huPAR structure. Side chains of mutated amino acids in *hGFD are show as spheres. The figure wasgenerated using data from PDB file 3BT1 19 and UCSF chimera molecular viewing software.
- FIG. 25 shows an amino acid sequence alignment of linker-mSMB variants from 5 separate DNA libraries. 10 sequences from each of 5 separate linker-mSMB DNA libraries with varying levels of mutation frequency are shown arranged by library from high to low mutation frequency. The wild-type linker-mSMB sequence is shown at top, and mutations in the variants below are highlighted in color. Libraries were generated in the context of the mGFD-mSMB fusion protein. The sequence of the adjoining mGFD region was not mutated, and is omitted here for clarity.
- FIG. 26 shows a sort progression of the Hnker-mS MB library.
- Six rounds of FACS were used to isolate high affinity variants from the linker-mSMB library. Sorts 1-2 were performed using equilibrium binding screens with the indicated concentrations of soluble muPAR, and sorts 3-6 were performed using kinetic off rate screens. Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 1 and 2, or by increasing the "off" time between sorts 3-6, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select variants are shown, along with the percentage of the expressing population collected.
- FIG. 27 shows a sequence analysis of the linker-mSMB library after sort 6.
- the amino acid sequence alignment of 10 linker-mSMB variants isolated after sort 6 is shown.
- the wild-type linker-mSMB sequence is shown at the top, and mutations in the variants below are highlighted in color.
- FIG. 28 shows equilibrium binding titrations of the yeast-displayed mGFD- mSMB protein and the evolved mGFD-*mSMB protein to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The K d values of mGFD-mSMB and the evolved mGFD-*mSMB are 0.751 nM and 0.126 nM, respectively. These data indicate directed evolution of the linker- mSMB region of the mGFD-mSMB fusion protein successfully generated a variant with 6-fold higher affinity for muPAR.
- FIG. 29 shows amino acid mutations in mGFD-*mSMB mapped onto the human GFD-SMB-uPAR structure.
- the structure of the murine SMB has not been solved. Therefore, mutations in the linker and SMB domain of the mGFD-*mSMB protein are shown here mapped onto the human GFD-SMB-uPAR complex.
- GFD and SMB are shown fused by a 25 -amino acid linker (black).
- the seven amino acid mutations in the mGFD-*mSMB protein are shown as dark spheres. The figure was generated using data from PDB files 3BT1 and UCSF chimera molecular viewing software.
- FIG. 29 shows amino acid mutations in mGFD-*mSMB mapped onto the human GFD-SMB-uPAR structure.
- the structure of the murine SMB has not been solved. Therefore, mutations in the linker and SMB domain of the mGFD-*mSMB protein are shown here mapped onto the
- FIG. 30 shows equilibrium binding titrations of a yeast-displayed hGFD-hSMB and hGFD F25A -hSMB to soluble muPAR.
- FIG. 31 shows amino acid sequence alignment of linker-hSMB variants from 1 of 5 separate DNA libraries. 5 separate linker-hSMB DNA libraries with varying levels of mutation frequency were generated using error-prone PCR. Sequences of 10 variants from the library with the highest mutation frequency are shown. Libraries were generated in the context of the hGFD F25A -hSMB fusion protein. The sequence of the adj oining hGFD F2:,A region was not mutated, and is omitted here for clarity. The wild-type linker- hSMB sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 32 shows sort progression of the linker-hSMB library.
- Five rounds of FACS were used to isolate high affinity variants from the linker-hSMB library. All sorts were performed using equilibrium binding screens with the indicated concentrations of soluble huPAR. Selective pressure for improved variants was increased by sequentially reducing the concentration of muPAR incubated with the library between sorts, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select vari ants are shown, along with the percentage of the expressing population collected.
- FIGS. 33A and 33B show analysis of linker-hSMB library variants remaining after the 5 th sort.
- FIG. 33 A shows an amino acid sequence alignment of 10 linker-hSMB library' variants isolated after the 5 th sort. The wild-type linker-hSMB sequence is shown at top, and mutations in the variants below are highlighted in color.
- FIG. 33B shows equilibrium binding titrations of the two yeast-displayed linker-hSMB variants identified after the 5 th sort to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
- FIG. 34 shows equilibrium binding titrations of the yeast-displayed hGFD F25A - hSMB and the evolved hGFD F25A -*hSMB protein to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
- the K d values of hGFD F25A -hSMB and the evolved hGFD F25A -*hSMB are 7.10 nM and 0.68 nM, respectively.
- FIG. 35 shows amino acid mutations in hGFD-*hSMB mapped onto the wild type human GFD-SMB-uPAR structure.
- hGFD and hSMB are shown fused by a 25-amino acid linker (black).
- Side-chains of the 5 amino acid mutations in hGFD-*hSMB are shown as dark spheres (absent in the case of mutations to glycine).
- Three additional amino acids (ALA) belonging to the signal peptide of SMB were mistakenly included at the ML-terminus of the SMB domain in the library. These were later removed and the affinity for uPAR was unchanged (data not shown).
- FIG. 36 shows amino acid mutations in the engineered *hGFD-*hSMB (hGS) and *mGFD-*mSMB (mGS) bispecific uPAR ligands mapped onto the wild type human GFD-SMB-uPAR structure.
- Proteins domains in the mGS-uPAR structure (left) and hGS-uPAR structure (right) are colored as in FIGS. 29 and 35, respectively.
- Side-chains of amino acid mutations are shown as dark spheres (absent in the case of mutations to glycine). The figure was generated using data from PDB files 3BT1 19 and UCSF chimera molecular viewing software.
- FIGS. 37A-37D show the purification of soluble recombinant Fc-fusion proteins by FPLC. Chromatograms are shown of mGFD-Fc (FIG. 37A), mGS-Fc (FIG. 37B), hGFD-Fc (FIG. 37C), and hGS-Fc (FIG. 37D) purified by FPLC on a Superdex 200 increase, 10/300 GL column. Proteins were suspended and run in PBS, pH 7.4 buffer at 0.4 mL/min. Collected fractions are highlighted in gray. FIGA. 38A and 38B show analyses of Fc-fusion proteins collected after purification by FPLC. Proteins were analyzed by 4-12% polyacrylamide gel
- Lanes contain, from left to right: (FIG. 38 A) mGFD-Fc, mGS-Fc, Novex Sharp protein ladder, and (FIG. 38 B) hGFD-Fc, hGS-Fc, Kaleidoscope protein ladder.
- FIGS. 39A and 39B show the purified Fc-fusion proteins inhibit uPA-uPAR binding.
- the GFD domain of uPA was displayed on the surface of yeast cells as a fusion to the aga2p coat protein, and binding to 2 nM uPAR was measured in the presence of increasing concentrations of (FIG. 39 A) mGFD-Fc and mGS-Fc, and (FIG. 39B) hGFD- Fc and hGS-Fc. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
- FIG. 40 shows uPAR-specific tumor localization of hGFD-Fc and hGS-Fc proteins.
- FIG. 41 shows the quantification of uPAR-specific tumor localization of hGFD- Fc and hGS-Fc proteins in vivo.
- the signal for uPAR-positive tumor fluorescence from images shown in FIG. 41 is plotted here divided by the uPAR-negative tumor fluorescence.
- a signal of 1 (dashed line) indicates zero uPAR-positive tumor specificity.
- FIG. 42 shows the average uPAR-specific tumor localization of hGFD-Fc and hGS-Fc proteins in vivo.
- Mice were inj ected with hGFD-Fc-680 or hGS-Fc-680 (3 each) as in FIG. 41, and uPAR-positive and uPAR-negative tumor fluorescence was measured each day for 22 days.
- the signal for uPAR-positive tumor fluorescence is plotted here divided by the uPAR-negative tumor fluorescence.
- a signal of 1 (dashed line) indicates zero uPAR-positive tumor specificity.
- FIGS. 43 A and 43 B show uPAR-specific tumor localization of hGFD (FIG. 43 A) and hGS (FIG. 43B) monomer proteins.
- the uPAR-positive human breast (MDA-MB- 231) tumors, and uPAR-negative human embryonic kidney (HEK 293 T) tumors were implanted into the left and right shoulders of athymic nude mice, respectively.
- 1.5 nmol of hGFD-680 or hGS-680 were inj ected via tail vein, and protein localization was tracked via whole-body fluorescence imaging at the indicated time points.
- FIGS. 44A-44C show internalization of hGFD-Fc and hGS-Fc proteins into human breast cancer (MDA-MB-231) cells in vitro.
- FIG. 44A shows cell fluorescence from surface-bound Alexa 488-labeled proteins is quenched by an anti -488 antibody.
- Cells were incubated with 2 nM hGFD-Fc-488 or hGS-Fc-488 at 4°C for 1 hr, washed, and incubated with an anti-Alexa-488 antibody (a488-Ab) for an additional 30 minutes where indicated prior to analysis by flow cytometry.
- a488-Ab anti-Alexa-488 antibody
- FIG. 44B shows internalization of hGFD-Fc-488 and hGS-Fc-488 proteins.
- Cells were incubated in culture flasks at 37°C with the indicated concentrations of 488-labeled proteins in the presence or absence of a 100-fold molar excess of unlabeled protein for 15 hours. Cells were then harvested, washed, and incubated at 4°C with a488-Ab for an additional 30 minutes to quench surface-bound protein fluorescence prior to analysis by flow cytometry.
- FIG. 44C shows internalization of hGFD-Fc and hGS-Fc-488 over time. Cells were incubated with 2 nM hGFD-Fc-488 or hGS-Fc-488 for the indicated times and analyzed as described in panel (FIG. 44B).
- FIG. 45 shows sequence alignments of wild type and engineered proteins.
- the wild type sequences of the murine and human GFD domains of urokinase (mGFD and hGFD, respectively), and the linker-SMB domains of vitronectin (linker-mSMB and linker-hSMB, respectively) were aligned to the corresponding engineered proteins generated by directed evolution. Only the linker- SMB domains of mGFD-mSMB and hGFD t2:,A -hSMB proteins are shown for clarity. Amino acid mutations in the engineered proteins are highlighted in gray.
- protein refers to any compound comprising naturally occurring or synthetic amino acid polymers or amino acid-like molecules including but not limited to compounds comprising amino and/or imino molecules. No particular size is implied by use of the terms “protein,” “peptide,” “oligopeptide” or “polypeptide” and these terms are used interchangeably. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring (e.g., synthetic).
- synthetic oligopeptides dimers, mul timers (e.g., tandem repeats, linearly-linked peptides), cyclized, branched molecules and the like, are included within the definition.
- the terms also include molecules comprising one or more peptoids (e.g., N-substituted glycine residues) and other synthetic amino acids or peptides. (See, e.g., U.S. Patent Nos. 5,831,005;
- Non-limiting lengths of peptides suitable for use in the present invention includes peptides of 3 to 5 residues in length, 6 to 10 residues in length (or any integer therebetween), 11 to 20 residues in length (or any integer therebetween), 21 to 75 residues in length (or any integer therebetween), 75 to 100 (or any integer therebetween), or polypeptides of greater than 100 residues in length.
- polypeptides useful in this invention can have a maximum length suitable for the intended application.
- the polypeptide is between about 3 and 100 residues in length.
- one skilled in art can easily select the maximum length in view of the teachings herein.
- proteins, peptides, and polypeptides, as described herein, for example synthetic proteins, peptides, and, polypeptides may include additional molecules such as localization sequences, tags, labels, or other chemical moieties. Such moieties may further enhance inhibition of the urokinase receptor, facilitate purification of ligands, and/or detection of the l igands.
- references to polypeptides or peptides also include derivatives of the amino acid sequences of the invention including one or more non-naturally occurring amino acids.
- a first polypeptide or peptide is "derived from" a second polypeptide or peptide if it is (i) encoded by a first polynucleotide derived from a second polynucleotide encoding the second polypeptide or peptide, or (ii) displays sequence identity to the second polypeptide or peptide as described herein. Sequence (or percent) identity can be determined as described below.
- derivatives exhibit at least about 50% percent identity, more preferably at least about 80%, and even more preferably between about 85% and 99% (or any value therebetween) to the sequence from which they were derived.
- Such derivatives can include post-expression modifications of the polypeptide or peptide, for example, glycosylation, acetylation, phosphorylation, and the like.
- Amino acid derivatives can also include modifications to the native sequence, such as deletions, additions and substitutions (generally conservative in nature), so long as the polypeptide or peptide maintains the desired activity (e.g., inhibits activity of a urokinase receptor). These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts that produce the proteins or errors due to PCR amplification. Furthermore, modifications may be made that have one or more of the following effects: increasing affinity and/or specificity for a urokinase receptor and facilitating cell processing. Ligands described herein can be made recombinantly, synthetically, or in tissue culture.
- a urokinase (uPA) polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide refers to a molecule derived from any source. The molecule need not be physically derived from an organism, but may be synthetically or recombinantly produced. A number of uPA nucleic acid and protein sequences are known.
- NCBI National Center for Biotechnology Information
- sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
- a urokinase receptor e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- nucleic acid encoding a ligand of a urokinase
- a vitronectin polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide refers to a molecule derived from any source. The molecule need not be physically derived from an organism, but may be synthetically or recombinantly produced. A number of vitronectin nucleic acid and protein sequences are known.
- SMB domain sequences are presented in SEQ ID NOS:5-8 and additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries: Accession Nos. NM__000638, NM__01 l707, NM 214104, NM_001082292,
- sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
- a urokinase receptor e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- nucleic acid encoding a ligand of a urokinase receptor
- fusion protein refers to a fusion comprising a growth factor domain (GFD) of urokinase (uPA) in combination with a somatomedin B (SMB) domain of vitronectin as part of a single continuous chain of amino acids, which chain does not occur in nature.
- GFD and SMB domains may be connected directly to each other by peptide bonds or may be separated by intervening amino acid sequences (i.e., a linker).
- Fusion proteins may also contain an immunoglobulin Fc domain as well as other sequences exogenous to the GFD and SMB domains.
- a fusion protein may also include targeting, localization, or tag sequences.
- a fusion protein may be conjugated to an anti- cancer therapeutic agent or a diagnostic agent.
- fragment is intended a mol ecule consi sting of only a part of the intact full- length sequence and structure.
- the fragment can include a C -terminal deletion an N- terminal deletion, and/or an internal deletion of the polypeptide.
- Active fragments of a particular protein or polypeptide will generally include at least about 5-14 contiguous amino acid residues of the full length molecule, but may include at least about 15-25 contiguous amino acid residues of the full length molecule, and can include at least about 20-50 or more contiguous amino acid residues of the full length molecule, or any integer between 5 amino acids and the full length sequence, provided that the fragment in question retains biological activity, such as anti -tumor activity or inhibitory activity (e.g., the ability to inhibit a urokinase receptor), as defined herein.
- biological activity such as anti -tumor activity or inhibitory activity (e.g., the ability to inhibit a urokinase receptor), as defined herein.
- substantially purified generally refers to isolation of a substance (compound, polynucleotide, protein, polypeptide, peptide composition) such that the substance comprises the majority percent of the sample in which it resides.
- a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample.
- isolated is meant, when referring to a polypeptide or peptide, that the indicated molecule is separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro molecules of the same type.
- isolated with respect to a polynucleotide is a nucleic acid molecul e devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences in association therewith; or a molecule disassociated from the chromosome.
- a ligand is said to "interact" with a receptor if it binds specifically (e.g., in a iock- and-key type mechanism), non-specifically or in some combination of specific and non specific binding.
- a first ligand "interacts preferentially” with a receptor if it binds (non- specifically and/or specifically) to the receptor with greater affinity and/or greater specificity than it binds to other proteins (e.g., binds to urokinase receptor to a greater degree than to other proteins).
- affinity refers to the strength of binding and can be expressed quantitatively as a dissociation constant (Kd).
- specific binding does not necessarily require interaction between specific amino acid residues and/or motifs of each peptide.
- the ligands described herein interact preferentially with a urokinase receptor but, nonetheless, may be capable of binding other proteins at a weak, yet detectable, level (e.g., 10% or less of the binding shown to the urokinase receptor).
- weak binding, or background binding is readily discernible from the preferential interaction with the protein or receptor of interest, e.g., by use of appropriate controls.
- the term "antagonist" as used herein refers to any molecule that inhibits urokinase receptor activity.
- the antagonist may comprise a fusion protein comprising a urokinase GFD linked to a vitronectin SM B domain. Inhibition of the urokinase receptor may be complete or partial (i.e., all activity, some activity, or most activity is blocked by an inhibitor).
- an antagonist may reduce the urokinase receptor activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount in between as compared to native or control levels.
- detection agent As used herein, the terms “detection agent”, “diagnostic agent”, and “detectable label” are used interchangeably and refer to a molecule or substance capable of detection, including, but not limited to, fluorescers, chemiluminescers, chromophores,
- bioluminescent proteins enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, isotopic labels, semiconductor nanoparticles, dyes, metal ions, metal sols, ligands (e.g., biotin, streptavidin or haptens) and the like.
- fluorescer refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range.
- Enzyme tags are used with their cognate substrate.
- the terms also include chemiluminescent labels such as luminol, isoluminol, acridinium esters, and peroxy oxalate and bioluminescent proteins such as firefly luciferase, bacterial luciferase, Renilla luciferase, and aequorin.
- the terms also include isotopic labels, including radioactive and non-radioactive isotopes, such as, 3 H, 2 H, 12lJ I, m I, 124 I, 125 l, 131 1, 35 S, U C, 13 C, 14 C, 32 P , 15 N, 13 N, 110 In, In, 177 Lu, 18 F, 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 90 Y, 89 Zr, 94m Tc, 94 Tc, 99m Tc, 154 Gd, 155 Gd, 156 Gd, 157 Gd, 158 Gd, 15 0, 186 Re, 188 Re, 51 M,’ 2m Mn, 55 Co, 2 As, 7 3 ⁇ 4r, 76 Br, 82m Rb, and 83 Sr.
- radioactive and non-radioactive isotopes such as, 3 H, 2 H, 12lJ I, m I, 124 I, 125 l,
- microspheres with xMAP technology produced by Luminex (Austin, TX)
- microspheres containing quantum dot nanocrystals, for example, containing different ratios and combinations of quantum dot colors e.g., Qdot nanocrystals produced by Life Technologies (Carlsbad, CA)
- glass coated metal nanoparticles see e.g., SERS nanotags produced by Nanoplex Technologies, Inc.
- SonoVue microbubbles comprising sulfur hexafluoride
- Optison microbubbles comprising an albumin shell and octafluoropropane gas core
- Levovist microbubbles comprising a lipid/galactose shell and an air core
- Perflexane lipid microspheres comprising perfluorocarbon microbubbles
- microspheres comprising octafluoropropane encapsulated in an outer lipid shell
- magnetic resonance imaging (MRI) contrast agents e.g., gadodiamide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid
- radiocontrast agents such as for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, i over sol, iopentol, iodixanol,
- “Pharmaceutically acceptable excipient or carrier” refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.
- “Pharmaceutically acceptable salt” includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethyl succinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts.
- tumor refers to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e g. a cell proliferative, hyperproliferative or differentiative disorder. Typically, the growth is uncontrolled.
- malignancy refers to invasion of nearby tissue.
- metastasis or a secondary', recurring or recurrent tumor, cancer or neoplasia refers to spread or dissemination of a tumor, cancer or neoplasia to other sites, locations or regions within the subj ect, in which the sites, locations or regions are distinct from the primary tumor or cancer.
- Neoplasia, tumors and cancers include benign, malignant, metastatic and non- metastatic types, and include any stage (I, II, III, IV or V) or grade (Gl, G2, G3, etc.) of neoplasia, tumor, or cancer, or a neoplasia, tumor, cancer or metastasis that is progressing, worsening, stabilized or in remission.
- the terms "tumor,” “cancer” and “neoplasia” include carcinomas, such as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, and small cell carcinoma.
- breast cancer prostate cancer
- lung cancer ovarian cancer
- testicular cancer colon cancer
- rectal cancer pancreatic cancer
- gastrointestinal cancer hepatic cancer
- endometrial cancer leukemia, lympho a, adrenal cancer, thyroid cancer, pituitary cancer, adrenocortical cancer, renal cancer, brain cancer (e.g., glioblastoma and astrocytoma), skin cancer (e.g., basal-cell cancer, squamous-cell cancer, and melanoma), head cancer, neck cancer, oral cavity cancer, tongue cancer, and esophageal cancer.
- brain cancer e.g., glioblastoma and astrocytoma
- skin cancer e.g., basal-cell cancer, squamous-cell cancer, and melanoma
- head cancer neck cancer
- oral cavity cancer tongue cancer
- esophageal cancer esophageal cancer
- an "effective amount" of a ligand of a urokinase receptor e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- a nucleic acid encoding such a ligand is an amount sufficient to effect beneficial or desired results, such as an amount that binds to and/or inhibits a urokinase receptor.
- An effective amount can be administered in one or more administrations, applications or dosages.
- anti-tumor activity is intended a reduction in the rate of cell proliferation, and hence a decline in growth rate of an existing tumor or in a tumor that arises during therapy, and/or destruction of existing neoplastic (tumor) cells or newly formed neoplastic cells, and hence a decrease in the overall size of a tumor during therapy. Such activity can be assessed using animal models.
- a ligand of a urokinase receptor e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- a nucleic acid encoding such a ligand is intended an amount that, when administered as described herein, brings about a positive therapeutic response, such as anti-tumor activity.
- the exact amount required will vary' from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like.
- An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
- tumor response means a reduction or elimination of all measurable lesions.
- the criteria for tumor response are based on the WHO Reporting Criteria [WHO Offset Publication, 48-World Health Organization, Geneva, Switzerland, (1979)]. Ideally, all uni- or bidimensionally measurable lesions should be measured at each assessment. When multiple lesions are present in any organ, such measurements may not be possible and, under such circumstances, up to 6 representative lesions should be selected, if available.
- complete response CR as used herein means a complete
- partial response means a 50% or greater reduction from baseline in the sum of the products of the longest perpendicular diameters of all measurable disease without progression of evaluable disease and without evidence of any new lesions as determined by at least two consecutive assessments at least four weeks apart. Assessments should show a partial decrease in the size of lytic lesions, recalcifications of lytic lesions, or decreased density of blastic lesions.
- subject any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
- Homology refers to the percent identity between two polynucleotide or two polypeptide molecules. Two nucleic acid, or two polypeptide sequences are
- substantially homologous to each other when the sequences exhibit at least about 50% sequence identity, preferably at least about 75% sequence identity, more preferably at least about 80% 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% 98% sequence identity over a defined length of the molecules.
- substantially homologous also refers to sequences showing complete identity to the specified sequence.
- identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M O. in Atlas of Protein Sequence and Structure M.O. Dayhoff ed., 5 Suppl.
- nucleotide sequence identity is available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above. For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions.
- Another method of establi shing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA) From this suite of packages, the Smith Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity.”
- Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters.
- homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single stranded specific nuclease(s), and size determination of the digested fragments.
- DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra, DNA Cloning, supra, Nucleic Acid Hybridization, supra.
- Recombinant as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation, is not associated with all or a portion of the polynucleotide with which it is associated in nature.
- the term "recombinant” as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide.
- the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions
- transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transduction or f-mating are included.
- the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
- Recombinant host cells refer to cells which can be, or have been, used as recipients for recombinant vector or other transferred DNA, and include the original progeny of the original cell which has been transfected.
- a “coding sequence” or a sequence which "encodes” a selected polypeptide is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or “control elements”).
- the boundaries of the coding sequence can be determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus.
- a coding sequence can include, but is not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic DNA sequences from viral or prokaryotic DNA, and even synthetic DNA sequences.
- a transcription termination sequence may be located 3' to the coding sequence.
- control elements include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5’ to the coding sequence), and translation termination sequences.
- “Operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function.
- a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper enzymes are present.
- the promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof.
- intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked" to the coding sequence.
- Encoded by refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a polypeptide encoded by the nucleic acid sequence.
- “Expression cassette” or “expression construct” refers to an assembly which is capable of di recting the expression of the sequence(s) or gene(s) of interest.
- An expression cassette generally includes control elements, as described above, such as a promoter which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenyl tion sequence as well.
- the expression cassette described herein may be contained within a plasmid construct.
- the plasmid construct may also include, one or more selectable markers, a signal which allows the plasmid construct to exist as single stranded DNA (e.g., a M13 origin of replication), at least one multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
- a signal which allows the plasmid construct to exist as single stranded DNA e.g., a M13 origin of replication
- at least one multiple cloning site e.g., a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
- Polynucleotide refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about at least 90%, of the protein with which the polynucleotide is naturally associated.
- Techniques for purifying polynucleotides of interest include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the
- transfection is used to refer to the uptake of foreign DNA by a cell.
- a cell has been "transfected” when exogenous DNA has been introduced inside the cell membrane.
- transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (2001) Molecular Cloning, a laboratory ⁇ manual, 3rd edition, Cold Spring Harbor Laboratories, New York, Davis et al. (1995) Basic Methods in Molecular Biology, 2nd edition, McGraw-Hill, and Chu et al. (1981) Gene 13 :197
- Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.
- the term refers to both stable and transient uptake of the genetic material, and includes uptake of peptide- or antibody-linked DNAs.
- a “vector” is capable of transferring nucleic acid sequences to target cells (e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes).
- target cells e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes.
- vector construct e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes.
- expression vector e transfer vector
- the term includes cloning and expression vehicles, as well as viral vectors.
- variant refers to biologically active derivatives of the reference molecule that retain desired activity, such as the ability to inhibit a urokinase receptor and having anti -tumor activity.
- analog refers to compounds having a native polypeptide sequence and structure with one or more amino acid additions, substitutions (generally conservative in nature) and/or deletions, relative to the native molecule, so long as the modifications do not destroy biological activity and which are "substantially homologous" to the reference molecule as defined below.
- amino acid sequences of such analogs will have a high degree of sequence homology to the reference sequence, e.g., amino acid sequence homology of more than 50%, generally more than 60%-70%, even more particularly 80%-85% or more, such as at least 90%-95% or more, when the two sequences are aligned.
- the analogs will include the same number of amino acids but will include substitutions, as explained herein.
- mutant further includes polypeptides having one or more amino acid-like molecules including but not limited to compounds comprising only amino and/or imino molecules, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring (e.g., synthetic), cyclized, branched molecules and the like.
- the term also includes molecules comprising one or more N- substituted glycine residues (a "peptoid") and other synthetic amino acids or peptides. (See, e.g., U.S. Patent Nos.
- analogs generally include substitutions that are conservative in nature, i.e., those substitutions that take place within a family of amino acids that are related in their side chains.
- amino acids are generally divided into four families: (1) acidic— aspartate and glutamate; (2) basic -- lysine, arginine, histidine; (3) non-polar— alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar— glycine, asparagine, glutamine, cysteine, serine threonine, and tyrosine.
- Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.
- the polypeptide of interest may include up to about 5-10 conservative or non-conservative amino acid substitutions, or even up to about 15-25 conservative or non-conservative amino acid substitutions, or any integer between 5-25, so long as the desired function of the molecule remains intact.
- One of skill in the art may readily determine regions of the mol ecule of interest that can tolerate change by reference to HoppAV oods and Kyte-Doolittle plots, well known in the art.
- Gene transfer refers to methods or systems for reliably inserting DNA or RNA of interest into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., epi somes), or integration of transferred genetic material into the genomic DNA of host cells.
- Gene delivery expression vectors include, but are not limited to, vectors derived from bacterial plasmid vectors, viral vectors, non- viral vectors, alphaviruses, pox viruses and vaccinia viruses.
- derived from is used herein to identify the original source of a molecule but is not meant to limit the method by which the molecule is made which can be, for example, by chemical synthesis or recombinant means.
- a polynucleotide "derived from" a designated sequence refers to a polynucleotide sequence which comprises a contiguous sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about 15-20 nucleotides corresponding, i.e., identical or complementary to, a region of the designated nucleotide sequence.
- the derived polynucleotide will not necessarily be derived physically from the nucleotide sequence of interest, but m ay be generated in any manner, including, but not limited to, chemical synthesis, replication, reverse transcription or transcription, which is based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. As such, it may represent either a sense or an anti sense orientation of the original polynucleotide.
- the present invention is based on the discovery that fusion proteins comprising a urokinase GFD linked to a vitronectin SMB domain can be used as ligands of the urokinase receptor for treatment of cancer.
- the inventors have engineered bispecific protein ligands that simultaneously bind to two distinct sites on the urokinase receptor with an affinity superior to the native ligands and have demonstrated that such ligands have anti -tumor activity (see Examples).
- ligands of the urokinase receptor and their use in treating cancer.
- the invention provides ligands having anti-tumor activity that are capable of binding, preferably speci fically binding, to a urokinase receptor.
- the ligands comprise a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin Inhibition of the urokinase receptor may be complete or partial (i.e., all activity, some activity, or most activity is blocked by an inhibitor).
- a ligand reduces urokinase receptor activity by 70% to 100%, or any amount in this range, such as 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% as compared to native or control levels in certain embodiments, the ligand binds to a urokinase receptor with a dissociation constant (KD) of less than 0.2 nM, more preferably, less than 100 pM, and most preferably, less than 10 pM.
- KD dissociation constant
- Urokinase (uPA) nucleic acid and protein sequences may be derived from any source A number of uPA nucleic acid and protein sequences are known. Representative uPa growth factor domain (GFD) sequences are presented in SEQ ID NOS: 1-4 and additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries: Accession Nos.
- NM_0Q 1145031 NM_001319191, NM_002658, XM_011539866, NM_008873, XM__017315919, NM__013085, NM__001163593, XM_014180296, NM_174147, NM_001082011, NM_001082011, NM_001252350, XM__020711866,
- sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
- uPA polypeptides can contain other amino acid sequences, such as amino acid linkers or signal sequences, as well as ligands or tags useful in protein purification or detectable labels.
- Vitronectin nucleic acid and protein sequences also may be derived from any source. A number of vitronectin nucleic acid and protein sequences are known.
- SMB domain sequences are presented in SEQ ID NOS:5-8 and additional representative sequences are listed in the National Center for Biotechnology' Information (NCBI) database. See, for example, NCBI entries: Accession Nos. NM_000638, NM_011707, NM_214104, NM_001082292,
- any of these sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
- vitronectin polypeptides can contain other amino acid sequences, such as amino acid linkers or signal sequences, as well as ligands or tags useful in protein purification or detectable labels.
- the ligand comprises engineered GFD and/or SMB domains that have been modified to improve affinity for the urokinase receptor, inhibition of the urokinase receptor, and/or anti-tumor activity.
- the ligand may be engineered to comprise one or more mutations that improve its ability to bind to and/or inhibit the urokinase receptor and its efficacy in treating cancer.
- the fusion protein comprises an engineered GFD comprising at least one amino acid substitution selected from the group consisting of R30W, K37G, K37R, Q39R, E41K, E41 R, and H42Y, wherein positions of the amino acids are numbered relative to the reference murine GFD sequence of SEQ ID NO: 1.
- the GFD comprises the R30W, K37R, Q39R, E41R, and H42Y amino acid substitutions.
- the fusion protein comprises an engineered GFD comprising at least one mutation comprising an amino acid substitution selected from the group consisting of L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R, and wherein positions of the amino acids are numbered relative to the reference human GFD sequence of SEQ ID NO:3.
- the GFD comprises the L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R amino acid substitutions.
- the fusion protein comprises an engineered SMB domain comprising at least one amino acid substitution selected from the group consisting of DIN, E3G, M14V, and KI E, wherein positions of the amino acids are numbered relative to the reference murine SMB domain sequence of SEQ ID NO:5.
- the SMB domain comprises the DIN, E3G, M14V, and K17E amino acid substitutions.
- the fusion protein comprises an engineered SMB domain comprising at least one amino acid substitution selected from the group consisting of D1G, E3G, K18E, and P41 S, and wherein positions of the amino acids are numbered relative to the reference human SMB domain sequence of SEQ ID NO:7.
- the SMB domain comprises the D1G, E3G, K18E, and P41 S amino acid substitutions.
- the fusion protein further comprises one or more linkers.
- Linkers are typically short peptide sequences of 2-30 amino acid residues, often composed of glycine and/or serine residues. Linker amino acid sequences will typically be short, e.g., 25 or fewer amino acids (i.e., 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1).
- Linkers may include restriction sites, which aid cloning and manipulation. Other suitable linker amino acid sequences will be apparent to those skilled in the art. (See e.g., Argos (1990) J. Mol Biol. 211(4):943-958; Crasto et al. (2000) Protein Eng 13:309-312;
- the fusion protein may comprise a linker connecting the GFD to the SMB domain.
- the linker ranges in size from about 40 angstroms to about 50 angstroms in length, including any length within this range such as, 40, 41,
- the linker comprises a sequence selected from the group consisting of SEQ ID NO: l 1, SEQ ID NO: 14, and SEQ ID NO: 15, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to tumor cells and/or inhibiting the urokinase receptor.
- the linker comprises at least one amino acid substitution selected from the group consisting of S5N, S10G, G12R, and G19S, and wherein positions of the amino acids are numbered relative to the reference linker sequence of SEQ ID NO: 11.
- the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12 and SEQ ID NO: 13, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to tumor cells and/or inhibiting the urokinase receptor and has anti tumor activity.
- the N-terminus or the C -terminus of the fusion protein may be modified to enhance solubility, stability and/or improve delivery' to tumors.
- the ends of the fusion protein may be modified by N-terminal acetylation and/or C-terminal amidation to reduce charge and increase stability.
- the fusion protein further comprises an immunoglobulin Fc domain.
- the immunoglobulin Fc domain may be derived from an IgG (e.g., IgGl, IgG2, IgG3, or IgG4), IgM, IgE, IgA or IgD, or a combination or hybrid thereof.
- the Fc fragment is derived from an IgGl or IgG2a isotype.
- the Fc fragment is derived from a human immunoglobulin.
- the immunoglobulin Fc domain may be covalently linked directly to the N-terminal or C- terminal end of the fusion protein or connected indirectly through a linker to the fusion protein.
- the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-20; or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
- the ligand is capable of binding to and/or inhibiting the urokinase receptor.
- the ligand targets tumors expressing the urokinase receptor in a mammal.
- the fusion protein further comprises a tag sequence, which may be located, for example, at the N-terminus or C -terminus of the fusion protein.
- exemplary tags that can be used in the practice of the invention include a His- tag, a Strep-tag, a TAP -tag, an S-tag, an SBP-tag, an Arg-tag, a calmodulin-binding peptide tag, a cellulose-binding domain tag, a DsbA tag, a c-myc tag, a glutathione S- transferase tag, a FLAG tag, a HAT -tag, a maltose-binding protein tag, a NusA tag, and a thioredoxin tag.
- the fusion protein further comprises a signal peptide.
- Signal peptides are typically located at the N-terminus of the fusion protein and range in size from about 16 to 30 amino acids in length (i.e., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30). Any signal peptide may be used that is capable of targeting the fusion protein to the cell membrane where the urokinase receptor is located.
- signal peptide sequences are listed in the Signal Peptide Database (proline.bic.nus.edu. sg/spdb/) and the Signal Peptide Website (signalpeptide.de/).
- the signal peptide is a urokinase signal peptide.
- the fusion protein further comprises a detectable label in order to facilitate detection of binding of the ligand to the urokinase receptor.
- detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means.
- labels include, but are not limited to radiolabels (e.g., ⁇ , 125 1, 35 S, 14 C, or 32 P), phycoerythrin, Alexa dyes, fluorescein, YPet, CyPet, Cascade blue, allophycocyanin, Cy3, Cy5, Cy7, rhodamine, dansyl, umbelliferone, Texas red, luminol, acradimum esters, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), Dronpa, Padron, mApple, mCherry, rsCherry, rsCherryRev, firefly luciferase, Renilla luciferase, biotin or other streptavidin- binding proteins, magnetic beads, electron dense reagents, NADPH, beta-
- the fusion protein may also be conjugated to a contrast agent suitable for imaging.
- contrast agents include ultrasound contrast agents (e.g. SonoVue microbubbles comprising sulfur hexafluoride, Optison microbubbles comprising an albumin shell and octafluoropropane gas core, Levovist microbubbles comprising a lipid/galactose shell and an air core, Perflexane lipid microspheres comprising perfluorocarbon microbubbles, and Perflutren lipid microspheres comprising
- ultrasound contrast agents e.g. SonoVue microbubbles comprising sulfur hexafluoride
- Optison microbubbles comprising an albumin shell and octafluoropropane gas core
- Levovist microbubbles comprising a lipid/galactose shell and an air core
- Perflexane lipid microspheres comprising perfluorocarbon microbubbles
- MRI magnetic resonance imaging
- contrast agents e.g., gadodi amide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid
- radiocontrast agents such as for computed tomography (CT), radiography, or fluoroscopy
- CT computed tomography
- fluoroscopy e.g., diatrizoic acid, metrizoic acid, iodamide, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, ioversol, iopentol, iodixanol, iomeprol
- CT computed tom
- Ligands of the urokinase receptor can be prepared in any suitable manner (e g., recombinant expression, purification from cell culture, chemical synthesis, etc.) and in various forms (e.g. tagged, labeled, li pi dated, ami dated, acetylated, etc.).
- Ligand fusion proteins may include naturally-occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing polypeptides are well understood in the art.
- Ligand fusion proteins are preferably prepared in substantially pure form (i.e. substantially free from other host cell or non-host cell proteins).
- the ligand fusion proteins are generated using recombinant techniques.
- Oligonucleotide probes can be devised based on the known sequences and used to probe genomic or cDNA libraries. The sequences can then be further isolated using standard techniques and, e.g., restriction enzymes employed to truncate the gene at desired portions of the full-length sequence.
- sequences of interest can be isolated directly from cells and tissues containing the same, using known techniques, such as phenol extraction and the sequence further manipulated to produce the desired truncations. See, e.g., Sambrook et al., supra, for a description of techniques used to obtain and isolate DNA.
- sequences encoding fusion proteins can also be produced synthetically, for example, based on the known sequences.
- the nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired.
- the complete sequence is generally assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) Nature 292:756; Nambair ei al. (1984) Science 223 : 1299; Jay et al (1984) J. Biol Chem.
- Recombinant techniques are readily used to clone sequences encoding peptides or polypeptides that can then be mutagenized in vitro by the replacem ent of the appropriate base pair(s) to result in the codon for the desired amino acid.
- Such a change can include as little as one base pair, effecting a change in a single amino acid, or can encompass several base pair changes.
- the mutations can be effected using a mismatched primer that hybridizes to the parent nucleotide sequence (generally cDNA corresponding to the RNA sequence), at a temperature below the melting temperature of the mismatched duplex.
- the primer can be made specific by keeping primer length and base composition within relatively narrow limits and by keeping the mutant base centrally located. See, e.g., Innis et al, (1990) PCR Applications: Protocols for
- Primer extension is effected using DNA polymerase, the product cloned and clones containing the mutated DNA, derived by segregation of the primer extended strand, selected.
- Selection can be accomplished using the mutant primer as a hybridization probe.
- the technique is also applicable for generating multiple point mutations. See, e.g., Dalbie- McFarland et al. Proc. Natl Acad. Sci USA (1982) 79:6409.
- coding sequences Once coding sequences have been isolated and/or synthesized, they can be cloned into any suitable vector or replicon for expression. (See, also, Examples). As will be apparent from the teachings herein, a wide variety of vectors encoding modified polypeptides can be generated by creating expression constructs which operably link, in various combinations, polynucleotides encoding polypeptides having deletions or mutations therein.
- cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice.
- recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage l (E. coli), pBR322 ( E . coli ), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFRl (gram -negative bacteria), pME290 (non-E. coli gram-negative bacteria), pH VI 4 (E.
- Insect cell expression systems such as baculovirus systems, can also be used and are known to those of skill in the art and described in, e.g. , Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit).
- Plant expression systems can also be used to produce the ligand fusion proteins described herein. Generally, such systems use virus-based vectors to transfect plant cells with heterologous genes. For a description of such systems, see, e.g., Porta et al., Mol. Biotech. (1996) 5:209-221; andhackland et al., Arch. Virol. (1994) 139: 1-22.
- Viral systems such as a vaccinia-based infection/transfection system, as described in Tomei et al., J. Virol. (1993) 67:4017-4026 and Selby et al., J. Gen. Virol. (1993) 74: 1103-1 1 13, will also find use with the present invention.
- cells are first transfected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays extraordinar specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the DNA of interest, driven by a T7 promoter.
- the polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA that is then translated into protein by the host translational machinery.
- the method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation product(s).
- the gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control " elements), so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the host cell transformed by a vector containing this expression construction.
- the coding sequence may or may not contain a signal peptide or leader sequence. With the present invention, both the naturally occurring signal peptides or heterologous sequences can be used. Leader sequences can be removed by the host in post-translational processing. See , e.g., U.S. Patent Nos. 4,431 ,739; 4,425,437;
- Such sequences include, but are not limited to, the TP A leader, as well as the honey bee mellitin signal sequence.
- Other regulatory sequences may also be desirable which allow for regulation of expression of the protein sequences relative to the growth of the host cell.
- Such regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
- Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
- control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector.
- the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.
- Mutants or analogs may be prepared by the deletion of a portion of the sequence encodi ng the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et ah, supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.
- the expression vector is then used to transform an appropriate host cell.
- mammalian cell lines include immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), Vero293 cells, as well as others.
- ATCC American Type Culture Collection
- CHO Chinese hamster ovary
- HeLa cells HeLa cells
- BHK baby hamster kidney
- COS monkey kidney cells
- human hepatocellular carcinoma cells e.g., Hep G293 cells
- bacterial hosts such as E. coli, Bacillus sub tilis, and Streptococcus spp., will find use with the present expression constructs.
- Yeast hosts useful in the present invention include inter alia, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hamenula polymorpha, Kluyveromyces fragilis, Khtyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrow ia lipolytica.
- Insect cells for use with baculovirus expression vectors include, inter alia, Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda , and Trichoplusia ni.
- the fusion proteins of the present invention are produced by growing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed.
- the selection of the appropriate growth conditions is within the skill of the art.
- the transformed cells secrete the peptide or polypeptide product into the surrounding media.
- Certain regulatory sequences can be included in the vector to enhance secretion of the protein product, for example using a tissue
- TPA plasminogen activator
- g or a interferon signal sequence or other signal peptide sequences from known secretory proteins.
- the secreted peptide or polypeptide product can then be isolated by various techniques described herein, for example, using standard purification techniques such as but not limited to, hydroxyapatite resins, column chromatography, ion-exchange chromatography, size-exclusion chromatography, electrophoresis, HPLC, immunoadsorbent techniques, affinity chromatography, immunoprecipitation, and the like.
- the transformed cells are disrupted, using chemical, physical or mechanical means, which lyse the cells yet keep the recombinant peptides or
- Intracellular proteins can also be obtained by removing components from the cell wall or membrane, e.g., by the use of detergents or organic solvents, such that leakage of the polypeptides occurs.
- detergents or organic solvents such that leakage of the polypeptides occurs.
- Such methods are known to those of skill in the art and are described in, e.g., Protein Purification Applications: A Practical Approach, (Simon Roe, Ed., 2001).
- methods of disrupting cells for use with the present invention include but are not limited to: soni cation or ultrasonication; agitation; liquid or solid extrusion; heat treatment; freeze-thaw; desiccation; explosive decompression; osmotic shock; treatment with lytic enzymes including proteases such as trypsin, neuraminidase and lysozyme; alkali treatment; and the use of detergents and solvents such as bile salts, sodium dodecyl sulphate, Triton, NP40 and CHAPS.
- the particular technique used to disrupt the cells is largely a matter of choice and will depend on the cell type in which the polypeptide is expressed, culture conditions and any pre-treatment used.
- cellular debris is removed, generally by centrifugation, and the intracellularly produced peptides or polypeptides are further purified, using standard purification techniques such as but not limited to, column chromatography, ion-exchange chromatography, size-exclusion chromatography, electrophoresis, HPLC, immunoadsorbent techniques, affinity chromatography, immunoprecipitation, and the like.
- one method for obtaining the fusion proteins of the present invention involves affinity purification, such as by immunoaffinity chromatography using antibodies (e.g., previously generated antibodies), or by lectin affinity chromatography.
- Particularly preferred lectin resins are those that recognize mannose moieties such as but not limited to resins derived from Galanthns nivalis agglutinin (GNA), Lens culinaris agglutinin (LCA or lentil lectin), Pisum sativum agglutinin (PSA or pea lectin), Narcissus pseudonarcissus agglutinin (NPA) and Allium ursinum agglutinin (AUA).
- GUA Galanthns nivalis agglutinin
- LCA Lens culinaris agglutinin
- PSA Pisum sativum agglutinin
- NPA Narcissus pseudonarcissus agglutinin
- AUA Allium ursin
- Ligand fusion proteins can also be conveniently synthesized chemically, for example by any of several techniques that are known to those skilled in the peptide art. See, e.g., Fmoc Solid Phase Peptide Synthesis: A Practical Approach (W. C. Chan and Peter D. White eds., Oxford University Press, 1 st edition, 2000) ; N.
- these methods employ the sequential addition of one or more amino acids to a growing peptide chain.
- a suitable protecting group either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group.
- the protected or derivatized amino acid can then be either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected, under conditions that allow for the formation of an amide linkage.
- the protecting group is then removed from the newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth.
- any remaining protecting groups and any solid support, if solid phase synthesis techniques are used are removed sequentially or concurrently, to render the final peptide or polypeptide.
- any remaining protecting groups and any solid support, if solid phase synthesis techniques are used are removed sequentially or concurrently, to render the final peptide or polypeptide.
- a protected tripeptide with a properly protected dipeptide to form, after deprotection, a pentapeptide.
- Typical protecting groups include t-butyl oxy carb onyl (Boc), 9- fluorenylmethoxycarbonyl (Fmoc) benzyloxycarbonyl (Cbz); p -tol uenesul fonyl (Tx); 2,4-dinitrophenyl; benzyl (Bzl); biphenylisopropyloxycarboxy-carbonyl, t- amyl oxy carb onyl , isobornyloxycarbonyl, o-bromobenzyloxycarbonyl, cyclohexyl, isopropyl, acetyl, o-nitrophenyl sulfonyl and the like.
- Typical solid supports are cross-linked polymeric supports. These can include divinylbenzene cross-linked-styrene-based polymers, for example, divinylbenzene- hy droxymethyl styrene copolymers, divinylbenzene-chloromethylstyrene copolymers and divinylbenzene-benzhydrylaminopolystyrene copolymers.
- Ligand fusion proteins can also be chemically prepared by other methods such as by the method of simultaneous multiple peptide synthesis. See, e g., Houghten Proc.
- Nucleic acids encoding ligands of the urokinase receptor can be used, for example, to treat cancer.
- Nucleic acids described herein can be inserted into an expression vector to create an expression cassette capable of producing the ligand fusion proteins in a suitable host cell.
- the ability of constructs to produce the ligand fusion proteins can be empirically determined (e.g., see Example 1 describing detection using immunofluorescent labeling).
- Expression cassettes typically include control elements operably linked to the coding sequence, which allow for the expression of the gene in vivo in the subject species.
- typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV immediate early promoter, the mouse mammary tu or virus LTR promoter, the adenovirus major late promoter (Ad MLP), and the herpes simplex vims promoter, among others.
- Other nonviral promoters such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression.
- transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon.
- a sequence for optimization of initiation of translation located 5' to the coding sequence, is also present.
- transcription terminator/polyadenylati on signals include those derived from SV40, as described in Sambrook et al., supra , as well as a bovine growth hormone terminator sequence.
- Enhancer elements ay also be used herein to increase expression levels of the mammalian constructs.
- Examples include the SV40 early gene enhancer, as described in Dijkema et al., EMPO J (1985) 4:761, the enhancer/ pro oter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., Proc. Natl. Acad. Sci. USA (l982b) 79:6777 and elements derived from human CMV, as described in Boshart et al., Cell (1985) 41 :521, such as elements included in the CMV intron A sequence.
- LTR long terminal repeat
- the constructs encoding the ligand fusion proteins can be administered to a subject using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g, U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466. Genes can be delivered either directly to a vertebrate subject or, alternatively, delivered ex vivo, to cells derived from the subject and the cells reimplanted in the subject.
- a number of viral based systems have been developed for gene transfer into mammalian cells. These include adenoviruses, retroviruses (g-retroviruses and lentiviruses), poxviruses, adeno-associated viruses, baculoviruses, and herpes simplex viruses (see e.g., Wamock et al. (2011) Methods Mol. Biol. 737: 1-25; Walther et al. (2000) Drugs 60(2):249-271; and Lundstrom (2003) Trends Biotechnol. 21 (3): 117-122; herein incorporated by reference).
- retroviruses provide a convenient platform for gene delivery systems. Selected sequences can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo.
- retroviral systems have been described (U.S. Pat. No. 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A. D. (1990) Human Gene Therapy 1 :5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA
- Lentiviruses are a class of retroviruses that are particularly useful for delivering polynucleotides to mammalian cells because they are able to infect both dividing and nondividing cells (see e.g., Lois et al (2002) Science 295:868-872; Durand et al. (2011) Viruses 3(2): 132-159; herein incorporated by reference).
- adenovirus vectors have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj -Ahmad and Graham, J. Virol. (1986) 57:267-274; Bett et al, J. Virol. (1993) 67:5911-5921; Mittereder et al. Human Gene Therapy (1994) 5:717-729; Seth et aladmi J. Virol. (1994) 68:933-940; Barr et al., Gene Therapy (1994) 1 :51-58; Berkner, K. L.
- AAV vector systems have been developed for gene delivery.
- AAV vectors can be readily constructed using techniques well known in the art.. See, e.g., U S. Pat. Nos. 5, 173,414 and 5, 139,941; International Publication Nos. WO 92/01070
- Another vector system useful for delivering the polynucleotides of the present invention is the enterically administered recombinant poxvirus vaccines described by Small, Jr., P. A., et al. (U.S. Pat. No. 5,676,950, issued Oct. 14, 1997, herein incorporated by reference).
- Additional viral vectors which will find use for delivering the nucleic acid molecules encoding the ligand fusion proteins of interest include those derived from the pox family of viruses, including vaccinia virus and avian poxvirus.
- vaccinia vims recombinants expressing the ligand fusion proteins can be constructed as follows. The DNA encoding the particular ligand fusion protein coding sequence is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia.
- TK thymidine kinase
- Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the coding sequences of interest into the viral genome.
- the resulting TK- recombinant can be selected by culturing the cells in the presence of 5- bromodeoxyuri dine and picking viral plaques resistant thereto.
- avipoxviruses such as the fowlpox and canarypox viruses
- Recombinant avipox viruses expressing immunogens from mammalian pathogens, are known to confer protective immunity when admini stered to non-avian species.
- the use of an avipox vector is particularly desirable in human and other mammalian species since members of the avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells.
- Methods for producing recombinant avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.
- Molecular conjugate vectors such as the adenovirus chimeric vectors described in Michael et al., J. Biol. Chem. (1993) 268:6866-6869 and Wagner et al., Proc. Natl. Acad. Sci. USA (1992) 89:6099-6103, can also be used for gene delivery.
- Alphavirus genus such as, but not limited to, vectors derived from the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan
- chimeric alphavirus vectors comprised of sequences derived from Sindbis virus and Venezuelan equine encephalitis virus. See, e.g., Perri et al. (2003) J. Virol . 77: 10394-10403 and International Publication Nos. WO 02/099035, WO 02/080982, WO 01/81609, and WO 00/61772; herein incorporated by reference in their entireties.
- a vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression of the coding sequences of interest (for example, a ligand fusion protein expression cassette) in a host cell.
- the coding sequences of interest for example, a ligand fusion protein expression cassette
- cells are first infected in vitro with a vaccinia virus recombinant that encodes the
- T7 RNA polymerase This polymerase displays extraordinar specificity in that it only transcribes templates bearing T7 promoters.
- cells are transfected with the polynucleotide of interest, dri ven by a T7 promoter.
- the polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into protein by the host translational machinery.
- the method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy- Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al., Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.
- an amplification system can be used that will lead to high level expression following introduction into host cells.
- a T7 RNA polymerase promoter preceding the coding region for T7 RNA polymerase can be engineered. Translation of RNA derived from this template will generate T7 RNA polymerase which in turn will transcribe more template.
- T7 RNA polymerase generated from translati on of the amplification template RNA will lead to transcription of the desired gene. Because some T7 RNA polymerase is required to initiate the amplification, T7 RNA polymerase can be introduced into cells along with the template(s) to prime the transcription reaction.
- the polymerase can be introduced as a protein or on a plasmid encoding the RNA
- the synthetic expression cassette of interest can also be delivered without a viral vector.
- the synthetic expression cassette can be packaged as DNA or RNA in liposomes prior to delivery' to the subject or to cells derived therefrom.
- Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid.
- the ratio of condensed DNA to lipid preparation can vary but will generally be around 1 : 1 (mg DNA:micromoles lipid), or more of lipid.
- liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight, Biochim Biophys Acta (1991.) 1097: 1-17; Straubinger et al., in Methods of Enzymology (1983), Vol. 101, pp. 512-527.
- Liposomal preparations for use in the present invention include cationic
- Cationic liposomes have been shown to mediate intracellular deliver ⁇ ' of plasmid DNA (Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077- 6081); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265: 10189- 10192), in functional form.
- Cationic liposomes are readily available.
- N-[l-(2,3- di ol eyl oxy)propyl ] -N,N,N -trimethyl ammonium chloride (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416).
- Other commercially available lipids include (DDAB/DOPE) and DOTAP/DOPE (Boerhinger).
- Other cationic liposomes can be prepared from readily available materials using techniques well known in the art.
- DO TAP l,2-bis(oleoyloxy)-3-(trimethylammonio)propane
- anionic and neutral liposomes are readily available, such as, from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials.
- Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), di ol eoylphosphati dyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others.
- DOPC dioleoylphosphatidyl choline
- DOPG di ol eoylphosphati dyl glycerol
- DOPE dioleoylphoshatidyl ethanolamine
- the liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs).
- MLVs multilammelar vesicles
- SUVs small unilamellar vesicles
- LUVs large unilamellar vesicles
- the various liposome-nucleic acid complexes are prepared using methods known in the art. See, e.g., Straubinger et al., in METHODS OF IMMUNOLOGY (1983), Vol. 101 , pp. 512-527; Szoka et al., Proc. Natl. Acad. Sci. USA (1978) 75:4194-4198; Papahadjopoulos et al., Biochim. Biophys.
- DNA and/or peptide(s) can also be delivered in cochleate lipid compositions similar to those described by Papahadjopoulos et al., Biochem. Biophys. Acta (1975) 394:483-491. See, also, U S. Pat. Nos. 4,663,161 and 4,871,488.
- the expression cassette of interest may also be encapsulated, adsorbed to, or associated with, particulate carriers.
- particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PEG. See, e.g., Jeffery et al., Pharm. Res. (1993) 10:362-368; McGee J. P., et al., J Microencapsul. 14(2): 197-210, 1997; O'Hagan D. T., et ai., Vaccine 11(2): 149-54, 1993.
- particulate systems and polymers can be used for the in vivo or ex vivo delivery of the nucleic acid of interest.
- polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules, are useful for transferring a nucleic acid of interest.
- DEAE dextran-mediated transfection, calcium phosphate precipitation or precipitation using other insoluble inorganic salts, such as strontium phosphate, aluminum silicates including bentonite and kaolin, chromic oxide, magnesium silicate, talc, and the like, will find use with the present methods. See, e.g., Felgner, P.
- Peptoids Zaerman, R. N., et al., U.S. Pat. No. 5,831 ,005, issued Nov. 3, 1998, herein incorporated by reference
- Peptoids may also be used for delivery of a construct of the present invention.
- biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering synthetic expression cassettes of the present invention.
- the particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun.”
- a gun powder discharge from a "gene gun” For a description of such techniques, and apparatuses useful therefore, see, e.g., U.S. Pat. Nos. 4,945,050; 5,036,006;
- compositions for delivery' to a vertebrate subject may either be prophylactic (e.g., to prevent cancer progression or metastasis) or therapeutic (e.g., to treat cancer).
- compositions will comprise a "therapeutically effective amount" of the nucleic acid of interest such that an amount of the ligand (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) can be produced in vivo so that the urokinase receptor is inhibited in the individual to which it is administered.
- the ligand is produced in a sufficient amount in the individual to have anti-tumor activity.
- the exact amount necessary will vary depending on the subject being treated; the age and general condition of the subject to be treated; the degree of protection desired; the severity of the condition being treated; the particular ligand fusion protein produced and its mode of administration, among other factors.
- An appropriate effective amount can be readily determined by one of skill in the art.
- a "therapeutically effective amount” will fall in a relatively broad range that can be determined through routine trials.
- compositions will generally include one or more "pharmaceutically acceptable excipients or vehicles" such as water, saline, glycerol, poly ethyleneglycol , hyaluronic acid, ethanol, etc. Additionally, auxiliary' substances, such as wetting or emulsifying agents, pH buffering substances, surfactants and the like, may be present in such vehicles. Certain facilitators of nucleic acid uptake and/or expression can also be included in the compositions or coadministered.
- pharmaceutically acceptable excipients or vehicles such as water, saline, glycerol, poly ethyleneglycol , hyaluronic acid, ethanol, etc.
- auxiliary' substances such as wetting or emulsifying agents, pH buffering substances, surfactants and the like.
- Certain facilitators of nucleic acid uptake and/or expression can also be included in the compositions or coadministered.
- compositions of the invention can be administered directly to the subject (e.g., as described above) or, alternatively, delivered ex vivo, to cells derived from the subject, using methods such as those described above.
- methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and can include, e.g., dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, lipofectamine and LT-l mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposom es, and direct microinjection of the DNA into nuclei.
- Direct delivery of synthetic expression cassette compositions in vivo will generally be accomplished with or without viral vectors, as described above, by injection using either a conventional syringe, needless devices such as Bioject or a gene gun, such as the Accell gene delivery system (PowderMed Ltd, Oxford, England).
- Ligands of the urokinase receptor can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients.
- excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof.
- Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants.
- a carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient.
- Specifi c carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cell obi ose, and the like; polysaccharides, such as raffmose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoi
- a composition of the invention can also include an antimicrobial agent for preventing or deterring microbial growth.
- antimicrobial agents suitable for the present invention include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenyl ethyl alcohol, phenylmer curie nitrate, thimersol, and combinations thereof.
- antioxidant can be present in the composition as well. Antioxidants are used to prevent oxidation, thereby preventing the deterioration of the ligand fusi on proteins or nucleic acids or other components of the preparation. Suitable antioxidants for use in the present invention include, for example, ascorbyl palmitate, butyl ated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.
- a surfactant can be present as an excipient.
- exemplary surfactants include: polysorbates, such as “Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (BASF, Mount Olive, New Jersey); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanol amines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations.
- Acids or bases can be present as an excipient in the composition.
- acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof.
- Suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
- the amount of the ligand (e.g., when contained in a drug delivery system) in the composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial).
- a therapeutically effective dose can be determined experimentally by repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.
- the amount of any individual excipient in the composition will vary depending on the nature and function of the excipient and particular needs of the composition.
- the optimal amount of any indi vidual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects.
- the excipient(s) will be present in the composition in an amount of about 1 % to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred.
- compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emul sions and liquid concentrates for dilution prior to administration.
- suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.
- solutions and suspensions are envisioned.
- Additional preferred compositions include those for oral, ocular, or localized delivery.
- compositions herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use.
- the compositions comprising one or more ligands of the urokinase receptor e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or nucleic acids encoding them
- compositions herein may optionally include one or more additional agents, such as drugs for treating cancer or other medications used to treat a subject for a condition or disease.
- Compounded preparations may include a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) and one or more drugs for treating cancer, such as, but not limited to, chemotherapy, immunotherapy, biologic or targeted therapy agents.
- a separate composition from the composition comprising a ligand of a urokinase receptor and co-administered concurrently, before, or after the composition comprising the ligand of the urokinase receptor.
- Bioconjugates may comprise a ligand of the urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) conjugated to one or more diagnostic or therapeutic agents, or a combination thereof.
- a ligand of the urokinase receptor may be attached to diagnostic and/or therapeutic agents in a variety of manners. For example, an agent may be attached at the N-terminus, C -terminus, at both the N-terminus and C -terminus, and/or internally, for example, at a residue in the peptide linker between the GFD and SMB domains.
- Diagnostic and/or therapeutic agents may be connected directly to the ligand of the urokinase receptor or indirectly through an intervening linker or chelating agent (e.g., for metal labeling such as with a radionuclide or paramagnetic metal ion).
- an intervening linker or chelating agent e.g., for metal labeling such as with a radionuclide or paramagnetic metal ion.
- Conjugation of ligands can be performed using methods well-known in the art.
- bioconjugation techniques see, e.g., Chemistry of Bioconjugates: Synthesis, Characterization, and Biomedical Applications (R. Narain ed., Wiley, 2014), G.T. Flermanson Bioconjugate Techniques (Academic Press, 3 rd edition, 2013), and Bioconjugalion Protocols: Strategies and Methods (Methods in Molecular Biology, S.S. Mark ed., Humana Press, 2 nd edition, 201 1), van Vught et al. (2014) Comput Struct Biotechnol J. 9 :e201402001; Gao et al.
- imaging and/or therapeutic agents can be conjugated to the side chain e-amine of lysine residues or the free thiol of cysteine residues.
- reactions of cysteine thiols with maleimides are commonly used for bioconjugation of proteins.
- Maleimide-functionalized imaging probes and compounds to facilitate bioconjugation for various imaging modalities are commercially available from a number of companies (e.g., ThermoFisher Scientific (Waltham, MA), GE Healthcare Life Sciences (Pittsburgh, PA), SigmaAldrich (St.
- maleimide lipid derivatives and maleimide albumin derivatives which can be incorporated into a microbubble shell for ultrasound imaging, maleimide fluorescent dye derivatives for fluorescence imaging, maleimide chelating agent derivatives for binding metals such as radionuclides and paramagnetic cations, and maleimide gold nanoparticle derivatives, which can be used in a variety of ways including as detection agents for electron microscopy and surface enhanced Raman spectroscopy, enhancement agents for radiotherapy, phototherm al agents for surface plasmon resonance, and delivery agents for attached drugs or other therapeutic agents.
- the l igand of the urokin ase receptor is engineered to include an N-terminal or C-terminal cysteine residue providing a free thiol group to facilitate conjugation to a reagent comprising a functional group that is reactive with thiols.
- a cysteine is incorporated into the linker peptide to allow attachment of reagents to the linker region between the VH and VL domains.
- cysteine residues may be introduced into the single-chain antibody, for example, by site-directed mutagenesis to allow attachment at other sites.
- a site of attachment away from the urokinase receptor binding sites of the GFD and SMB domains should be chosen to avoid interfering with targeting of the bioconjugate to the urokinase receptor.
- a diagnostic or therapeutic agent is conjugated to a ligand of the urokinase receptor comprising a sequence selected from the group consisting of SEQ ID NOS: 12, 13, and 17-20.
- Click chemistry reactions include the Huisgen 1,3 -dipolar cycloaddition copper catalyzed reaction (Tornoe et al, 2002, 1 Organic Chem 67:3057-64), cycloaddition reactions such as Diels- Alder reactions, nucleophilic substitution reactions (especially to small strained rings like epoxy and aziridine compounds), reactions involving form ation of urea compounds, and reactions involving carbon-carbon double bonds, such as alkynes in thiol -yne
- Ligands of the urokinase receptor can be conjugated to diagnostic agents (e.g., probes or detection agents) suitable for various imaging modalities, including, but not limited to, ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), or fluorescence imaging.
- diagnostic agents e.g., probes or detection agents
- imaging UI ultrasound imaging
- PET positron emission tomography
- SPECT single photon emission computed tomography
- MRI magnetic resonance imaging
- CT computed tomography
- OI optical imaging
- PI photoacoustic imaging
- fluorescence imaging Conjugation of a diagnostic agent comprising a detectable moiety or label to a ligand of the urokinase receptor localizes the diagnostic agent to tumors or cancerous cells expressing the urokinase receptor.
- Useful diagnostic agents that can be used in the practice of the invention include, but are not limited to, contrast agents, photoactive agents, radioisotopes, nonradioactive isotopes, dyes, fluorescent compounds or proteins, chemiluminescent compounds, bioluminescent proteins, enzymes, and enhancing agents (e.g., paramagnetic ions).
- the ligand of the urokinase receptor is conjugated to a contrast agent.
- Exemplary contrast agents include ultrasound contrast agents (e.g.
- SonoVue microbubbles comprising sulphur hexafluoride
- Optison microbubbles comprising an albumin shell and octafluoropropane gas core
- Levovist microbubbles comprising a lipi d/galactose shell and an air core
- Perflexane lipid microspheres comprising perfluorocarbon microbubbles
- Perflutren lipid microspheres comprising octafl uoropropane encapsulated in an outer lipid shell
- magnetic resonance imaging (MRI) contrast agents e.g., gadodi mide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid
- radiocontrast agents such as for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iod
- the diagnostic agent is a radioactive metal, paramagnetic ion, or other diagnostic cation.
- the ligand of the urokinase receptor can be conjugated to a chelating group for binding cations.
- Exemplary chelating agents include ethylenedi aminetetraaceti c acid (EDTA), di ethyl enetriaminepentaacetic acid (DTP A), l,4,7, 10-tetraazacyclododecane-l,4,7, 10-tetraacetic acid (DOT A), 1,4,7- triazacyclononane-N,N’,N”-triacetic acid (NOTA), NET A, p-bromoacetami do-benzyl - tetraethylaminetetraacetic acid (TETA), porphyrins, polyamines, crown ethers, bis- thiosemicarbazones, polyoximes, and like groups known to be useful for this purpose.
- EDTA ethylenedi aminetetraaceti c acid
- DTP A di ethyl enetriaminepentaacetic acid
- DOT A 1,4,7- triazacyclononane-N,N
- Chelates are coupled to the single-chain antibodies using standard chemistries, which then can be used to bind diagnostic isotopes such as 125 I, 131 I, 123 I, 124 1, 62 Cu, b4 Cu, 18 F, m In, 67 Ga, 68 Ga, 99m Tc, 223 Ra, n C, 13 N, !5 0, and 76 Br for radioimaging.
- diagnostic isotopes such as 125 I, 131 I, 123 I, 124 1, 62 Cu, b4 Cu, 18 F, m In, 67 Ga, 68 Ga, 99m Tc, 223 Ra, n C, 13 N, !5 0, and 76 Br for radioimaging.
- non-radioactive metals such as manganese, iron and gadolinium are useful for MRI, when used along with the ligands of the urokinase receptor.
- Diagnostic agents comprising 18 F or n C can be used in PET imaging.
- the ligand of the urokinase receptor is conjugated to a fluorescent label.
- fluorescent labels include fluorescein derivatives, rhodamine derivatives, coumarin derivatives, cyanine derivatives, acridine derivatives, squaraine derivatives, naphthalene derivatives, oxadiazol derivatives, anthracene derivatives, pyrene derivatives, oxazine derivatives, arylmethine derivatives, and tetrapyrrole derivatives.
- the fluorescent label may comprise a fluorescent protein, such as, but not limited to, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, rsCherry, and rsCherryRev.
- GFP green fluorescent protein
- EGFP enhanced green fluorescent protein
- YFP yellow fluorescent protein
- EYFP enhanced yellow fluorescent protein
- BFP blue fluorescent protein
- RFP red fluorescent protein
- TagRFP TagRFP
- Dronpa Padron
- Padron mApple
- mCherry mCherry
- rsCherry rsCherryRev.
- the ligand of the urokinase receptor is conjugated to a bioluminescent label such as a bioluminescent protein.
- bioluminescent proteins include, but are not limited to, firefly luciferase, bacterial luciferase, Renilla luciferase, and aequorin.
- Fluorescence or bioluminescence images may be recorded by any suitable method.
- a CCD image sensor e.g., intensified CCD (ICCD) or electron multiplying CCD (EMCCD)
- EMCCD electron multiplying CCD
- CMOS image sensor e.g., CMOS image sensor
- digital camera e.g., CMOS image sensor
- the image may be a still photo or a video in any format (e.g., bitmap, Graphics Interchange Format, JPEG file interchange format, TIFF, or mpeg).
- images may be captured by an analog camera and converted into an electronic form.
- luminescence can be detected by a luminometer, and fluorescence can be detected by a fluorimeter, a fluorescence microscope, a fluorescence microplate reader, a fluorometric imaging plate reader, fluorescence-activated cell sorting, a fiber-optic fluorescence imaging system, or a medical fluorescence imaging device (e.g., a handheld fluorescence microscope, a laparoscope, an endoscope, or a microendoscope).
- a medical fluorescence imaging device e.g., a handheld fluorescence microscope, a laparoscope, an endoscope, or a microendoscope.
- Various medical imaging systems have been developed for open surgery as well as for laparoscopic, thoracoscopic, and robot-assisted surgery and can be used in the practice of the invention.
- Conventional laparoscopes and endoscopes can be equipped with a photodetector (e.g., camera or CCD detector) to provide guidance during medical procedures.
- a photodetector e.g., camera or CCD detector
- Fiber-optic imaging systems can also be used, which include portable handheld microscopes, flexible endoscopes, and microendoscopes.
- An illumination source can be added to such devices to allow fluorescence imaging.
- the excitation light source and photodetector can be integrated into a single medical imaging device or the excitation light source and/or photodetector may reside apart, in which case, imaging is performed with remote delivery of excitation light.
- Miniaturized imaging systems can be used that allow imaging inside small cavities and constricted spaces.
- miniaturized imaging devices may be implanted within a subject for long-term imaging studies.
- An imaging system that can simultaneously detect fluorescence or bioluminescence at multiple wavelengths can be used for detection of multiple fluorescent and/or bioluminescent agents that emit light at different wavelengths.
- a camera may be used to take both photographic images of a subject and to detect fluorescence and bioluminescence, so that photographic images and fluorescent or bioluminescent images can be superimposed to allow regions of fluorescence or bioluminescence to be mapped to the subject’s anatomy for identification of the source of light emissions.
- a detectably effective amount of a urokinase receptor-targeted imaging agent e.g., a ligand of the urokinase receptor conjugated to a diagnostic agent
- a detectably effective am ount of the urokinase receptor-targeted imaging agent may be admini stered in more than one injection if needed.
- the detectably effective amount of the urokinase receptor- targeted imaging agent needed for an individual may vary according to factors such as the degree of binding of the imaging agent to cancerous tissue, the age, sex, and weight of the individual, and the particular medical imaging method used. Optimization of such factors is within the level of skill in the art.
- Imaging with urokinase receptor-targeted imaging agents can be used in assessing efficacy of therapeutic drugs in treating cancer. For example, images can be acquired after treatment with an anti -cancer therapy to determine if the individual is responding to treatment. In a subject with cancer, imaging with a urokinase receptor-targeted imaging agent can be used to evaluate whether a tumor is shrinking or growing. Further, the extent of cancerous disease (stage of cancer progression) can be determined to aid in determining prognosis and evaluating optimal strategies for treatment (e.g., surgery, radiation, or chemotherapy).
- urokinase receptor-targeted imaging agents can be used in image- guided surgery.
- Cells or tissue of interest can be contacted with a urokinase receptor- targeted imaging agent, such that the urokinase receptor-targeted imaging agent binds to urokinase receptors present on the surface of cells or tissue (e.g., urokinase receptors overexpressed on tumors or cancerous cells).
- Imaging of tissues labeled with the urokinase receptor-targeted imaging agent in this way can be used, for example, for detection of pathology, tumor margin delineation, evaluation of the completeness of resection, and evaluation of the efficacy of treatment.
- the ligands of the invention localize specifically to uPAR-expressing tumors where they are internalized by cancerous cells (see Example 2).
- ligands can also be used to target therapeutic agents to the location of uPAR-expressing tumors or cancerous cells to directly treat cancer in a subject.
- a ligand of the invention e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- a ligand can be conjugated to one or more chemotherapeutic agents such as, but not limited to, abitrexate, adriamycin, adrucil, amsacrine, asparaginase, anthracyclines, azacitidine, azathioprine, bicnu, blenoxane, busulfan, bleomycin, camptosar, camptothecins, carboplatin, carmustine, cerubidine, chlorambucil, cisplatin, cladribine, cosmegen, cytarabine, cytosar, cyclophosphamide, cytoxan, dactinomycin, docetaxel, doxorubicin, daunorubicin, ellence, el spar, epirubicin, etoposide, fludarabine, fluorouracil, fludara, gemcitabine, gemzar, hycamtin, hydroxyure
- a ligand can be conjugated to, one or more tyrosine- kinase inhibitors, such as Imatinib mesylate (Gleevec, also known as STI-571), Gefitinib (Iressa, also known as ZD 1839), Erlotinib (marketed as Tarceva), Sorafenib (Nexavar), Sunitinib (Sutent), Dasatinib (Sprycel), Lapatinib (Tykerb), Nilotinib (Tasigna), and Bortezomib (Velcade); Janus kinase inhibitors, such as tofacitinib; ALK inhibitors, such as crizotinib; Bel -2 inhibitors, such as obatoclax and gossypol; PARP inhibitors, such as Iniparib and Olaparib; PI3K inhibitors, such as perifosine; VEGF Receptor 2 inhibitors,
- serine/threonine kinase inhibitors such as Temsirolimus (Torisel), Everolimus (Afmitor), Vemurafenib (Zelboraf), Trametinib (Mekinist), and Dabrafenib (Tafinlar).
- a ligand is conjugated to a hormonal blocking therapeutic agent for treatment of a cancer depending on estrogen for growth (e.g., cancer expressing estrogen receptors (ER+ cancer)).
- the anti-B7-H3 antibody can be conjugated to a drug that blocks ER receptors (e.g. tamoxifen) or a drug that blocks the production of estrogen, such as an aromatase inhibitor (e.g. anastrozole, or letrozole).
- the ligand is conjugated to a toxin.
- the toxin can be of animal, plant or microbial origin.
- Exemplary toxins include Pseudomonas exotoxin, ricin, abrin, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, and Pseudomonas endotoxin.
- the ligand is conjugated to an immunomodulator, such as a cytokine, a lymphokine, a monoline, a stem cell growth factor, a lymphotoxin (LT), a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, a transforming growth factor (TGF), such as TGF-oc or TGF-b, insulin-like growth factor (IGF), erythropoietin, thrombopoietin, a tumor necrosis factor (TNF) such as TNF-ct or TNF-b, a mullerian-in
- Particularly useful therapeutic radionuclides include, but are not limited to m In, 17 Lu,
- the therapeutic radionuclide has a decay energy in the range of 20 to 6,000 keV (e.g., 60 to 200 keV for an Auger emitter, 100-2,500 keV for a beta emitter, and 4,000-6,000 keV for an alpha emitter).
- the radionuclide is an Auger-emitter (e.g., Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt- 109, In-111, Sb- 1 19, 1-125, Ho-161 , Os-189m and Ir-192).
- the radionuclide is an alpha-emitter (e.g., Dy-152, At-21 1, Bi-212, Ra-223, Rn-219, Po-215,
- Additional therapeutic radioisotopes include 41 C, l3 N, 15 0, 7 3 ⁇ 4r, 198 Au, 224 Ac, 126 I,
- Ligands may also be conjugated to a boron addend-loaded carrier for thermal neutron activation therapy.
- boron addends such as carboranes
- Carboranes can be prepared with carboxyl functions on pendant side chains, as is well-known in the art. Attachment of carboranes to a carrier, such as aminodextran, can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier.
- the intermediate conjugate is then conjugated to the B7-H3-targeting agent.
- a boron addend is activated by thermal neutron irradiation and converted to radioactive atoms which decay by alpha-emission to produce highly toxic, short-range effects.
- the methods of the invention can be used for treating a subj ect for cancer.
- ligands of the urokinase receptor can be used for treating a subject for a tumor, cancer, or metastasis that is progressing, worsening, stabilized or in remission as well as precancerous lesions.
- At least one therapeutically effective cycle of treatment with a ligand of the urokinase receptor will be admini stered to a subject for treatment of cancer.
- a ligand of the urokinase receptor e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or a bioconjugate thereof
- an amount of a ligand of the urokinase receptor that provides an anti-tumor effect as defined herein.
- positive therapeutic response is intended the individual undergoing the treatment according to the invention exhibits an improvement in one or more symptoms of the cancer for which the individual is undergoing therapy.
- a "positive therapeutic response" would be an improvement in the disease in association with the therapy, and/or an improvement in one or more symptoms of the disease in association with the therapy. Therefore, for example, a positive therapeutic response would refer to one or more of the following improvements in the disease: (1) reduction in tumor size; (2) reduction in the number of cancer cells;
- Such therapeutic responses may be further characterized as to degree of improvement.
- an improvement may be characterized as a complete response.
- compositions comprising a ligand of the urokinase receptor (e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or a bioconjugate thereof) and/or one or more other therapeutic agents, such as other drugs for treating cancer, or other medications will be administered according to a daily dosing regimen, or intermittently.
- a therapeutically effective dose can be administered, one day a week, two days a week, three days a week, four days a week, or five days a week, and so forth.
- the therapeutically effective dose can be administered, for example, every other day, every two days, every three days, and so forth.
- a ligand will be administered twice-weekly or thrice-weekly for an extended period of time, such as for 1, 2, 3, 4, 5, 6, 7, 8...10...15...24 weeks, and so forth.
- two therapeutically effective doses of the agent in question is administered to the subject within a 7-day period, beginning on day 1 of the first week of administration, with a minimum of 72 hours, between doses and a maximum of 96 hours between doses.
- thrice weekly or “three times per week” is intended that three therapeutically effective doses are administered to the subject within a 7-day period, allowing for a minimum of 48 hours between doses and a maximum of 72 hours between doses.
- this type of dosing is referred to as "intermittent" therapy.
- a subject can receive intermittent therapy (i.e., twice-weekly or thrice-weekly administration of a therapeutically effective dose) for one or more weekly cycles until the desired therapeutic response is achieved.
- the agents can be administered by any acceptable route of administration as noted herein below.
- compositions of the present invention are typically, although not necessarily, administered orally, via injection (subcutaneously, intravenously, or intramuscularly), by infusion, or locally. Additional modes of administration are also contemplated, such as intra-arterial, intraperitoneal, pulmonary, nasal, topical, transderm al, intralesion, intrapleural, intraparenchymatous, rectal, transdermal, transmucosal, intrathecal, pericardial, intra-arterial, intraocular, and so forth.
- the administration ay be by continuous infusion or by single or multiple boluses.
- the preparati ons according to the invention are also suitable for local treatment.
- compositions of the invention are used for localized delivery of a ligand of the urokinase receptor for the treatment of cancer.
- compositions may be administered directly into a tumor or cancerous cells.
- Administration may be by perfusion through a regional catheter or direct intralesional injection.
- the pharmaceutical preparation can be in the form of a liquid solution or suspension immediately prior to administration, but may also take another form such as a syrup, cream, ointment, tablet, capsule, powder, gel, matrix, suppository, or the like.
- the pharmaceutical compositions comprising a ligand of the urokinase receptor and other agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
- compositions comprising a ligand of the urokinase receptor and/or other agents are administered prophylactically, e.g., to prevent cancer progression or metastasis in tissue.
- prophylactic uses will be of particular value for subjects with a potentially precancerous or premalignant condition (e.g., precancerous lesions, dysplasia or benign neoplasia), or who have a genetic predisposition to developing cancer.
- the pharmaceutical compositions comprising a ligand of the urokinase receptor and/or other agents are in a sustained- release formulation, or a formulation that is administered using a sustained-release device.
- sustained-release devices include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.
- the invention also provides a method for administering a conjugate comprising a ligand of the urokinase receptor (e.g., conjugated to a diagnostic or therapeutic agent) as provided herein to a patient suffering from cancer.
- the method comprises administering, via any of the herein described modes, a therapeutically effective amount of the conjugate or drug delivery system, preferably provided as part of a pharmaceutical composition.
- the method of administering may be used to treat any cancer that is responsive to treatment with a ligand of the urokinase receptor. More specifically, the compositions herein are effective in treating cancer.
- ligand of the urokinase receptor can effectively treat.
- the actual dose to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered.
- Therapeutically effective amounts can be determined by those skilled in the art, and will be adjusted to the particular requirements of each particular case.
- a therapeutically effective amount will range from about 0.50 mg to 5 grams of a ligand of the urokinase receptor daily, more preferably from about 5 mg to 2 grams daily, even more preferably from about 7 mg to 1.5 grams daily.
- such doses are in the range of 10-600 mg four times a day (QID), 200-500 mg QID, 25 - 600 mg three times a day (TID), 25-50 mg TID, 50-100 mg TID, 50-200 mg TID, 300-600 mg TID, 200-400 mg TID, 200-600 mg TID, 100 to 700 mg twice daily (BID), 100-600 mg BID, 200-500 mg BID, or 200-300 mg BID.
- the amount of compound administered will depend on the potency of the specific ligand of the urokinase receptor and the magnitude or effect desired and the route of administration.
- a purified ligand of the urokinase receptor (again, preferably provided as part of a pharmaceutical preparation) can be administered alone or in combination with one or more other therapeutic agents, such as chemotherapy, immunotherapy, biologic or targeted therapy agents, or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth.
- therapeutic agents such as chemotherapy, immunotherapy, biologic or targeted therapy agents, or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth.
- dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof
- Preferred compositions are those requiring dosing no more than once a day.
- a ligand of the urokinase receptor can be administered prior to, concurrent with, or subsequent to other agents. If provided at the same time as other agents, the ligand of the urokinase receptor can be provided in the same or in a different composition. Thus, the ligand of the urokinase receptor and other agents can be presented to the individual by way of concurrent therapy.
- concurrent therapy is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy.
- concurrent therapy may be achieved by administering a dose of a pharmaceutical composition comprising a ligand of the urokinase receptor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating cancer, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen.
- a pharmaceutical composition comprising a ligand of the urokinase receptor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating cancer, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen.
- the ligand of the urokinase receptor and one or more other therapeutic agents can be administered in at least one therapeutic dose.
- compositions can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
- a subject undergoing therapy in accordance with the previously mentioned dosing regimens exhibits a partial response or a relapse following a prolonged period of remission
- subsequent courses of concurrent therapy may be needed to achieve complete remission of the disease.
- a subject may receive one or more additional treatment periods with the ligand of the urokinase receptor.
- Such a period of time off between treatment periods is referred to herein as a time period of discontinuance. It is recognized that the length of the time peri od of discontinuance is dependent upon the degree of tumor response (i.e., complete versus partial) achieved with any prior treatment periods of concurrent therapy with these therapeutic agents
- treatment with a ligand of the urokinase receptor may be combined with any other medical treatment for cancer, such as, but not limited to, surgery, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or molecularly targeted or biologic therapy. Any combination of these other medical treatment methods with a ligand of the urokinase receptor may be used to effectively treat cancer in a subject.
- treatment with a ligand of the urokinase receptor may be combined with chemotherapy with one or more chemotherapeutic agents such as, but not limited to, abitrexate, adriamycin, adrucil, amsacrine, asparaginase, anthracyclines, azacitidine, azathioprine, bicnu, blenoxane, busulfan, bleomycin, camptosar, camptothecins, carboplatin, carmustine, cerubidine, chlorambucil, cisplatin, cladribine, cosmegen, cytarabine, cytosar, cyclophosphamide, cytoxan, dactinomycin, docetaxel, doxorubicin, daunorubicin, ellence, el spar, epirubicin, etoposide, fludarabine, fluorouracil, fludara, gemcitabine,
- treatment with a ligand of the urokinase receptor may be combined with targeted therapy with one or more small molecule inhibitors or monoclonal antibodies such as, but not limited to, tyrosine-kinase inhibitors, such as Imatinib mesylate (Gleevec, also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as Tarceva), Sorafenib (Nexavar), Sunitinib (Sutent), Dasatinib (Sprycel), Lapatinib (Tykerb), Nilotinib (Tasigna), and Bortezomib (Velcade); Janus kinase inhibitors, such as tofacitinib; ALK inhibitors, such as crizotinib; Bcl-2 inhibitors, such as obatoclax and gossypol; PARP inhibitors, such as Inipa
- trasmetinib (Mekinist), and Dabrafenib (Tafmlar); and monoclonal antibodies, such as Rituximab (marketed as MabThera or Rituxan), Trastuzumab (Herceptin), Alemtuzumab, Cetuximab (marketed as Erbitux), Panitumumab, Bevacizumab (marketed as Avastin), and Ipilimumab (Yervoy).
- Rituximab marketed as MabThera or Rituxan
- trasstuzumab Herceptin
- Alemtuzumab (marketed as Erbitux)
- Panitumumab (marketed as Avastin)
- Bevacizumab (marketed as Avastin)
- Ipilimumab (Yervoy).
- treatment with a ligand of the urokinase receptor may be combined with immunotherapy, including, but not limited to, using any of the following: a cancer vaccine (e.g., E75 HER2-derived peptide vaccine, nelipepimut-S (NeuVax), Sipuleucel-T), antibody therapy (e.g., Trastuzumab, Ado-trastuzumab emtansine, Alemtuzumab, Ipilimumab, Ofatumumab, Nivolumab, Pembrolizumab, or Rituximab), cytokine therapy (e.g., interferons, including type I (IFNa and PTNGb), type II (LFNy) and type III (ITNl) and interleukins, including interleukin-2 (IL-2)), adjuvant
- a cancer vaccine e.g., E75 HER2-derived peptide vaccine, nelipepimut-S
- kits comprising one or more containers holding compositions comprising at least one ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a bioconjugate thereof (e.g. conjugated to a therapeutic and/or diagnostic agent), or a nucleic acid encoding such a ligand and optionally one or more other drugs for treating cancer.
- a urokinase receptor e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain
- a bioconjugate thereof e.g. conjugated to a therapeutic and/or diagnostic agent
- nucleic acid encoding such a ligand and optionally one or more other drugs for treating cancer.
- compositions can be in liquid form or can be lyophilized, as can individual peptides, polypeptides, or nucleic acids.
- Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic.
- a container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the kit can further comprise a second container comprising a pharmaceutically- acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices.
- a pharmaceutically- acceptable buffer such as phosphate-buffered saline, Ringer's solution, or dextrose solution.
- the delivery device may be pre-filled with the compositions.
- the kit can also comprise a package insert containing written instructions for methods of treating cancer.
- the package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
- FDA Food and Drug Administration
- the kit comprises a ligand comprising a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NOS: 17-20, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor.
- Previously developed uPAR antagonists can be categorized by the specific uPAR functions they inhibit. For example, there are inhibitors of uPAR’s interaction with its soluble ligand urokinase, and with an assortment of integrins, FPRL1, vitronectin, and P AI- 1 , and there are direct inhibitors of urokinase catalytic activity.
- a close evaluation of these antagonists reveals key shared characteristics between them, 1) they each effectively reduce cancer establishment, growth, and/or metastasis in vivo, even though 2) they bind uPAR with similar or weaker affinity compared to the competing wild-type uPAR ligands, and 3) each antagonist alone only partially inhibits uPAR activity.
- Targeting the uPAR receptor with an antagonist engineered to: a) have orders-of- magnitude higher binding affinity than uPAR’s native ligands, and thus more effectively outcompete native ligand binding in vivo, and b) simultaneously block multiple cancer- associated uPAR interactions is therefore an attractive strategy for developing a next- generation uPAR antagonist.
- Such an antagonist would overcome the limitations of previously developed molecules, and potentially have a more dramatic effect on cancer metastasis in vivo.
- a bispecific protein that simultaneously binds to two distinct functional uPAR epitopes with an affinity superior to the native ligands.
- Possible strategies for engineering said protein include 1) developing and fusing together two antibodies that each bind a separate functional uPAR epitope, such that both simultaneously bind uPAR, 2) developing two antibodies that each bind a separate functional uPAR epitope, and then creating a "knob-in-hole" heterodimer 3 6 composed of one arm from each antibody that simultaneously bind uPAR, 3) engineering non-antibody scaffold proteins de novo to bind two distinct uPAR epitopes, and then chemically or genetically fusing them such that each simultaneously bind uPAR, or 4) Re-engineering two natural uPAR ligands that already simultaneously bind uPAR to function as antagonists, and fusing them together such that they simultaneously bind the receptor.
- the first challenge is developing a high-throughput assay capable of separating off-target uPAR binders from binders of the desired epitope
- the second is engineering de novo ligand with binding affinities superior to the wild-type ligands.
- the latter challenge is particularly difficult in the case of interrupting the uPA-uPAR interaction, which has an affinity of approximately 230 pM'.
- each ligand starts with a binding affinity equal to the wild-type interaction; any further improvement in affinity from engineering efforts would result in ligands already more capable of outcompeting the natural ligands for binding. Therefore, we focused our efforts on re-engineering uPAR’s natural ligands to form a bispecific ligand.
- uPA contains a growth factor domain, a kringle domain, and a protease domain.
- GFD lacks both the protease domain and kringle domain that are required for focalizing ECM degradation at the cell surface, and for uPAR interactions with anb3 integrin 8 ’ 9 , gp 130 (ref 10 ) and PAI- 1 (ref u ) that play roles in cancer metastasis (FIG. 1 A, FIG. IB, i).
- GFD by itself already has a baseline level of anti -cancer activity; treating mice with GFD fused to the Fc domain of an antibody (GFD-Fc) has been shown to reduce tumor growth in vivo 12 ’ 13 .
- GFD-uPAR complex also binds vitronectin 14 , which induces cell migration.
- GFD is predicted to be the only urokinase domain required to induce EGFR activation via formation of "the proliferasome" 15 , and downstream signaling for cell proliferation, migration, and angiogenesis. Therefore, GFD alone is a sub optimal uPAR antagonist; it inhibits a subset of uPAR functions, but activates others that facilitate cancer metastasis.
- the somatomedin B domain (SMB, amino acids 1 -44) of vitronectin binds the urokinase-uP AR complex with a cooperative affinity of 300 nM, or binds uPAR alone with a K d of ⁇ 2 pM 7 .
- SMB blocks uPAR from binding vitronectin 7 and FPR1/2 7 , and is predicted to block EGFR activation by binding the same domain required for uRAII/a ⁇ bi integrin/EGFR complex formation 16 17 (FIG. IB, ii).
- a bispecific ligand comprising GFD linked to SMB is expected to simultaneously block multiple uPAR interactions that coordinate cancer metastasis (FIG. I B, iii).
- the huPAR ligand will not inhibit mouse uPAR present on the vasculature that facilitates tumor-associated angiogenesis and tumor growth.
- Inhibiting muPAR in a syngeneic mouse model avoids these issues.
- the murine cancer cell-surface muPAR would be stimulated by endogenous mouse uPA, which when inhibited is expected to result in a more substantial and accurate response.
- the muPAR on endothelial cells facilitating tumor-associated angiogenesis will also be inhibited. Targeting muPAR activity in a syngeneic mouse model is thus expected to more accurately represent the full potential of a uPAR antagonist.
- mice GFD-SMB proteins containing a [Gly 4 Ser] 3 , [Gly 4 Ser] 4 , or [Gly 4 Ser]s linker.
- the [Gly 4 Ser] 3 linker was included as a negative control, as modeling predicts it is too short to allow GFD and SMB to simultaneously bind uPAR.
- the mouse GFD-SMB proteins were first displayed on the surface of yeast as N-terminal fusions to the aga2p yeast coat protein, and their binding affinities for soluble muPAR were measured.
- mouse GFD (mGFD) and SMB (mSMB) were also displayed and their binding affinities were measured for comparison.
- the mutant mGFD- mSMB Y2 /A ’ Y28A protein bound muPAR with the same affinity as mGFD (FIG. 6).
- the affinity of mSMB alone is too low ( ⁇ 2 mM) 7 to detect binding to muPAR using this assay, and therefore those data are not included here.
- the hGFD-hSMB and hGFD-hSMB proteins already block multiple functions of uPAR with superior affinities compared to the wild-type ligands.
- both epitopes of uPAR are available for mGFD- mSMB to bind, which will not always be the case in vivo.
- the mGFD-mSMB protein affinity will be effectively reduced to that of wild-type mouse uPA.
- muPAR is already bound to mouse uPA
- the mGFD-mSMB affinity will be effectively reduced to that of wild-type vitronectin.
- uPAR Directed evolution and characterization of the uPAR ligands was expected to require significant amounts of recombinant uPAR protein. Therefore, we established methods for producing and purifying these proteins.
- the cDNA sequences coding for soluble human and mouse uPAR were cloned into the mammalian expression vector pCEP4, and the proteins were expressed in suspension Freestyle 293 -F cells using transient transfection.
- the recombinant proteins lack amino acid G305 (huPAR) or G298 (muPAR) required for lipidation, and are thus released from the cell as soluble proteins after being exported to the extracellular space.
- huPAR and muPAR Two versions of huPAR and muPAR were expressed, one with an NH2-terminal FLAG tag as a handle for detection in vitro by a fluorescent anti -FLAG antibody, and one without. All proteins were expressed with C- terminal 6x -histidine tags as handles for purification.
- the 6x-histidine tagged huPAR and muPAR (henceforth simply called “huPAR” and “muPAR”) and the FLAG-tagged muPAR (henceforth called muPAR-FLAG”) were expressed and purified by nickel-NTA affinity chromatography followed by size exclusion chromatography (FIG. 10A). The final products were > 95-99% pure (FIG.
- Amino acids 19 - 31 in the mouse GFD protein are primarily responsible for forming the interaction between muPA and muPAR, with additional potential interactions between amino acids 39-42. Exhaustively testing every possibl e combination of amino acids in these regions using saturation mutagenesis would require a library of 1.3 c IQ 22 variants, which is far larger than the ⁇ 10 8 variant limit that can be practically screened using FACS. Therefore, we instead used error-prone PCR to make random mutations across the entire 46 amino acid sequence. In addition to exploring mutations at the binding interface, this approach also has the potential to identify mutations distal from the binding interface that have a positive allosteric effect on binding affinity, and/or that enhance the stability and expression of the protein 24 .
- the mGFD library was sorted using equilibrium binding conditions to separate variants with improved binding affinities from those with weaker affinities.
- the library was incubated with 1 nM muPAR-FLAG and approximately 50% of the binding population (10% of the library) was collected (FIG. 12).
- the purpose of the first sort round is primarily to remove the non-binding and low-binding variants and reduce the library size to a level that can be sorted at higher coverage (e.g., lOx) in the next sort.
- the library was again incubated with 1 nM muPAR-FLAG, but only 1% of the binding population was collected to increase the rate of enrichment of high- affinity variants.
- DNA isolated after the 4 th sort of the first library was mutagenized again using error-prone PCR.
- Five separate DNA libraries were generated using a range of dNTP analog concentrations and sequenced to determine which had the desired mutation frequency (FIG. 14).
- DNA from three of the libraries with averages of 3.4, 2.5, and 1.5 amino acid mutations per gene were pooled and transformed into yeast resulting in a protein library of approximately 2 x 10' variants. Preliminary analysis indicated ⁇ 20% of the library retained binding to soluble muPAR (data not shown).
- the library was sorted first using equilibrium binding conditions to reduce the library to an amenable size, and then using a kinetic off-rate screen to isolate variants with slower off-rates and thus improved binding affinities for muPAR.
- the library was incubated with 1 nM muPAR-FLAG and approximately 50% of the binding population (10% of the l ibrary) was collected (FIG. 15).
- the concentration of muPAR-FLAG was reduced to 500 pM in the next sort to increase the selective pressure for binding, and only the top 1% of the binding population was collected to further enrich for higher-affinity variants.
- the remaining library was estimated to contain around 4.5 x 10 5 unique variants, which is an amenable size to sort using a kinetic off-rate screen.
- This type of screen is used when the average affinity of the library approaches the 1 x 10 10 - to - 1 x 10 11 M range, whereafter issues with ligand depletion and the incubation times required for binding to go to completion in an equilibrium binding screen become impractical to manage.
- the library is completely saturated with muPAR-FLAG such that all surface-displayed variants are bound, and then the unbound muPAR-FLAG is thoroughly washed away and replaced with a molar excess of a "competitor" protein that renders dissociation of muP AR-FLAG from displayed variants irreversible.
- a 1, 000-fold molar excess of muPAR without a FLAG tag was used as the competitor.
- muPAR-FLAG dissociates from a displayed variant, its place is rapidly taken by the competing muPAR protein.
- the library is sorted for yeast cells expressing variants that remain bound to FLAG-muPAR by using an anti-FLAG fluorescent antibody.
- the library was incubated with 50 nM muPAR-FLAG to saturate the displayed variants. The excess unbound muPAR-FLAG was then removed and replaced with 2 mM muPAR and the library was incubated for an additional 2 hours (here called "2 hour off). Subsequently, the library was sorted for cells that had the highest percentage of displayed variants still bound to muPAR-FLAG. The incubation time with 2 mM muPAR was successively increased from 2 hours in the 3rd sort to 3 hours in the 4 th and 5 th sorts, and finally to 12 hours in the 6 th sort to increase the selective pressure for variants with improved off-rates.
- 35 clones and 10 clones were isolated from the library after the 5 th and 6 th sorts, respectively, and their DNA were sequenced to identify consensus amino acid mutations responsible for the improved binding properties.
- the library converged on a single variant, with 100% of the 10 clones isolated having identical sequences (FIG. 16B).
- the remaining variant was missing consensus mutations identified after the previous sort, and had a new mutation, R30W, that was yet to be detected in previous sequences.
- hGFD was engineered in parallel with mGFD using the same strategy Error-prone PCR was used to generate 5 separate DNA libraries of hGFD variants, and the libraries were sequenced to identify those with the desirable level of mutation (FIG 18).
- Two libraries that had an average of 1 -2 mutations per gene were pooled and transformed into yeast resulting in a protein library of - 3 c 10 ' variants. Preliminary analysis indicated approximately 30% of the library retained significant binding to soluble huPAR (data not shown).
- the hGFD library was sorted using equilibrium binding conditions to isolate variants with improved affinities for huPAR.
- the library was incubated with 1 nM huPAR and approximately 40% of the binding population (-10% of the library) was collected (FIG. 19).
- the binding population was separated into two distinct groups with different levels of expression. It’s still not clear what caused this, but we decided to continue sorting the library' nonetheless.
- Two gates were drawn to collect variants from both binding populations. The same conditions were used for the second sort, and approximately 5% of the top binding populations were collected.
- the concentration of huPAR was reduced to 500 pM and 400 pM in the 3 rd and 4 th sorts, respectively, and only the top 1% of binders were collected to increase the selective pressure and further enrich for higher-affinity variants.
- the third sort the two distinct binding populations converged and it was only possible to gate cells from the left-most population.
- Both hGFD libraries were first sorted separately using an equilibrium binding screen to reduce them to a size amenable to sorting using an off-rate screen. Each library was incubated with 1 nM huPAR and approximately 5 - 15% of the top binders were collected and combined. For sorts 2-4 the concentration of huPAR incubated with the library was reduced to 0.5 nM, 0.25 nM, and 0.15 nM respectively, and the top 0.5 - 1% of binders were collected. In the following sorts the remaining variants were subjected to an off-rate screen to further increase the selective pressure for binding.
- hGFD-Fc soluble hGFD fused to the Fc domain of an antibody
- the hGFD-Fc competitor effectively renders dissociation of huPAR irreversible, as unbound uPAR is rapidly bound by the excess hGFD-Fc.
- the library was then incubated with hGFD-Fc for an additional 24 hours and sorted for cells displaying the highest percentage of variants that remained bound to huPAR. In each sort, 0.5 - to - 1% of the top binding variants were collected. There was a noticeable increase in the amount of huPAR bound to the library between sort 5 and 6 (FIG. 21), indicating the kinetic screen successfully enriched for superior variants in the library.
- the linker-mSMB library was first sorted using an equilibrium binding screen, followed by a kinetic off-rate screen to isolate high-affinity variants.
- the library was incubated with 500 pM and 100 pM muPAR-FLAG, and the top 10% and 1% of binders were collected, respectively (FIG. 26). From the 3 rd sort onward, the variants were sorted based on their off-rates as previously described for the mGFD library- in Section 3.3.4.
- the library was incubated with 50 nM muPAR-FLAG to saturate all displayed variants.
- the variant contains a total of seven mutations, three in the linker region, and four in the SMB domain.
- K d 125 pM
- the enhanced affinity is thus likely a result of the mutations improving the linker’s proficiency to coordinate simultaneous binding of the GFD and SMB domains to muPAR. Whereas mutations that add additional binding interactions reduce the off-rate of the interaction, these mutations are effectively increasing the on-rate of the second ligand after the first has bound muPAR.
- K d 15 nM
- huPAR huPAR
- Error-prone PCR was used to generate ten separate DNA libraries with varying levels of mutation. The libraries were sequenced (FIG. 31), and seven were pooled to form an overall library with an average of 3-4 amino acid mutations per gene.
- the pooled DNA library was transformed into yeast resulting in a protein library of approximately 5 x 10 6 variants, of which only approximately 5% retained binding to soluble huPAR (data not shown). Both the library size and the percent of variants retaining huPAR binding were about 10-fold lower than desired. However, due to limited time we decided to sort the library regardless.
- the hGFD F25A -*hSMB protein contains 5 amino acid mutations total, 1 in the linker region and 4 in the SMB domain. Just as with the mGFD- *mSMB variant, none of the mutations in the hSMB domain are at the binding interface of the h SMB -huPAR interaction (FIG. 35). This suggests the amino acid mutations in hGFD-*hSMB are instead increasing the capability of both ligands to simultaneously engage huPAR. 3.4 DISCUSSION
- Yeast display was then used to enhance the individual affinities of GFD and SMB, and improve the linkers abili ty to coordinate simultaneous binding of both ligands to uPAR.
- the affinities of the human and mouse GFD proteins were improved by 30-fold, and 235- fold, respectively.
- the linker and SMB regions were then engineered as a single unit, and additional 10-fold and 6-fold improvements in affinity were achieved for the bispecific human and mouse uPAR ligands, respectively.
- bispecific proteins comprising the improved human and mouse GFD and linker-SMB domains (henceforth referred to as hGS and mGS, respectively, Table 1 and FIG 36) are thus expected to have over 1, 000-fold higher affinity for uPAR relative to the wild-type ligands, representing the highest affinity uPAR ligand developed to date that also simultaneously block multiple functions of uPAR involved in cancer metastasis.
- the numbers designating amino acid position are offset by 1 between the mouse and human proteins due to mGFD having an additional amino acid at the Fb-termimus.
- These mutations are located outside of the growth factor-like binding loop (amino acids 19 - 31) that is primarily responsible for the high-affinity interaction with uPAR. Therefore, although the interaction between the primary binding loop of uPA and uPAR has diverged significantly between the human and mouse proteins (eliminating cross reactivity between them) it appears the region in human and mouse uPAR that interacts with amino acids 37 and 41 in mGFD, and 36 and 40 in hGFD, has not. It is still possible other mutations identified in *mGFD may benefit *hGFD, and vice versa. Of particular interest i s the R30W mutation found in *mGFD that appears to dramatically improve binding affinity. Although we did not add this mutation to *hGFD, it may be worth investigating if future improvement of *hGFD is desired.
- SD-CAA media was composed of 20 g/L dextrose, 6.7 g/L yeast nitrogenous based without amino acids, 5.4 g/L Na 2 HP0 4 , 8.6 g/L NatLPQ ⁇ ILO, and 5 g/L Bacto casamino acid, pH 4.5.
- SG-CAA media was identical except for galactose replacing the dextrose, and was titrated to pH 6.0.
- YPD media contained 20 g/L dextrose, 20 g/L peptone, and 10 g/L yeast extract.
- SD-CAA plates contained 182 g/L sorbitol and 15 g/L agar in addition to the media components.
- PBS A was lx phosphate buffered saline with 1 g/L bovine serum albumin added and sterile filtered using a 0.22-micron filter
- Human and murine uPAR were expressed in Freestyle 29 -F cells (Thermo Fisher Scientific) suspension cells, and purified by nickel -NT A metal affinity chromatography followed by size exclusion chromatography.
- cDNA encoding amino acids 1-303 for huPAR and 1-296 for muPAR were cloned into the mammalian expression vector pCEP4 (Thermo Fisher Scientific) between the Hindlll and Xhol (huPAR) and Hindlll and BamHI (muPAR) restriction sites.
- the human signal peptide was used in place of the murine signal peptide for the muPAR gene.
- GCCACC Kozak sequence
- CACC Kozak sequence
- C -terminal 6x-histidine tag A separate version of the muPAR protein was expressed that contained a GGGS linker (SEQ ID NO: 16) and FLAG tag (GGGGSDYKDDDDK, SEQ ID NO: 10) between the signal peptide and L-terminus of the receptor.
- Freestyle 293F cells were transiently transfected with the expression vectors following the manufacturers protocols. Briefly, cells were grown in suspension culture at 37°C in a humidified atmosphere with 5% CO 2 in Freestyle 293 -F culture medium (Thermo Fisher Scientific) to density of
- cells were diluted to 0.5 million/mL in fresh medium, cultured overnight to a density of 1 million cells/mL, and then transfected with a DNA/polyethyleneimine mixture.
- a DNA/polyethyleneimine mixture For example, for a 0.5 L culture, 0.5 mg plasmid DNA and 1 01L of 1 g/L linear polyethyl eneimine (MW 25 kDa, Polysciences), pH 7.0 were separately diluted in 10 mL OptiPro SFM (Thermo Fisher Scientific) and incubated for 15 minutes. The DNA and PEI dilutions were then gently mixed and incubated for an additional 15 minutes, and finally added dropwise to the cell culture while mixing.
- OptiPro SFM Thermo Fisher Scientific
- the eluted protein was kept in storage buffer (lx PBS, pH 7.4, 0.1% BSA, and 10% glycerol) at concentrations of 10 mM (huPAR and muP AR-F LAG) or 100 mM (muPAR) at -80°C.
- the genes encoding human and murine GFD, SMB, and the GFD-SMB fusion proteins were generated by PCR-diiven overlap extension and used as templates for error-prone PCR. Mutations were introduced by PCR amplification of the genes in the presence of the dNTP analogs 8-oxo-dGTP and dPTP (TriLink Biotech) using low- fidelity Taq polymerase (New England Biolabs). Five separate PCR reactions were used with varying analog concentrations and PCR cycles to generate a range of mutation frequency: ten cycles with (400 pM, 200 pM, 100 pM), and twenty cycles with (80 pM, 40 pM).
- the DNA libraries were sequenced and those with the desired level of mutation (-2-5%) were combined and used to generate yeast-displayed protein libraries.
- the combined DNA libraries were PCR amplified absent dNTP analogs using primers that generate 50-base pair overlapping regions upstream and downstream of the Nhel and BamHI cloning sites in the yeast display pCTcon2 vector.
- the pCTcon2 vector was linearized by double digestion with Nhel and BamHI-HF (New England Biolabs), and the PCR amplification and double digestion products were purified by agarose gel electrophoreses on a 1% gel, extracted using a Gene Jet kit (Fisher Scientific), ethanol precipitated, and resuspended in sterile nuclease-free water.
- Yeast cells displaying variants with a range of affinities for uPAR were stratified by their equilibrium dissociation constants (K d ) or their kinetic off-rate constants (koff) and then sorted by FACS to isolate variants with superior affinities.
- the binding reaction volumes were adjusted to prevent [L]o from changing significantly throughout the reaction (i.e. to prevent ligand depletion).
- Cells were pelleted and resuspended with secondary antibodies (anti -chi cken-PE and anti-6histidine-488 for reactions with huPAR, and anti chicken-488 and anti-FLAG-PE for reactions with muPAR) at a 1 : 100 dilution in PBS A and mixed for 30 minutes at 4°C, washed with cold PBS A, pelleted, and immediately sorted by FACS.
- secondary antibodies anti -chi cken-PE and anti-6histidine-488 for reactions with huPAR, and anti chicken-488 and anti-FLAG-PE for reactions with muPAR
- cells were incubated with the indicated concentrations of uPAR required to saturate high-affmity variants for 3 hours at room temperature, after which cells were washed 3 times to remove unbound uPAR, resuspended in PBS A containing a molar excess of either muPAR or hGFD-Fc for the mouse or human uPAR ligand libraries, respectively, and incubated for the indicated times at room temperature. During the last hour, a 1 :250 dilution of chicken anti-c-myc was added to the reaction. Cells were then pelleted, washed, and labeled with secondary antibodies as described for the equilibrium binding sorts.
- the labeled yeast libraries were sorted using a BD Aria FACS instrument (Stanford FACS Core Facility) and FACSDiva software (BD biosciences).
- the number of cells sorted was between l-10x the estimated library diversity, depending on the library size and available instrument time.
- the number of cells sorted was at least lOx the estimated library diversity to ensure adequate sampling of the library diversity. Collected cells were propagated in SD-CAA and induced in SG-CAA as previously described, and subjected to additional rounds of sorting.
- plasmid DNA was extracted from the library using a Zymoprep kit (Zymo Research Corp.), transformed into DHlOb electrocompetent cells, isolated using a plasmid miniprep kit (Qiagen), and sequenced by MC Lab.
- Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-57 (2002).
- the urokinase receptor has been a target for therapeutic intervention of cancer metastasis since its discovery in 1988 1 .
- countless molecules have been developed to antagonize the cancer-promoting functions of the receptor, including small molecules, linear peptides, cyclic peptides, proteins, and antibodies, though these have failed to reach the clinic because of their insufficient efficacy in vivo, owing to their inability to effectively antagonize the urokinase receptor.
- Example 1 we outlined a strategy for creating an improved uPAR ligand that has the potential to overcome these shortfalls.
- bispecific ligands of murine and human uPAR comprising the GFD domain of urokinase and the SMB domain of vitronectin genetically fused by a 25 -amino acid [Gly- Serjs linker (mGFD-mSMB and hGFD-hSMB, respectively).
- the bi specific ligands simultaneously engage the urokinase and vitronectin binding sites of uPAR with an apparent affinity approximately 8 -fold higher than wild- type urokinase due to the avidity effects of multivalent binding.
- the affinities of the individual GFD and linker-SMB domains were enhanced using directed evolution; mGFD, and the linker-mSMB domains were improved 235 -fold and 6-fold, respectively, and the hGFD and linker-hSMB regions were improved 30-fold and 10- fold, respectively.
- Combining the evolved domains is expected to generate bispecific ligands with over 1,000-fold higher affinity for uPAR relative to the native ligands.
- the high affinity and multi -functionality of the engineered proteins thus have the potential to overcome the limitations of previously developed ligands.
- *mGFD-*mSMB and *hGFD-*hSMB proteins as fusions to the Fc domain of an antibody (henceforth referred to as hGS-Fc and mGS-Fc, respectively) to increase their molecular weight above the renal clearance cutoff of 60 kDa, and as a result extend serum half-life to approximately 24 hours in vivo.
- the human and murine GFD domains were also expressed as Fc fusion proteins (hGFD-Fc and mGFD-Fc, respectively) to include as positive controls and for comparison in these studies.
- hGS-Fc and mGS-Fc proteins bind to multiple uPAR-expressing cancer cell lines and inhibit the uPA-uPAR binding interaction. Additionally, the hGS-Fc protein demonstrates increased tumor targeting and localization in vivo compared to the hGFD-Fc control, and is also shown to internalize into cancer cells in vitro via a uPAR-dependent mechanism, thus offering exciting potential for delivery of cytotoxic agents specifically to cancer cells.
- bispecific uPAR ligands For the bispecific uPAR ligands to be effective in vivo, their concentration in the blood must be maintained at or above the level required to sufficiently inhibit uPAR function. This is problematic given the 12 kDa proteins will rapidly filter out of the blood through the kidneys with a circulating half-life of only 10-20 minutes, necessitating frequent and/or high doses to be effective. Furthermore, the proteins must be delivered intravenously or subcutaneously due to their instability in the denaturing and proteolytic environment of the gastrointestinal tract. Therefore, to avoid expensive and impractical dosing requirements, we reformatted the bi specific ligands as fusions to the fragment crystal lizable (Fc) region of the mouse IgG2a antibody.
- Fc fragment crystal lizable
- the resulting cysteine-linked dimers have molecular weights of 77 kDa for the hGS-Fc and mGS-Fc proteins, and 64 kDa for hGFD-Fc and mGFD-Fc, which are above the 60 kDa renal clearance cutoff and thus have extended serum half-lives of approximately 24 hours in vivo.
- the Fc-fusion proteins were recombinantly expressed by transient transfection of suspension Freestyle 293 cells and purified by protein A affinity chromatography, followed by size exclusion chromatography to remove undesired oligomers of the Fc domain (FIG. 37).
- the purified products were subsequently analyzed by polyacrylamide gel electrophoresis; they were of high purity and ran at the expected homodimer mol ecular weights of approximately 64 kDa and 77 kDa for the GFD-Fc and GS-Fc proteins, respectively (FIG. 38).
- the final protein yields from cell culture were 11.5 mg/L, 7.5 mg/1,, 7 mg/L and 4 mg/L for hGFD-Fc, hGS-Fc, mGFD-Fc, and mGS-Fc, respectively.
- hGS-Fc and mGS-Fc proteins are capable of inhibiting the uPA-uPAR binding interaction. Since uPA-uPAR binding is coordinated by the growth factor domain (GFD) of uPA, we displayed GFD on the surface of yeast cells as a fusion to the aga2p coat protein and measured its binding to soluble uPAR in the presence of the hGS-Fc and mGS-Fc proteins. The wild-type hGFD-Fc and mGFD-Fc proteins were also included as a positive control. All Fc fusion proteins successfully inhibited tire GFD-uPAR interaction in a typical dose-dependent manner (FIG. 39).
- the assay used required a minimum of 2 nM uPAR to obtain a signal with sufficient dynamic range to measure inhibition of uPAR binding. Since 2 nM uPAR is orders of magnitude above the K d of the engineered proteins, the binding reaction between hGS-Fc and huPAR, and mGS-Fc and muPAR were concentration-driven, rather than K d -driven, and thus accurate values for the half-maximal inhibitory concentrations (ICso) could not be determined. Regardless, these results qualitatively indicate the engineered bispecific uPAR ligands hGS-Fc and mGS-Fc inhibit the uPA-uPAR binding interaction.
- mice were injected with 1.5 nmol of either Alex a 680 fluorophore-labeled hGFD-Fc (hGFD-Fc-680) or hGS-Fc (hGS-Fc- 680), and localization of the labeled proteins was tracked via whole-body fluorescence imaging using an IVIS Lumina III in vivo imaging system.
- the hGS-Fc-680 protein Compared to the wild-type hGFD-Fc-680 control, the hGS-Fc-680 protein demonstrated enhanced tumor localization that persisted for over 3 weeks after injection (FIG. 40).
- the fluorescence signal from the uPAR-positive breast cancer tumor was divided by the signal from the uPAR-negative tumor and plotted over the course of the experiment (FIG. 41).
- the hGS-Fc-680 protein exhibited substantially higher uPAR- positive tumor specificity. These results were consistent when the experiment was repeated in two additional pairs of mice (FIG. 42).
- the engineered hGS-Fc fusion protein thus demonstrates enhanced tumor targeting and localization in vivo compared to the wild-type hGFD-Fc control. Given GFD-Fc has been shown to effectively inhibit cancer growth and metastasis in vivo 5 7 , these results suggest the engineered hGS-Fc protein may demonstrate more significant efficacy in vivo.
- hGFD-680 As with the Fc-fusion proteins, 1.5 nmol of Alexa 680-1 abeled hGFD (hGFD-680) and hGS (hGS-680) were injected into mice with uPAR-positive MDA-MB- 231 and uPAR-negative HEK 293T tumors in their left and right shoulders, respectively. As expected, both proteins rapidly cleared from circulation through the kidneys (FIG.
- hGS-Fc-680 Given the prolonged tumor accumulation of hGS-Fc-680 observed in vivo , we suspected the protein may be internalizing into cancer cells following uPAR binding.
- the hGS-Fc protein was actually designed to inhibit active uPAR internalization; after formation of the uPA-uPAR complex, pl asminogen activator inhibitor 1 (P AI- 1 ) binds to the protease domain of uPA, and PAI-1 is then bound by the low-density lipoprotein receptor-related protein (LRP1) 8 , which drives internalization of the entire protein assembly 9,10 , degradation of PAI-1 -uP A in the lysosome 9 , and recycling of uPAR back to the cell surface 11 .
- P AI- 1 pl asminogen activator inhibitor 1
- LRP1 low-density lipoprotein receptor-related protein
- hGS-Fc-uPAR complex may still be internalized passively given uPAR’s localization at focal adhesion sites 13 , where various adhesion receptors such as integrins are constantly internalized and recycled to the cell surface 14 . Intemalization of the hGFD-Fc and hGS-Fc proteins was confirmed in vitro.
- Human breast cancer (MDA-MB-231) cells were incubated with Alexa 488-labeled hGS- Fc (hGS-Fc -488) and hGFD-Fc (hGFD-Fc-488) for 15 hours, harvested by non- enzymatic cell dissociation, and incubated with an anti -Alexa 488 antibody that quenches extracellular Alexa 488 fluorescence (FIG. 44 A). The cells were then analyzed by flow cytometry to detect the presence of intracellular hGFD-Fc-488 or hGS-Fc-488. Both proteins internalized into the cancer cells (FIG. 44B).
- the engineered protein may also be an effective vehicle for intracellular delivery of cytotoxic agents specifically to cancer cells in vivo, which may further increase the efficacy of the hGS-Fc protein for inhibiting cancer growth and metastasis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ligands of the urokinase receptor and methods of treating, detecting, and imaging cancer with such ligands are disclosed. In particular, the invention relates to a ligand comprising a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin that binds with high affinity to the urokinase receptor. Urokinase receptor-targeted imaging agents can be produced by conjugation of such ligands of the urokinase receptor to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of tumors that overexpress the urokinase receptor.
Description
LIGANDS OF THE UROKINASE RECEPTOR AND THEIR USE IN TREATING, DETECTING, AND IMAGING CANCER
CROSS REFERENCE
This application claims the benefit of United States Provisional Application No.
62/635,509, filed February 26, 2018, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with government support under contracts CA186478 and 1176631-1-PAECO awarded by the National Institutes of Health. The government has certain rights in the invention.
TECHNICAL FIELD
The present invention pertains generally to anti-cancer therapeutics and cancer diagnostic agents and methods of treating, detecting, and imaging cancer. In particular, the invention relates to engineered ligands that bind to the urokinase receptor and methods of treating, detecting, and imaging cancer using such ligands. BACKGROUND
Approximately 90% of cancer-related deaths are a result of cancers reaching the metastatic stage, where cells from the primary tumor begin to migrate through the vasculature and form new tumors throughout the body. Once cancers reach this stage, the available treatment options are scarce and largely ineffective, and as a result the median survival time for patients is on the order of 1-2 years. There is thus a dire need for therapies that specifically target the mechanisms of metastasis to reduce the mortality caused by this disease.
SUMMARY
The invention relates to engineered ligands that bind to the urokinase receptor and methods of treating, detecting, and imaging cancer using such ligands.
In one aspect, the invention includes a ligand of a urokinase receptor (uPAR) comprising a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin.
In certain embodiments, the ligand further comprises a linker connecting the GFD to the SMB domain. In some embodiments, the linker is about 40 to about 50 angstroms in length.
In another embodiment, the linker comprises a sequence selected from the group consisting of SEQ ID NO: l 1, SEQ ID NO: 14, and SEQ ID NO: 15, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence i dentity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor. In certain embodiments, the linker comprises at least one amino acid substitution selected from the group consisting of S5N, S10G,
G12R, and G19S, and wherein positions of the amino acids are numbered relative to the reference linker sequence of SEQ ID NO: 11.
In certain embodiments, the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of R30W, K37G, K37R,
Q39R, E41K, E41R, and H42Y, and wherein positions of the amino acids are numbered relative to the reference murine GFD sequence of SEQ ID NO: 1. In one embodiment, the GFD comprises the R30W, K37R, Q39R, E41R, and H42Y amino acid substitutions.
In other embodiments, the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R, and wherein positions of the amino acids are numbered relative to the reference human GFD sequence of SEQ ID NO:3. In one embodiment, the GFD comprises the L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R amino acid
substitutions.
In certain embodiments, the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DIN, E3G, MT4V, and K17E, and wherein positions of the amino acids are numbered relative to the reference murine SMB domain sequence of SEQ ID NO:5. In one embodiment, the SMB domain comprises the DIN, E3G, M14V, and K17E amino acid substitutions.
In other embodiments, the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DI G, E3G, K18E, and P41S, and wherein positions of the amino acids are numbered relative to the reference human SMB domain sequence of SEQ ID NO:7. In one embodiment, the SMB domain comprises the DIG, E3G, K18E, and P41 S amino acid substitutions.
In certain embodiments, the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12 and SEQ ID NO: 13, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding and/or inhibiting the urokinase receptor.
In certain embodiments, the ligand further comprises an immunoglobulin Fc domain covalently linked to the fusion protein. The immunoglobulin Fc domain may be derived from an IgG (e.g., IgGl, IgG2, IgG3, or lgG4), IgM, IgE, IgA or IgD, or a combination or hybrid thereof. In one embodiment, the Fc fragment is derived from an IgG2a immunoglobulin. In another embodiment, the Fc domain is derived from a human IgGl isotype. The immunoglobulin Fc domain may be linked for example, to the N- terminal or C -terminal end of the fusion protein. In certain embodiments, the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-20; or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor.
In certain embodiments, the ligand further comprises an anti-cancer therapeutic agent conjugated to the fusion protein. The anti-cancer therapeutic agent may include, but is not limited to, a cytotoxic agent, a drug, a toxin, a nuclease, a hormone, an
immunomodulator, a pro-apoptotic agent, an anti-angiogenic agent, a boron compound, a photoactive agent, and a radioisotope. In another embodiment, a composition for use in the treatment of cancer is provided comprising the ligand, wherein the anti-cancer therapeutic agent is conjugated to the fusion protein.
In another embodiment, the fusion protein further comprises a signal peptide (e.g., a urokinase signal peptide).
In another embodiment, the fusion protein further comprises a tag or detectable label.
In another aspect, the invention includes a composition for use in the treatment of cancer comprising a ligand of a urokinase receptor described herein. In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient. In another embodiment, the composition further comprises one or more other anti-cancer therapeutic agents, such as, but not limited to, ch emotherapeuti c,
immunotherapeutic, or biologic therapeutic agents.
In another aspect, the invention includes a method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a ligand of a urokinase receptor described herein. Multiple cycles of treatment may be administered to a subj ect. In certain embodiments, the ligand is admini stered according to a daily dosing regimen or intermittently. Preferably, the ligand is administered for a time period sufficient to efFect at least a partial tumor response, and more preferably a complete tumor response in the subject.
A ligand of a urokinase receptor may be administered by any suitable mode of administration. In certain embodiments, the ligand is administered intravenously, subcutaneously, or intralesionally to a subject. In another embodiment, the ligand is administered locally at a site of a tumor or cancerous cells in the subject.
In another embodiment, the method further comprises performing surgery, radiation therapy, chemotherapy, immunotherapy, or biologic therapy, or a combination thereof.
In another aspect, the invention includes a kit comprising a pharmaceutical composition compri sing a ligand of a urokinase receptor and instructions for treating cancer. The kit may further comprise means for delivering the composition to a subject.
In another aspect, the invention includes a urokinase receptor-targeted imaging agent comprising a ligand of the urokinase receptor described herein conjugated to a diagnostic agent. The diagnostic agent can be, for example, an isotopic label, a fluorescent label, a chemiluminescent label, a bioluminescent label, a paramagnetic ion, an enzyme, a contrast agent (e.g., ultrasound contrast agent, a magnetic resonance imaging (MRI) contrast agent, or a radiocontrast agent), or a photoactive agent.
Exemplary' fluorescent labels include fluorescein derivatives, rhodamine derivatives, coumarin derivatives, cyanine derivatives, acridine derivatives, squaraine derivatives, naphthalene derivatives, oxadiazol derivatives, anthracene derivatives, pyrene derivatives, oxazine derivatives, arylmethine derivatives, and tetrapyrrole derivatives. Alternatively, the fluorescent label may comprise a fluorescent protein, such as, but not limited to, a green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, rsCherry, and rsCherryRev.
Isotopic labels may comprise radioactive isotopes (e.g., gamma-emitters, beta- emitters, and positron-emitters) or non-radioactive isotopes (e.g., stable trace isotopes), such as, but not limited to, ¾, 2H,1 20I, 123I, 124I, l25I, 131I, 35S, nC, 13C, 14C, 32P , 15N, 13N, 1 10In, mIn, 177LU, 18F, 52Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 86Y, 90Y, 89Zr, 94mTc, 94Tc, 99mTc, 154Gd, 155Gd, 156Gd, 1S7Gd, 1 58Gd, lsO, 186Re, 188Re, 51M, 52mMn, 55Co, 72As, 75Br,
76Br, 8 mRbj and 83 Sr
Exemplary paramagnetic ions include chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium
(III), gadolinium (III), vanadium (II), terbium (ill), dysprosium (III), holmium (ill) and erbium (IP).
In another embodiment, the invention includes a urokinase receptor-targeted imaging agent comprising a ligand of a urokinase receptor, described herein, conjugated to a contrast agent. For example, the contrast agent may be an ultrasound contrast agent (e.g., a microbubble), a magnetic resonance imaging (MRI) contrast agent, or a radi ocontrast agent.
In another aspect, the invention includes a method of detecting cancer, the method comprising: a) administering a detectably effective amount of a urokinase receptor- targeted imaging agent, described herein, to a patient suspected of having cancer, under conditions wherein the urokinase receptor-targeted imaging agent binds to urokinase receptors present on tumors or cancerous cells, if present, in the patient; and b) detecting the urokinase receptor-targeted imaging agent bound to the tumors or cancerous cells, if present, by imaging tissue of the patient.
In certain embodiments, imaging of tissue is performed using a method selected from the group consisting of ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), and fluorescence imaging.
The methods of the invention can be used for determining the prognosis of the patient. Detection of a precan cerous lesion indicates the patient is at risk of developing cancer. Detection of increased levels of the urokinase receptor on the surface of tumors or cancerous cells is associated with tumor growth and cancer progression.
In another aspect, the invention includes a method of imaging tissue of a patient suspected of having cancer, the method comprising: a) contacting tissue of the patient with a detectably effective amount of a urokinase receptor-targeted imaging agent described herein under conditions wherein the urokinase receptor-targeted imaging agent binds to urokinase receptors present on tumors and cancerous cells, if present in the tissue; and b) imaging the tissue of the patient, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient compared to a
control indicates that the patient has cancer. The tissue may he contacted with the urokinase receptor-targeted imaging agent either in vivo or in vitro.
In certain embodiments, imaging of tissue is performed using a method selected from the group consisting of ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), and fluorescence imaging.
In another aspect, the invention includes a method of monitoring progression of cancer in a patient, the method comprising: imaging tissue of the patient according to a method described herein, wherein a first image is obtained at a first time point and a second image is obtained later at a second time point, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is worsening, and detecti on of decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is improving. Increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient may be caused, for example, by growth of a tumor or the presence of more tumors or cancerous cells at the second time point, which can be determined by inspection of the images. Alternatively, decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient may be caused, for example, by tumor shrinkage or the presence of fewer tumors or cancerous cells.
In another aspect, the invention includes a method for evaluating the effect of an agent for treating cancer in a patient, the method comprising: imaging tissue of the patient according to a method described herein before and after the patient is treated with the agent, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from tumor growth or increase in number of tumors or cancer cells) after the patient is treated with the agent compared to before the patient is treated with the agent indicates that the patient is worsening, and decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from reduction in tumor size or reduction in the number of cancer cells) after the subject
is treated with the agent compared to before the patient is treated with the agent indicates that the patient is improving.
A method for monitoring the efficacy of a therapy for treating cancer in a patient, the method comprising: imaging tissue of the patient according to a method described herein before and after the subject undergoes said therapy, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from tumor growth or increase in number of tumors or cancer cells) after the patient undergoes said therapy compared to before the patient undergoes said therapy indicates that the patient is worsening, and decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient (e.g., from reduction in tumor size or reduction in the number of cancer cells) after the patient undergoes said therapy compared to before the patient undergoes said therapy indicates that the patient is improving.
In another aspect, the invention includes a method of treating a patient suspected of having cancer, the method comprising: a) receiving information regarding whether or not cancer was detected in the patient using a urokinase receptor-targeted imaging agent according to a method described herein; and b) administering anti-cancer therapy to the subject if cancer was detected in the patient. In certain embodiments, the anti -cancer therapy comprises surgery, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy, or any combination thereof.
In another embodiment, the invention includes a method of using a urokinase receptor-targeted imaging agent comprising a fluorescent label for fluorescence imaging of cancerous cells, the method comprising: a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the fluorescent label, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor-targeted imaging agent; b) illuminating the cell with light at a fluorescence excitation wavelength of the fluorescent label; and c) recording a fluorescence image of the cancerous cells by detecting fluorescence emitted by the fluorescent label of the urokinase receptor-targeted imaging agent. Fluorescence images may be visualized, for example, with a fluorescence microscope, a fiber-optic fluorescence imaging system, or a medical fluorescence
imaging device, such as a miniaturized medical imaging system (e.g., a handheld microscope, a laparoscope, an endoscope, or a microendoscope).
In another embodiment, the invention includes a method of using a urokinase receptor-targeted imaging agent comprising a bioluminescent label for bioluminescence imaging of cancerous cells, the method comprising: a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the bioluminescent label, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor- targeted imaging agent; b) contacting the cancerous cells with a chemiluminescent substrate; and c) recording a bioluminescence image of the cancerous cells by detecting bioluminescence emitted from the bioluminescent label of the urokinase receptor-targeted imaging agent.
In another aspect, the invention includes a kit comprising an imaging agent comprising a ligand of a urokinase receptor and instructions for imaging cancer. The kit may further comprise means for delivering the composition to a subject.
In another aspect, the invention includes a recombinant polynucleotide compri sing a promoter operably linked to a polynucl eotide encoding a ligand of a urokinase receptor described herein. In another embodiment, the recombinant polynucleotide is provided by a vector such as a bacterial plasmid vector or a viral expression vector. Exemplary viral vectors include adenovirus, retrovirus (e.g., g- retrovirus and lenti virus), poxvirus, adeno-associated virus, baculovirus, or herpes simplex virus vectors. In another embodiment, the invention includes a host cell or host subject comprising the recombinant polynucleotide.
In another embodiment, the invention includes a method for producing a ligand of a urokinase receptor, the method comprising: a) transforming a host cell with a recombinant polynucleotide comprising a promoter operably linked to a polynucleotide encoding a ligand of a urokinase receptor described herein; b) culturing the transformed host cell under conditions whereby the ligand of the urokinase receptor is expressed; and c) isolating the ligand of the urokinase receptor from the host cell.
In another embodiment, the invention includes a method for producing a ligand of a urokinase receptor in a host subject, the method comprising introducing into the host
subject a recombinant polynucleotide comprising a promoter operably linked to a nucleotide sequence encoding the ligand of the urokinase receptor, wherein the ligand of the urokinase receptor is expressed in the host subj ect in an amount sufficient to inhibit the urokinase receptor and/or have anti-tumor activity in the subject.
In another aspect, the invention includes a method for treating cancer compri sing administering to a subject in need thereof a therapeutically effective amount of a recombinant polynucleotide comprising a promoter operably linked to a nucleotide sequence encoding the ligand of the urokinase receptor.
These and other embodiments of the subject invention will readily occur to those of skill in the art in view of the disclosure herein.
BRIEF DESCRIPTION OF THE FIGURES
FIGS. 1A and IB show the strategy for developing a bispecific (i.e., biepitopic) ligand that binds different domains of uPAR. FIG. 1 A shows that uPAR is a key regulator of numerous biological processes that drive cancer growth and metastasis. Binding of the soluble ligand uPA to uPAR localizes ECM degradation at the cell surface and uPAR- driven cancer growth and metastasis via pathways 1 -7. uPAR also binds vitronectin in the absence of uPA (pathway 8), facilitating migration and metastasis. FIG. 1B shows our approach to target uPAR-driven cancer growth and metastasis: i) The growth factor domain (GFD) of uPA binds uPAR and blocks localized ECM degradation and pathways 3, 5, and 6 in panel A, but not pathways 2, 4, 7, and 8. ii) SMB binds uPAR and blocks pathways 4, 7, and 8, and is expected to block 2, but not 3, 5, and 6, and ECM
degradation iii) GFD and SMB simultaneously bind uPAR, and will be linked together to form a high affinity bispecific ligand that simultaneously blocks multiple uPAR-mediated processes driving cancer growth and metastasis.
FIG. 2 shows modeling the GDF-SMB fusion protein with a 4x(GGGGS) amino acid linker. The GFD domain of uPA and the SMB domain of vitronectin are shown genetically fused by a 20-amino acid linker comprising four GGGGS (SEQ ID NO: 9) repeats (black), and simultaneously bound to uPAR. Three different possible orientations of the l inker are shown from multiple views of the complex to indicate the presence or
absence of potential steric clash between the linker and proteins. The figures were generated by editing data from PDB 3BT1 (Huai et al (2008) Nat. Struct. Mol Biol. 15, 422-423) using IJCSF chimera molecular viewing software (Pettersen et al. (2004) J. Comput. Chem. 25, 1605-1612).
FIG. 3 shows modeling the GDF-SMB fusion protein with a 5x(GGGGS) amino acid linker (SEQ ID NO: 11). The GFD domain of uPA and the SMB domain of vitronectin are shown genetically fused by a 25-amino acid linker comprising four GGGGS repeats (black), and simultaneously bound to uPAR. Three different possible orientations of the linker are shown from multiple views of the complex to indicate the presence or absence of potential steric clash between the linker and proteins. The figures were generated by editing data from PDB 3BT1 (Huai et al., supra) using UCSF chimera molecular viewing software (Pettersen et al., supra).
FIG. 4 shows equilibrium binding titrations of three different yeast-displayed mGFD-mSMB fusion protein designs to soluble muPAR. Three different mGFD-mSMB designs containing either a 3x, 4x, or 5x GGGGS linker (SEQ ID NO: 11) bridging the GFD and SMB domains were displayed on the surface of yeast and their binding affinities for uPAR were compared. Binding reactions were incubated at room
temperature for 24 hours and analyzed by flow cytometry. The mGFD-mSMB fusion protein with the 5x(GGGGS) linker (henceforth simply referred to as "mGFD-mSMB) had the highest affinity for muPAR, indicating the 5x(GGGGS) linker is the most optimal of the three tested.
FIG. 5 shows equilibrium binding titrations of yeast-displayed mGFD and mGFD-mSMB to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values are 1.83 nM and 0.22 nM for mGFD and mGFD-mSMB, respectively. These data indicate the bispecific mGFD- mSMB fusion protein has approximately 8.3-fold higher affinity for muPAR compared to the wild type mGFD ligand.
FIGS. 6A and 6B show analyses of specific amino acids driving the enhanced affinity of the mGFD-mSMB fusion protein for muPAR. FIG. 6A shows a structural representation of the binding interaction between the SMB domain of mGFD-mSMB and
muPAR. The mouse SMB structure has not been solved; therefore, the human proteins are shown here as an example. Amino acids Y27 and Y28 (grey sticks) in SMB form the specific binding interaction with uPAR (Deng, et al. (1996) J. Biol. Chem. 271 , 12716- 12723; Deng et al. (1996) J. Cell Biol. 134, 1563-1571; and Okumura et al. (2002) J.
Biol. Chem. 277, 9395-9404). The linker fusing GFD and SMB is shown in black. FIG. 6B shows amino acid mutations Y27A and Y28A in SMB abolishes its affinity for uPAR. As expected, these mutations effectively render the affinity of mGFD-mSMB
approximately equal to that of mGFD for muPAR. The figure was generated using data from the PDB file 3BT1 (Huai et al., supra).
FIG. 7 shows a structural alignment of the mouse GFD -uPAR complex with the human GFD-uPAR-SMB complex. The structure of human uPAR bound to hGFD and hSMB is shown aligned to the structure of mouse uPAR bound by mGFD. The figure was generated using data from PDB files 3BT1 (Huai et al., supra) and 3LAQ (Lin et al. (2010) J. Biol. Chem. 285, 10982-1092) and UCSF chimera molecular viewing software (Pettersen et al., supra).
FIG. 8 shows equilibrium binding titrations of yeast-displayed hGFD and the hGFD-hSMB fusion protein to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values are 1.04 nM and 0.12 nM for hGFD and hGFD-hSMB, respectively. These data indicate the bispecific hGFD-hSMB fusion protein has approximately 8.7-fold higher affinity for huPAR compared to the wild type hGFD ligand.
FIGS. 9A and 9B show analyses of specific amino acids driving the enhanced affinity of the hGFD-hSMB fusion protein for uPAR. FIG. 9 A shows a structural representation of the binding interaction between the SMB domain of hGFD-hSMB and huPAR. Amino acids Y27 and Y28 (grey sticks) in SMB form the specific binding interaction with huPAR. The linker fusing hGFD and hSMB is shown in black. FIG. 9B shows that amino acid mutations Y27A and Y28A in SMB abolish its affinity for uPAR. As expected, these mutations effectively render the affinity of hGFD-hSMB equal to that of hGFD for huPAR. These data indicate the superior uPAR binding of hGFD-hSMB compared to hGFD alone is due to the additional interactions between amino acids Y27
and Y28 of SMB and uPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
FIGS. 10 A and 10B show the purification of soluble recombinant uPAR proteins. FIG. 10A shows chromatograms of huPAR, muPAR, and muPAR-FLAG purified by FPLC on a Superdex 75, 10/300 GL column. Proteins were diluted and run in PBS, pH 7.4 buffer at 0.4 mL/min. Collected fractions are highlighted in gray. FIG. 10B shows an analysi s of proteins collected after FPLC. Proteins were analyzed by 4-12%
polyacrylamide gel electrophoresis run at 140 V for 55 minutes, and subsequently stained with Coomassie blue. Lanes contain, from left to right: huPAR, muPAR, muPAR-FLAG, and Kaleidoscope protein ladder.
FIG. 11 shows amino acid sequence alignment of mGFD variants from 5 separate DNA libraries. 10 sequences from each of 5 separate mGFD DNA libraries are shown arranged by library from high-to-low mutation frequency. The wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
FIG. 12 shows sort progression of mGFD library 1. Four rounds of FACS were used to isolate high affinity variants from the first mGFD library. Equilibrium binding screens were used to perform all sorts. Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 2 and 3, and by collecting a smaller percentage of the top binding variants in each successive sort. The gates used to select variants are shown, along with the percentage of the expressing population collected.
FIGS. 13A and 13B show analyses of mGFD library 1 after sort 4. FIG. 13A shows an amino acid sequence alignment of 20 mGFD variants after sort 4. The wild- type mGFD sequence is highlighted in light gray, and mutations are highlighted with colored squares. FIG. I3B shows equilibrium binding titrations of yeast-displayed mGFD and the bulk mGFD library after sort 4 to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd of mGFD is 3.89 nM, and the apparent Kd of the library is 1.52 nM. These data indicate the first round of directed evolution generated marginally improved mGFD variants.
FIG. 14 shows amino acid sequence alignment of mGFD library 2 variants. DNA from the mGFD library 1 variants remaining after the 4th sort was mutagenized using error-prone PCR for a subsequent round of directed evolution. Five separate DNA libraries were generated with varying mutation frequency, and 10 sequences from three of the libraries are shown here aligned to the wild-type mGFD sequence. Sequences are arranged by library (1, 3, and 5) from top to bottom, with libraries 1 and 5 having the highest and lowest mutation frequency, respectively. The wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
FIG. 15 shows sort progression of mGFD library 2. Six rounds of FACS were used to isolate high affinity variants from the second mGFD library. Sorts 1 -2 were performed using equilibrium binding screens with the indicated concentrations of soluble muPAR, and sorts 3-6 were performed using kinetic off rate screens. Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 1 and 2, or by increasing the‘off" time in sorts 3-6, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select variants are shown, along with the percentage of the expressing population collected.
FIGS. 16A and 16B show sequence analyses of mGFD library 2 after sorts 5 and 6. Amino acid sequence alignment of (FIG. 16A) 35 mGFD variants isolated after sort 5, and (FIG. 16B) 10 mGFD variants isolated after sort 6. The wild-type mGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
FIGS. 17A and 17B show analyses of the engineered *mGFD protein generated by directed evolution . FIG. 17A shows equilibrium binding titrations of yeast-displayed wild-type mGFD and the engineered *mGFD protein to soluble muPAR. Binding reactions were incubated at room temperature for 48 hours and analyzed by flow cytometry. The Kd values of mGFD and *mGFD are 2.11 nM and 0 009 nM, respectively. These data indicate directed evolution of the mGFD protein successfully generated a variant with 235 -fold higher affinity for muPAR. FIG 17B shows amino acid mutations in *mGFD mapped onto the wild-type mGFD-muPAR complex. mGFD and muPAR are shown in green and blue ribbon, respectively. Side chains of the five amino
acids mutated in *mGFD are show as red spheres. The figure was generated using data from PDB file 3LAQ28 and UCSF chimera molecular viewing software (Pettersen et al., supra).
FIG. 18 shows amino acid sequence alignment of hGFD variants from 5 separate DNA libraries.10 sequences from each of 5 separate hGFD DNA libraries with varying levels of mutation frequency are shown arrange from high to low mutation frequency.
The wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
FIG. 19 shows sort progression of hGFD library 1. Four rounds of FACS were used to isolate high affinity variants from the first hGFD library. Equilibrium binding screens were used to perform all sorts. Selective pressure for improved variants was increased by reducing the concentration of huPAR incubated with the library between sorts, and by collecting a smaller percentage of the top binding variants in each successive sort. The gates used to select variants are shown, along with the percentage of the expressing population collected.
FIGS. 20A and 20B show analyses of hGFD library 1 variants remaining after the 4th sort. FIG. 20A shows an amino acid sequence alignment of 20 hGFD library 1 variants isolated after the 4th sort. The wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color. FIG. 20B shows equilibrium binding titrations of yeast-displayed hGFD variants and wt hGFD to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values are: wt mGFD = 0.43 nM, mGFDK46R = 0.32 nM, mGFDDMG = 0.2 nM, mGFDD14G,K48R =: 0.13 nM. These data indicate the first round of directed evolution generated marginally improved hGFD variants.
FIG. 21 shows sort progression of hGFD library 2. Six rounds of FACS were used to isolate high affinity variants from the second hGFD library. For the first sort, two libraries were sorted separately and the collected variants were combined for subsequent sorts. Sorts 1 -4 were performed using equilibrium binding screens with the indicated concentrations of soluble huPAR, and sorts 5-6 were performed using kinetic off rate screens. Selective pressure for improved variants was increased by reducing the
concentration of huPAR incubated with the library between sorts, or by increasing the "off time in sorts 5-6, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select variants are shown, along with the percentage of the expressing population collected.
FIGS. 22A and 22B show sequence analyses of the hGFD library 2 after sorts 4 and 6. Amino acid sequence alignments of (FIG. 22A) 10 hGFD variants isolated after sort 4, and (FIG. 22B) 40 hGFD variants isolated after sort 6. The wild-type hGFD sequence is shown at top, and mutations in the variants below are highlighted in color.
FIGS. 23 A and 23B show analyses of hGFD Library 2 variants after sort 6. FIG. 23 A shows an amino acid sequence alignment of seven hGFD variants isolated after sort 6 to wild type hGFD. FIG. 23B shows kinetic dissociation of soluble huPAR from the yeast-displayed hGFD library 2 variants listed in panel A as a function of incubation time. Samples were incubated at room temperature for the indicated time and analyzed by flow cytometry. The hGFD L2.S6.15 variant (henceforth referred to as *hGFD, FIG. 45) displayed marginally slower dissociation kinetics than all other variants.
FIGS. 24 A and 24B show an analysis of the engineered *hGFD protein generated by directed evolution. FIG. 24A show equilibrium binding titrations of yeast-displayed wild-type hGFD and the engineered *hGFD protein to soluble huPAR. Binding reactions were incubated at room temperature for 48 hours and analyzed by flow cytometry. The Kd values of hGFD and *hGFD are 0.843 nM and 0.028 nM, respectively. These data indicate directed evolution of the hGFD protein successfully generated a variant with 30- fold higher affinity for huPAR. FIG. 24B shows amino acid mutations in *hGFD mapped onto the wri ld-type hGFD-huPAR structure. Side chains of mutated amino acids in *hGFD are show as spheres. The figure wasgenerated using data from PDB file 3BT119 and UCSF chimera molecular viewing software.
FIG. 25 shows an amino acid sequence alignment of linker-mSMB variants from 5 separate DNA libraries. 10 sequences from each of 5 separate linker-mSMB DNA libraries with varying levels of mutation frequency are shown arranged by library from high to low mutation frequency. The wild-type linker-mSMB sequence is shown at top, and mutations in the variants below are highlighted in color. Libraries were generated in
the context of the mGFD-mSMB fusion protein. The sequence of the adjoining mGFD region was not mutated, and is omitted here for clarity.
FIG. 26 shows a sort progression of the Hnker-mS MB library. Six rounds of FACS were used to isolate high affinity variants from the linker-mSMB library. Sorts 1-2 were performed using equilibrium binding screens with the indicated concentrations of soluble muPAR, and sorts 3-6 were performed using kinetic off rate screens. Selective pressure for improved variants was increased by reducing the concentration of muPAR incubated with the library between sorts 1 and 2, or by increasing the "off" time between sorts 3-6, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select variants are shown, along with the percentage of the expressing population collected.
FIG. 27 shows a sequence analysis of the linker-mSMB library after sort 6. The amino acid sequence alignment of 10 linker-mSMB variants isolated after sort 6 is shown. The wild-type linker-mSMB sequence is shown at the top, and mutations in the variants below are highlighted in color.
FIG. 28 shows equilibrium binding titrations of the yeast-displayed mGFD- mSMB protein and the evolved mGFD-*mSMB protein to soluble muPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values of mGFD-mSMB and the evolved mGFD-*mSMB are 0.751 nM and 0.126 nM, respectively. These data indicate directed evolution of the linker- mSMB region of the mGFD-mSMB fusion protein successfully generated a variant with 6-fold higher affinity for muPAR.
FIG. 29 shows amino acid mutations in mGFD-*mSMB mapped onto the human GFD-SMB-uPAR structure. The structure of the murine SMB has not been solved. Therefore, mutations in the linker and SMB domain of the mGFD-*mSMB protein are shown here mapped onto the human GFD-SMB-uPAR complex. GFD and SMB are shown fused by a 25 -amino acid linker (black). The seven amino acid mutations in the mGFD-*mSMB protein are shown as dark spheres. The figure was generated using data from PDB files 3BT1 and UCSF chimera molecular viewing software.
FIG. 30 shows equilibrium binding titrations of a yeast-displayed hGFD-hSMB and hGFDF25A-hSMB to soluble muPAR. A single F25A amino acid mutation in the growth factor-like binding loop of hGFD (hGFDFi5A) reduces the overall affinity of the hGFD-hSMB fusion protein for huPAR by over two orders of magnitude (Kd = 15 nM). Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry.
FIG. 31 shows amino acid sequence alignment of linker-hSMB variants from 1 of 5 separate DNA libraries. 5 separate linker-hSMB DNA libraries with varying levels of mutation frequency were generated using error-prone PCR. Sequences of 10 variants from the library with the highest mutation frequency are shown. Libraries were generated in the context of the hGFDF25A-hSMB fusion protein. The sequence of the adj oining hGFDF2:,A region was not mutated, and is omitted here for clarity. The wild-type linker- hSMB sequence is shown at top, and mutations in the variants below are highlighted in color.
FIG. 32 shows sort progression of the linker-hSMB library. Five rounds of FACS were used to isolate high affinity variants from the linker-hSMB library. All sorts were performed using equilibrium binding screens with the indicated concentrations of soluble huPAR. Selective pressure for improved variants was increased by sequentially reducing the concentration of muPAR incubated with the library between sorts, and by collecting a smaller percentage of the top binding variants in successive sorts. The gates used to select vari ants are shown, along with the percentage of the expressing population collected.
FIGS. 33A and 33B show analysis of linker-hSMB library variants remaining after the 5th sort. FIG. 33 A shows an amino acid sequence alignment of 10 linker-hSMB library' variants isolated after the 5th sort. The wild-type linker-hSMB sequence is shown at top, and mutations in the variants below are highlighted in color. FIG. 33B shows equilibrium binding titrations of the two yeast-displayed linker-hSMB variants identified after the 5th sort to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values were essentially equal for both variants, 0.49 nM for L1.S6.5, and 0.42 nM for L1.S6.1 (henceforth referred to as hGFDF25A-*hSMB).
FIG. 34 shows equilibrium binding titrations of the yeast-displayed hGFDF25A- hSMB and the evolved hGFDF25A-*hSMB protein to soluble huPAR. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. The Kd values of hGFDF25A-hSMB and the evolved hGFDF25A-*hSMB are 7.10 nM and 0.68 nM, respectively. These data indicate directed evolution of the linker-hSMB region of the hGFD-hSMB fusion protein successfully generated a variant with 10-fold higher affinity for huPAR.
FIG. 35 shows amino acid mutations in hGFD-*hSMB mapped onto the wild type human GFD-SMB-uPAR structure. hGFD and hSMB are shown fused by a 25-amino acid linker (black). Side-chains of the 5 amino acid mutations in hGFD-*hSMB are shown as dark spheres (absent in the case of mutations to glycine). Three additional amino acids (ALA) belonging to the signal peptide of SMB were mistakenly included at the ML-terminus of the SMB domain in the library. These were later removed and the affinity for uPAR was unchanged (data not shown). Therefore, for future consistency these amino acids are omitted from the sequence here; the 5x(GGGGS) linker (SEQ ID NO: 11) ends at S73, and the SMB domain begins at D74 The figure was generated using data from PDB files 3BT119 and UCSF chimera molecular viewing software.
FIG. 36 shows amino acid mutations in the engineered *hGFD-*hSMB (hGS) and *mGFD-*mSMB (mGS) bispecific uPAR ligands mapped onto the wild type human GFD-SMB-uPAR structure. Proteins domains in the mGS-uPAR structure (left) and hGS-uPAR structure (right) are colored as in FIGS. 29 and 35, respectively. Side-chains of amino acid mutations are shown as dark spheres (absent in the case of mutations to glycine). The figure was generated using data from PDB files 3BT119 and UCSF chimera molecular viewing software.
FIGS. 37A-37D show the purification of soluble recombinant Fc-fusion proteins by FPLC. Chromatograms are shown of mGFD-Fc (FIG. 37A), mGS-Fc (FIG. 37B), hGFD-Fc (FIG. 37C), and hGS-Fc (FIG. 37D) purified by FPLC on a Superdex 200 increase, 10/300 GL column. Proteins were suspended and run in PBS, pH 7.4 buffer at 0.4 mL/min. Collected fractions are highlighted in gray.
FIGA. 38A and 38B show analyses of Fc-fusion proteins collected after purification by FPLC. Proteins were analyzed by 4-12% polyacrylamide gel
electrophoresis run at 140 V for 55 minutes, and subsequently stained with SimplyBlue Safestain. Lanes contain, from left to right: (FIG. 38 A) mGFD-Fc, mGS-Fc, Novex Sharp protein ladder, and (FIG. 38 B) hGFD-Fc, hGS-Fc, Kaleidoscope protein ladder.
FIGS. 39A and 39B show the purified Fc-fusion proteins inhibit uPA-uPAR binding. The GFD domain of uPA was displayed on the surface of yeast cells as a fusion to the aga2p coat protein, and binding to 2 nM uPAR was measured in the presence of increasing concentrations of (FIG. 39 A) mGFD-Fc and mGS-Fc, and (FIG. 39B) hGFD- Fc and hGS-Fc. Binding reactions were incubated at room temperature for 24 hours and analyzed by flow cytometry. Accurate icso values for the Fc-fusion proteins cannot be derived from these results, given the uPAR concentration used in the assay is orders of magnitude above the Kd of the mGS-Fc and hGS-Fc proteins, and thus binding is concentration-dependent and not Ka-dependent. These data simply verify the purified Fc- fusion proteins are active and capable of inhibiting the uPA-uPAR binding interaction.
FIG. 40 shows uPAR-specific tumor localization of hGFD-Fc and hGS-Fc proteins. The uPAR-positive human breast (MDA-MB-231) tumors, and uPAR-negative human embryonic kidney (HEK 293 T) tumors were implanted into the left and right shoulders of athymic nude mice, respectively. Once tumors reached 5-10 mm in diameter, 1.5 nmol of hGFD-Fc-680 or hGS-Fc-680 were inj ected via tail vein, and protein localization was tracked via whole-body fluorescence imaging at the indicated time points. Images are of mice injected with PBS (left), hGFD-Fc-680 (middle), and hGS-Fc-680 (right). Radiant efficiency scale: min =: 6E8, max = 3.8E9.
FIG. 41 shows the quantification of uPAR-specific tumor localization of hGFD- Fc and hGS-Fc proteins in vivo. The signal for uPAR-positive tumor fluorescence from images shown in FIG. 41 is plotted here divided by the uPAR-negative tumor fluorescence. A signal of 1 (dashed line) indicates zero uPAR-positive tumor specificity.
FIG. 42 shows the average uPAR-specific tumor localization of hGFD-Fc and hGS-Fc proteins in vivo. Mice were inj ected with hGFD-Fc-680 or hGS-Fc-680 (3 each) as in FIG. 41, and uPAR-positive and uPAR-negative tumor fluorescence was measured
each day for 22 days. The signal for uPAR-positive tumor fluorescence is plotted here divided by the uPAR-negative tumor fluorescence. A signal of 1 (dashed line) indicates zero uPAR-positive tumor specificity.
FIGS. 43 A and 43 B show uPAR-specific tumor localization of hGFD (FIG. 43 A) and hGS (FIG. 43B) monomer proteins. The uPAR-positive human breast (MDA-MB- 231) tumors, and uPAR-negative human embryonic kidney (HEK 293 T) tumors were implanted into the left and right shoulders of athymic nude mice, respectively. 1.5 nmol of hGFD-680 or hGS-680 were inj ected via tail vein, and protein localization was tracked via whole-body fluorescence imaging at the indicated time points. Radiant efficiency scale: min = 2.6E8, max = 1.6E9.
FIGS. 44A-44C show internalization of hGFD-Fc and hGS-Fc proteins into human breast cancer (MDA-MB-231) cells in vitro. FIG. 44A shows cell fluorescence from surface-bound Alexa 488-labeled proteins is quenched by an anti -488 antibody. Cells were incubated with 2 nM hGFD-Fc-488 or hGS-Fc-488 at 4°C for 1 hr, washed, and incubated with an anti-Alexa-488 antibody (a488-Ab) for an additional 30 minutes where indicated prior to analysis by flow cytometry. Given that incubation at 4°C precludes internalization, the cell fluorescence measured in this case is caused by the Alexa 488-labeled proteins binding to cell-surface uPAR. FIG. 44B shows internalization of hGFD-Fc-488 and hGS-Fc-488 proteins. Cells were incubated in culture flasks at 37°C with the indicated concentrations of 488-labeled proteins in the presence or absence of a 100-fold molar excess of unlabeled protein for 15 hours. Cells were then harvested, washed, and incubated at 4°C with a488-Ab for an additional 30 minutes to quench surface-bound protein fluorescence prior to analysis by flow cytometry. The hGS-Fc protein demonstrated significantly higher internalization compared to hGFD-Fc (** p < 0.005, *** p < 0.0001). FIG. 44C shows internalization of hGFD-Fc and hGS-Fc-488 over time. Cells were incubated with 2 nM hGFD-Fc-488 or hGS-Fc-488 for the indicated times and analyzed as described in panel (FIG. 44B).
FIG. 45 shows sequence alignments of wild type and engineered proteins. The wild type sequences of the murine and human GFD domains of urokinase (mGFD and hGFD, respectively), and the linker-SMB domains of vitronectin (linker-mSMB and
linker-hSMB, respectively) were aligned to the corresponding engineered proteins generated by directed evolution. Only the linker- SMB domains of mGFD-mSMB and hGFDt2:,A-hSMB proteins are shown for clarity. Amino acid mutations in the engineered proteins are highlighted in gray. Three additional amino acids (ALA) belonging to the signal peptide of human SMB were mistakenly included at the NIL-terminus in the linker-hSMB library. These were later removed and the affinity for uPAR was unchanged (data not shown). Therefore, for future consistency these amino acids are omitted from the sequence here; the [GlyrSer]? linker ends at S73, and the hSMB domain begins at D74.
DETAILED DESCRIPTION
The practice of the present invention will employ, unless otherwise indicated, conventional methods of medicine, pharmacology, chemistry, biochemistry, molecular biology and recombinant DNA techniques, and immunol ogy, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Wolbarst et al. Medical Imaging: Essentials for Physicians (Wiley-Blackwell, 2013); Handbook of Experimental Immunology, Vols. I-IV (D.M Weir and C.C. Blackwell eds., Blackwell Scientific Publications); A.L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd Edition, 2001); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Fmoc Solid Phase Peptide Synthesis: A Practical Approach (W. C. Chan and Peter D. White eds., Oxford University Press, 1st edition, 2000) ; N. Leo Benoiton, Chemistry of Peptide Synthesis (CRC Press; 1st edition, 2005); Peptide Synthesis and. Applications (Methods in Molecular Biology, John Howl ed., Humana Press, 1st ed., 2005); and Pharmaceutical Formulation Development of Peptides and Proteins (The Taylor & Francis Series in Pharmaceutical Sciences, Lars Hovgaard, Sven Frokjaer, and Marco van de Weert eds., CRC Press; 1st edition, 1999).
All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entireties.
I. DEFINITIONS
In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.
It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a ligand" includes a mixture of two or more ligands, and the like.
The term "about," particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.
The terms "protein," "peptide," "oligopeptide" and "polypeptide" refer to any compound comprising naturally occurring or synthetic amino acid polymers or amino acid-like molecules including but not limited to compounds comprising amino and/or imino molecules. No particular size is implied by use of the terms "protein," "peptide," "oligopeptide" or "polypeptide" and these terms are used interchangeably. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring (e.g., synthetic). Thus, synthetic oligopeptides, dimers, mul timers (e.g., tandem repeats, linearly-linked peptides), cyclized, branched molecules and the like, are included within the definition. The terms also include molecules comprising one or more peptoids (e.g., N-substituted glycine residues) and other synthetic amino acids or peptides. (See, e.g., U.S. Patent Nos. 5,831,005;
5,877,278; and 5,977,301; Nguyen et al. (2000) Chem. Biol. 7(7):463-473; and Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89(20):9367-9371 for descriptions of peptoids). Non-limiting lengths of peptides suitable for use in the present invention includes peptides of 3 to 5 residues in length, 6 to 10 residues in length (or any integer therebetween), 11 to 20 residues in length (or any integer therebetween), 21 to 75 residues in length (or any integer therebetween), 75 to 100 (or any integer therebetween), or polypeptides of greater than 100 residues in length. Typically, polypeptides useful in this invention can have a maximum length suitable for the intended application.
Preferably, the polypeptide is between about 3 and 100 residues in length. Generally, one skilled in art can easily select the maximum length in view of the teachings herein.
Further, proteins, peptides, and polypeptides, as described herein, for example synthetic proteins, peptides, and, polypeptides may include additional molecules such as localization sequences, tags, labels, or other chemical moieties. Such moieties may further enhance inhibition of the urokinase receptor, facilitate purification of ligands, and/or detection of the l igands.
Thus, references to polypeptides or peptides also include derivatives of the amino acid sequences of the invention including one or more non-naturally occurring amino acids. A first polypeptide or peptide is "derived from" a second polypeptide or peptide if it is (i) encoded by a first polynucleotide derived from a second polynucleotide encoding the second polypeptide or peptide, or (ii) displays sequence identity to the second polypeptide or peptide as described herein. Sequence (or percent) identity can be determined as described below. Preferably, derivatives exhibit at least about 50% percent identity, more preferably at least about 80%, and even more preferably between about 85% and 99% (or any value therebetween) to the sequence from which they were derived. Such derivatives can include post-expression modifications of the polypeptide or peptide, for example, glycosylation, acetylation, phosphorylation, and the like.
Amino acid derivatives can also include modifications to the native sequence, such as deletions, additions and substitutions (generally conservative in nature), so long as the polypeptide or peptide maintains the desired activity (e.g., inhibits activity of a urokinase receptor). These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts that produce the proteins or errors due to PCR amplification. Furthermore, modifications may be made that have one or more of the following effects: increasing affinity and/or specificity for a urokinase receptor and facilitating cell processing. Ligands described herein can be made recombinantly, synthetically, or in tissue culture.
A urokinase (uPA) polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide refers to a molecule derived from any source. The molecule need not be physically derived from an organism, but may be synthetically or recombinantly
produced. A number of uPA nucleic acid and protein sequences are known.
Representative uPa growth factor domain (GFD) sequences are presented in SEQ ID NOS: 1-4 and additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries: Accession Nos. NG_011904, NM 001145031 , NM_001319191, NM_002658, XM O 11539866, NM_0Q8873, XM_017315919, NM_013085, NM_001163593, XM__014180296, NM 74147, NM__001082011, NM__001082011 , NM__001252350, XM_020711866, NM_001201525, XM_021480008, and XM__009306977; all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference.
Any of these sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
A vitronectin polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide refers to a molecule derived from any source. The molecule need not be physically derived from an organism, but may be synthetically or recombinantly produced. A number of vitronectin nucleic acid and protein sequences are known.
Representative vitronectin somatomedin B (SMB) domain sequences are presented in SEQ ID NOS:5-8 and additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries: Accession Nos. NM__000638, NM__01 l707, NM 214104, NM_001082292,
XM_008309129, XM_013942476, XM_012825212, XMJ303968478, XM__Q06Q95517, XM_ 004385445, XM 004635422, XM 003469567, XM 011360077, XM 003770025, XM_003996497, XM_004543802, XM_007259609, XM_022595435, XM_848947,
XM 022210765, XM 003912492, XM 008066715, XM 021704164, XM 012449385, XM_021177950, XM 021213035, and XM O 19982376; all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference.
Any of these sequences or a variant thereof comprising a sequence having at least about
80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein.
The terms "fusion protein," "fusion polypeptide," or "fusion peptide" as used herein refer to a fusion comprising a growth factor domain (GFD) of urokinase (uPA) in combination with a somatomedin B (SMB) domain of vitronectin as part of a single continuous chain of amino acids, which chain does not occur in nature. The GFD and SMB domains may be connected directly to each other by peptide bonds or may be separated by intervening amino acid sequences (i.e., a linker). Fusion proteins may also contain an immunoglobulin Fc domain as well as other sequences exogenous to the GFD and SMB domains. For example, a fusion protein may also include targeting, localization, or tag sequences. In addition, a fusion protein may be conjugated to an anti- cancer therapeutic agent or a diagnostic agent.
By "fragment" is intended a mol ecule consi sting of only a part of the intact full- length sequence and structure. The fragment can include a C -terminal deletion an N- terminal deletion, and/or an internal deletion of the polypeptide. Active fragments of a particular protein or polypeptide will generally include at least about 5-14 contiguous amino acid residues of the full length molecule, but may include at least about 15-25 contiguous amino acid residues of the full length molecule, and can include at least about 20-50 or more contiguous amino acid residues of the full length molecule, or any integer between 5 amino acids and the full length sequence, provided that the fragment in question retains biological activity, such as anti -tumor activity or inhibitory activity (e.g., the ability to inhibit a urokinase receptor), as defined herein.
"Substantially purified" generally refers to isolation of a substance (compound, polynucleotide, protein, polypeptide, peptide composition) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample, a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample. Techniques for purifying polynucleotides and polypeptides of
interest are well-known in the art and include, for example, ion-exchange
chromatography, affinity chromatography and sedimentation according to density.
By "isolated" is meant, when referring to a polypeptide or peptide, that the indicated molecule is separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro molecules of the same type. The term "isolated" with respect to a polynucleotide is a nucleic acid molecul e devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences in association therewith; or a molecule disassociated from the chromosome.
A ligand is said to "interact" with a receptor if it binds specifically (e.g., in a iock- and-key type mechanism), non-specifically or in some combination of specific and non specific binding. A first ligand "interacts preferentially" with a receptor if it binds (non- specifically and/or specifically) to the receptor with greater affinity and/or greater specificity than it binds to other proteins (e.g., binds to urokinase receptor to a greater degree than to other proteins). The term "affinity" refers to the strength of binding and can be expressed quantitatively as a dissociation constant (Kd). It is to be understood that specific binding does not necessarily require interaction between specific amino acid residues and/or motifs of each peptide. For example, in certain embodiments, the ligands described herein interact preferentially with a urokinase receptor but, nonetheless, may be capable of binding other proteins at a weak, yet detectable, level (e.g., 10% or less of the binding shown to the urokinase receptor). Typically, weak binding, or background binding, is readily discernible from the preferential interaction with the protein or receptor of interest, e.g., by use of appropriate controls.
The term "antagonist" as used herein refers to any molecule that inhibits urokinase receptor activity. For example, the antagonist may comprise a fusion protein comprising a urokinase GFD linked to a vitronectin SM B domain. Inhibition of the urokinase receptor may be complete or partial (i.e., all activity, some activity, or most activity is blocked by an inhibitor). For example, an antagonist may reduce the urokinase receptor activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount in between as compared to native or control levels.
As used herein, the terms "detection agent", "diagnostic agent", and "detectable label" are used interchangeably and refer to a molecule or substance capable of detection, including, but not limited to, fluorescers, chemiluminescers, chromophores,
bioluminescent proteins, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, isotopic labels, semiconductor nanoparticles, dyes, metal ions, metal sols, ligands (e.g., biotin, streptavidin or haptens) and the like. The term "fluorescer” refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used in the practice of the invention include, but are not limited to, SYBR green, SYBR gold, a CAL Fluor dye such as CAL Fluor Gold 540, CAL Fluor Orange 560, CAL Fluor Red 590, CAL Fluor Red 610, and CAL Fluor Red 635, a Quasar dye such as Quasar 570, Quasar 670, and Quasar 705, an Alexa Fluor such as Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 594, Alexa Fluor 647, and Alexa Fluor 784, a cyanine dye such as Cy 3, Cy3.5, Cy5, Cy5.5, and Cy7, fluorescein, 2', 4', 5', 7'-tetrachloro-4-7- dichlorofluorescein (TET), carboxyfluorescein (FAM), 6-carboxy-4',5'-dichloro-2',7'- dimethoxyfluorescein (JOE), hexachlorofluorescein (FIEX), rhodamine, carboxy-X- rhodamine (ROX), tetramethyl rhodamine (TAMRA), FITC, dansyl, umbelliferone, dimethyl acridinium ester (DMAE), Texas red, luminol, and quantum dots, enzymes such as alkaline phosphatase (AP), beta-lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neor, 0418 dihydrofolate reductase (DPIFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), b-galactosidase (lacZ), and xanthine guanine phosphoribosyltransferase (XGPRT), beta-glucuronidase (gus), placental alkaline phosphatase (PLAP), and secreted embryonic alkaline phosphatase (SEAP). Enzyme tags are used with their cognate substrate. The terms also include chemiluminescent labels such as luminol, isoluminol, acridinium esters, and peroxy oxalate and bioluminescent proteins such as firefly luciferase, bacterial luciferase, Renilla luciferase, and aequorin. The terms also include isotopic labels, including radioactive and non-radioactive isotopes, such as, 3H, 2H,12lJI, mI, 124I, 125l, 1311, 35 S, UC, 13C, 14C, 32P , 15N, 13N, 110In, In, 177Lu, 18F, 52Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 86Y, 90Y, 89Zr, 94mTc, 94Tc, 99mTc, 154Gd, 155Gd, 156Gd, 157Gd, 158Gd, 150,
186Re, 188Re, 51M,’2mMn, 55Co, 2As, 7¾r, 76Br, 82mRb, and 83Sr. The terms also include color-coded microspheres of known fluorescent light intensities (see e g., microspheres with xMAP technology produced by Luminex (Austin, TX); microspheres containing quantum dot nanocrystals, for example, containing different ratios and combinations of quantum dot colors (e.g., Qdot nanocrystals produced by Life Technologies (Carlsbad, CA); glass coated metal nanoparticles (see e.g., SERS nanotags produced by Nanoplex Technologies, Inc. (Mountain View, CA); barcode materials (see e.g., sub-micron sized striped metallic rods such as Nanobarcodes produced by Nanoplex Technologies, Inc.), encoded microparticles with colored bar codes (see e.g., CellCard produced by Vitra Bioscience, vitrabio.com), glass microparticles with digital holographic code images (see e.g., CyVera microbeads produced by Illumina (San Diego, CA), near infrared (NIR) probes, and nanoshells. The terms also include contrast agents such as ultrasound contrast agents (e.g. SonoVue microbubbles comprising sulfur hexafluoride, Optison microbubbles comprising an albumin shell and octafluoropropane gas core, Levovist microbubbles comprising a lipid/galactose shell and an air core, Perflexane lipid microspheres comprising perfluorocarbon microbubbles, and Perflutren lipid
microspheres comprising octafluoropropane encapsulated in an outer lipid shell), magnetic resonance imaging (MRI) contrast agents (e.g., gadodiamide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid), and radiocontrast agents, such as for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, i over sol, iopentol, iodixanol, iomeprol, iobitridol, ioxilan, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, and calcium iopodate).
"Pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.
"Pharmaceutically acceptable salt" includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethyl succinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
The terms "tumor," "cancer" and "neoplasia" are used interchangeably and refer to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e g. a cell proliferative, hyperproliferative or differentiative disorder. Typically, the growth is uncontrolled. The term "malignancy" refers to invasion of nearby tissue. The term "metastasis" or a secondary', recurring or recurrent tumor, cancer or neoplasia refers to spread or dissemination of a tumor, cancer or neoplasia to other sites, locations or regions within the subj ect, in which the sites, locations or regions are distinct from the primary tumor or cancer. Neoplasia, tumors and cancers include benign, malignant, metastatic and non- metastatic types, and include any stage (I, II, III, IV or V) or grade (Gl, G2, G3, etc.) of neoplasia, tumor, or cancer, or a neoplasia, tumor, cancer or metastasis that is progressing, worsening, stabilized or in remission. In particular, the terms "tumor," "cancer" and "neoplasia" include carcinomas, such as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, and small cell carcinoma. These terms include, but are not limited to, breast cancer, prostate cancer, lung cancer, ovarian cancer, testicular cancer, colon cancer, rectal cancer, pancreatic cancer, gastrointestinal cancer, hepatic cancer, endometrial cancer, leukemia, lympho a, adrenal cancer, thyroid cancer, pituitary cancer, adrenocortical cancer, renal cancer, brain cancer (e.g., glioblastoma and astrocytoma), skin cancer (e.g., basal-cell
cancer, squamous-cell cancer, and melanoma), head cancer, neck cancer, oral cavity cancer, tongue cancer, and esophageal cancer.
An "effective amount" of a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding such a ligand is an amount sufficient to effect beneficial or desired results, such as an amount that binds to and/or inhibits a urokinase receptor. An effective amount can be administered in one or more administrations, applications or dosages.
By "anti-tumor activity" is intended a reduction in the rate of cell proliferation, and hence a decline in growth rate of an existing tumor or in a tumor that arises during therapy, and/or destruction of existing neoplastic (tumor) cells or newly formed neoplastic cells, and hence a decrease in the overall size of a tumor during therapy. Such activity can be assessed using animal models.
By "therapeutically effective dose or amount" of a ligand of a urokinase receptor (e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding such a ligand is intended an amount that, when administered as described herein, brings about a positive therapeutic response, such as anti-tumor activity. The exact amount required will vary' from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like. An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
The term "tumor response" as used herein means a reduction or elimination of all measurable lesions. The criteria for tumor response are based on the WHO Reporting Criteria [WHO Offset Publication, 48-World Health Organization, Geneva, Switzerland, (1979)]. Ideally, all uni- or bidimensionally measurable lesions should be measured at each assessment. When multiple lesions are present in any organ, such measurements may not be possible and, under such circumstances, up to 6 representative lesions should be selected, if available.
The term "complete response" (CR) as used herein means a complete
disappearance of all clinically detectable malignant disease, determined by 2 assessments at least 4 weeks apart.
The term "partial response" (PR) as used herein means a 50% or greater reduction from baseline in the sum of the products of the longest perpendicular diameters of all measurable disease without progression of evaluable disease and without evidence of any new lesions as determined by at least two consecutive assessments at least four weeks apart. Assessments should show a partial decrease in the size of lytic lesions, recalcifications of lytic lesions, or decreased density of blastic lesions.
By "subject" is meant any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
"Homology" refers to the percent identity between two polynucleotide or two polypeptide molecules. Two nucleic acid, or two polypeptide sequences are
"substantially homologous" to each other when the sequences exhibit at least about 50% sequence identity, preferably at least about 75% sequence identity, more preferably at least about 80% 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% 98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified sequence.
In general, "identity" refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer
programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M O. in Atlas of Protein Sequence and Structure M.O. Dayhoff ed., 5 Suppl. 3:353 358, National biomedical Research Foundation, Washington, DC, which adapts the local homology algorithm of Smith and Waterman Advances in Appl. Math. 2:482 489, 1981 for peptide analysis. Programs for determining nucleotide sequence identity are available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above. For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions.
Another method of establi shing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA) From this suite of packages, the Smith Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used using the following default parameters: genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs are readily available.
Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by
digestion with single stranded specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra, DNA Cloning, supra, Nucleic Acid Hybridization, supra.
"Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation, is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. In general, the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions
The term "transformation" refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transduction or f-mating are included. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
"Recombinant host cells," "host cells," "cells", "cell lines," "cell cultures, " and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vector or other transferred DNA, and include the original progeny of the original cell which has been transfected.
A "coding sequence" or a sequence which "encodes" a selected polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence can be determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA
from viral, prokaryotic or eukaryotic mRNA, genomic DNA sequences from viral or prokaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence.
Typical "control elements," include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5’ to the coding sequence), and translation termination sequences.
"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper enzymes are present. The promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.
"Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a polypeptide encoded by the nucleic acid sequence.
"Expression cassette" or "expression construct" refers to an assembly which is capable of di recting the expression of the sequence(s) or gene(s) of interest. An expression cassette generally includes control elements, as described above, such as a promoter which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenyl tion sequence as well. Within certain embodiments of the invention, the expression cassette described herein may be contained within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also include, one or more selectable markers, a signal which allows the plasmid construct to exist as single stranded DNA (e.g., a M13 origin of
replication), at least one multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
"Purified polynucleotide" refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about at least 90%, of the protein with which the polynucleotide is naturally associated. Techniques for purifying polynucleotides of interest are well-known in the art and include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the
polynucleotide(s) and proteins by ion-exchange chromatography, affinity
chromatography and sedimentation according to density.
The term "transfection" is used to refer to the uptake of foreign DNA by a cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (2001) Molecular Cloning, a laboratory^ manual, 3rd edition, Cold Spring Harbor Laboratories, New York, Davis et al. (1995) Basic Methods in Molecular Biology, 2nd edition, McGraw-Hill, and Chu et al. (1981) Gene 13 :197 Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells. The term refers to both stable and transient uptake of the genetic material, and includes uptake of peptide- or antibody-linked DNAs.
A "vector" is capable of transferring nucleic acid sequences to target cells (e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes). Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a nucleic acid of interest and which can transfer nucleic acid sequences to target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.
The terms "variant," "analog" and "mutein" refer to biologically active derivatives of the reference molecule that retain desired activity, such as the ability to inhibit a urokinase receptor and having anti -tumor activity. In general, the terms "variant" and "analog" refer to compounds having a native polypeptide sequence and structure with one or more amino acid additions, substitutions (generally conservative in nature) and/or
deletions, relative to the native molecule, so long as the modifications do not destroy biological activity and which are "substantially homologous" to the reference molecule as defined below. In general, the amino acid sequences of such analogs will have a high degree of sequence homology to the reference sequence, e.g., amino acid sequence homology of more than 50%, generally more than 60%-70%, even more particularly 80%-85% or more, such as at least 90%-95% or more, when the two sequences are aligned. Often, the analogs will include the same number of amino acids but will include substitutions, as explained herein. The term "mutein" further includes polypeptides having one or more amino acid-like molecules including but not limited to compounds comprising only amino and/or imino molecules, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring (e.g., synthetic), cyclized, branched molecules and the like. The term also includes molecules comprising one or more N- substituted glycine residues (a "peptoid") and other synthetic amino acids or peptides. (See, e.g., U.S. Patent Nos. 5,831,005; 5,877,278; and 5,977,301; Nguyen et al., Chem. Biol. (2000) 7:463-473; and Simon et al„ Proc. Natl. Acad. Sci. USA (1992) 89:9367- 9371 for descriptions of peptoids). Methods for making polypeptide analogs and muteins are known in the art and are described further below.
As explained above, analogs generally include substitutions that are conservative in nature, i.e., those substitutions that take place within a family of amino acids that are related in their side chains. Specifically, amino acids are generally divided into four families: (1) acidic— aspartate and glutamate; (2) basic -- lysine, arginine, histidine; (3) non-polar— alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar— glycine, asparagine, glutamine, cysteine, serine threonine, and tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. For example, it is reasonably predictable that an isolated replacement of leucine with isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid, will not have a major effect on the biological activity.
For example, the polypeptide of interest may include up to about 5-10 conservative or non-conservative amino acid substitutions, or even up to about 15-25 conservative or non-conservative amino acid substitutions, or any integer between 5-25, so long as the desired function of the molecule remains intact. One of skill in the art may readily determine regions of the mol ecule of interest that can tolerate change by reference to HoppAV oods and Kyte-Doolittle plots, well known in the art.
"Gene transfer" or "gene delivery" refers to methods or systems for reliably inserting DNA or RNA of interest into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., epi somes), or integration of transferred genetic material into the genomic DNA of host cells. Gene delivery expression vectors include, but are not limited to, vectors derived from bacterial plasmid vectors, viral vectors, non- viral vectors, alphaviruses, pox viruses and vaccinia viruses.
The term "derived from" is used herein to identify the original source of a molecule but is not meant to limit the method by which the molecule is made which can be, for example, by chemical synthesis or recombinant means.
A polynucleotide "derived from" a designated sequence refers to a polynucleotide sequence which comprises a contiguous sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about 15-20 nucleotides corresponding, i.e., identical or complementary to, a region of the designated nucleotide sequence. The derived polynucleotide will not necessarily be derived physically from the nucleotide sequence of interest, but m ay be generated in any manner, including, but not limited to, chemical synthesis, replication, reverse transcription or transcription, which is based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. As such, it may represent either a sense or an anti sense orientation of the original polynucleotide.
P. Modes of Carrying Out the Invention
Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.
The present invention is based on the discovery that fusion proteins comprising a urokinase GFD linked to a vitronectin SMB domain can be used as ligands of the urokinase receptor for treatment of cancer. In particular, the inventors have engineered bispecific protein ligands that simultaneously bind to two distinct sites on the urokinase receptor with an affinity superior to the native ligands and have demonstrated that such ligands have anti -tumor activity (see Examples). In order to further an understanding of the invention, a more detailed discussion is provided below regarding ligands of the urokinase receptor and their use in treating cancer.
A. Ligands of the Urokinase Receptor
In one aspect, the invention provides ligands having anti-tumor activity that are capable of binding, preferably speci fically binding, to a urokinase receptor. The ligands comprise a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin Inhibition of the urokinase receptor may be complete or partial (i.e., all activity, some activity, or most activity is blocked by an inhibitor). In certain embodiments, a ligand reduces urokinase receptor activity by 70% to 100%, or any amount in this range, such as 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% as compared to native or control levels in certain embodiments, the ligand binds to a urokinase receptor with a dissociation constant (KD) of less than 0.2 nM, more preferably, less than 100 pM, and most preferably, less than 10 pM.
Urokinase (uPA) nucleic acid and protein sequences may be derived from any source A number of uPA nucleic acid and protein sequences are known. Representative uPa growth factor domain (GFD) sequences are presented in SEQ ID NOS: 1-4 and additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries: Accession Nos.
NG_011904, NM_0Q 1145031, NM_001319191, NM_002658, XM_011539866, NM_008873, XM__017315919, NM__013085, NM__001163593, XM_014180296, NM_174147, NM_001082011, NM_001082011, NM_001252350, XM__020711866,
NM 001201525, XM 021480008, and XM 009306977; all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference.
Any of these sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein. If desired, uPA polypeptides can contain other amino acid sequences, such as amino acid linkers or signal sequences, as well as ligands or tags useful in protein purification or detectable labels.
Vitronectin nucleic acid and protein sequences also may be derived from any source. A number of vitronectin nucleic acid and protein sequences are known.
Representative vitronectin somatomedin B (SMB) domain sequences are presented in SEQ ID NOS:5-8 and additional representative sequences are listed in the National Center for Biotechnology' Information (NCBI) database. See, for example, NCBI entries: Accession Nos. NM_000638, NM_011707, NM_214104, NM_001082292,
XM_ 008309129, XM_ 013942476, XM 012825212, XM 003968478, XM 006095517, XM_004385445, XM_004635422, XM_003469567, XM O 11360077, XM_003770025, XM 003996497, XM 004543802, XM 007259609, XM 022595435, XM 848947, XM_022210765, XM 003912492, XM_008066715, XM 021704164, XM O 12449385, XM_021177950, XM_ 021213035, and XM_019982376; all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference.
Any of these sequences or a variant thereof comprising a sequence having at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used to construct a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a nucleic acid encoding a ligand of a urokinase receptor, as described herein. If desired, vitronectin polypeptides can contain other amino acid sequences, such as amino acid linkers or signal sequences, as well as ligands or tags useful in protein purification or detectable labels.
In certain embodiments, the ligand comprises engineered GFD and/or SMB domains that have been modified to improve affinity for the urokinase receptor, inhibition of the urokinase receptor, and/or anti-tumor activity. For example, the ligand may be engineered to comprise one or more mutations that improve its ability to bind to and/or inhibit the urokinase receptor and its efficacy in treating cancer.
In certain embodiments, the fusion protein comprises an engineered GFD comprising at least one amino acid substitution selected from the group consisting of R30W, K37G, K37R, Q39R, E41K, E41 R, and H42Y, wherein positions of the amino acids are numbered relative to the reference murine GFD sequence of SEQ ID NO: 1. In one embodiment, the GFD comprises the R30W, K37R, Q39R, E41R, and H42Y amino acid substitutions. Although the foregoing numbering is relative to reference murine GFD sequence of SEQ ID NO: 1, it is to be understood that the corresponding positions in other GFDs obtained from other species are also intended to be encompassed by the present invention.
In other embodiments, the fusion protein comprises an engineered GFD comprising at least one mutation comprising an amino acid substitution selected from the group consisting of L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R, and wherein positions of the amino acids are numbered relative to the reference human GFD sequence of SEQ ID NO:3. In one embodiment, the GFD comprises the L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R amino acid substitutions. Although the foregoing numbering is relative to reference human GFD sequence of SEQ ID NO:3, it is to be understood that
the corresponding positions in other GFDs obtained from other species are also intended to be encompassed by the present invention.
In further embodiments, the fusion protein comprises an engineered SMB domain comprising at least one amino acid substitution selected from the group consisting of DIN, E3G, M14V, and KI E, wherein positions of the amino acids are numbered relative to the reference murine SMB domain sequence of SEQ ID NO:5. In one embodiment, the SMB domain comprises the DIN, E3G, M14V, and K17E amino acid substitutions. Although the foregoing numbering is relative to reference murine SMB domain sequence of SEQ ID NO:5, it is to be understood that the corresponding positions in other SMBs obtained from other species are also intended to be encompassed by the present invention.
In yet other embodiments, the fusion protein comprises an engineered SMB domain comprising at least one amino acid substitution selected from the group consisting of D1G, E3G, K18E, and P41 S, and wherein positions of the amino acids are numbered relative to the reference human SMB domain sequence of SEQ ID NO:7. In one embodiment, the SMB domain comprises the D1G, E3G, K18E, and P41 S amino acid substitutions. Although the foregoing numbering is relative to reference human SMB domain sequence of SEQ ID NO:7, it is to be understood that the corresponding positions in other SMBs obtained from other species are also intended to be encompassed by the present invention.
In certain embodiments, the fusion protein further comprises one or more linkers. Linkers are typically short peptide sequences of 2-30 amino acid residues, often composed of glycine and/or serine residues. Linker amino acid sequences will typically be short, e.g., 25 or fewer amino acids (i.e., 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1). Examples include short peptide sequences which facilitate cloning, poly-glycine linkers (Glyn where n = 2, 3, 4, 5, 6, 7, 8, 9, 10 or more), histidine tags (Hisn where n = 3, 4, 5, 6, 7, 8, 9, 10 or more), linkers composed of glycine and serine residues ([Gly-Gly-Gly-Gly-Ser]n (SEQ ID NO: 9), wherein n = 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more), GSAT, SEG, and Z-EGFR linkers.
Linkers may include restriction sites, which aid cloning and manipulation. Other suitable
linker amino acid sequences will be apparent to those skilled in the art. (See e.g., Argos (1990) J. Mol Biol. 211(4):943-958; Crasto et al. (2000) Protein Eng 13:309-312;
George et al. (2002) Protein Eng. 15:871 -879; Arai et al. (2001) Protein Eng. 14:529-532; and the Registry of Standard Biological Parts (partsregistry.org/Protein domains/Linker).
In particular, the fusion protein may comprise a linker connecting the GFD to the SMB domain. In certain embodiments, the linker ranges in size from about 40 angstroms to about 50 angstroms in length, including any length within this range such as, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, or 50 angstroms in length. In another embodiment, the linker comprises a sequence selected from the group consisting of SEQ ID NO: l 1, SEQ ID NO: 14, and SEQ ID NO: 15, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to tumor cells and/or inhibiting the urokinase receptor. In certain embodiments, the linker comprises at least one amino acid substitution selected from the group consisting of S5N, S10G, G12R, and G19S, and wherein positions of the amino acids are numbered relative to the reference linker sequence of SEQ ID NO: 11.
In certain embodiments, the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12 and SEQ ID NO: 13, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to tumor cells and/or inhibiting the urokinase receptor and has anti tumor activity. In certain embodiments, the N-terminus or the C -terminus of the fusion protein may be modified to enhance solubility, stability and/or improve delivery' to tumors. For example, the ends of the fusion protein may be modified by N-terminal acetylation and/or C-terminal amidation to reduce charge and increase stability.
In certain embodiments, the fusion protein further comprises an immunoglobulin Fc domain. The immunoglobulin Fc domain may be derived from an IgG (e.g., IgGl, IgG2, IgG3, or IgG4), IgM, IgE, IgA or IgD, or a combination or hybrid thereof. In one
embodiment, the Fc fragment is derived from an IgGl or IgG2a isotype. In another embodiment, the Fc fragment is derived from a human immunoglobulin. The immunoglobulin Fc domain may be covalently linked directly to the N-terminal or C- terminal end of the fusion protein or connected indirectly through a linker to the fusion protein. In certain embodiments, the ligand comprises a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17-20; or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor. In certain embodiments, the ligand targets tumors expressing the urokinase receptor in a mammal.
In certain embodiments, the fusion protein further comprises a tag sequence, which may be located, for example, at the N-terminus or C -terminus of the fusion protein. Exemplary tags that can be used in the practice of the invention include a His- tag, a Strep-tag, a TAP -tag, an S-tag, an SBP-tag, an Arg-tag, a calmodulin-binding peptide tag, a cellulose-binding domain tag, a DsbA tag, a c-myc tag, a glutathione S- transferase tag, a FLAG tag, a HAT -tag, a maltose-binding protein tag, a NusA tag, and a thioredoxin tag.
In certain embodiments, the fusion protein further comprises a signal peptide. Signal peptides are typically located at the N-terminus of the fusion protein and range in size from about 16 to 30 amino acids in length (i.e., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30). Any signal peptide may be used that is capable of targeting the fusion protein to the cell membrane where the urokinase receptor is located.
Representative signal peptide sequences are listed in the Signal Peptide Database (proline.bic.nus.edu. sg/spdb/) and the Signal Peptide Website (signalpeptide.de/). In one embodiment, the signal peptide is a urokinase signal peptide.
In certain embodiments, the fusion protein further comprises a detectable label in order to facilitate detection of binding of the ligand to the urokinase receptor. Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or
chemical means. Particular examples of labels that may be used with the invention include, but are not limited to radiolabels (e.g., Ή, 1251, 35S, 14C, or 32P), phycoerythrin, Alexa dyes, fluorescein, YPet, CyPet, Cascade blue, allophycocyanin, Cy3, Cy5, Cy7, rhodamine, dansyl, umbelliferone, Texas red, luminol, acradimum esters, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), Dronpa, Padron, mApple, mCherry, rsCherry, rsCherryRev, firefly luciferase, Renilla luciferase, biotin or other streptavidin- binding proteins, magnetic beads, electron dense reagents, NADPH, beta-galactosidase, horseradish peroxidase, glucose oxidase, alkaline phosphatase, chloramphenical acetyl transferase, and urease. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
The fusion protein may also be conjugated to a contrast agent suitable for imaging. Exemplary contrast agents include ultrasound contrast agents (e.g. SonoVue microbubbles comprising sulfur hexafluoride, Optison microbubbles comprising an albumin shell and octafluoropropane gas core, Levovist microbubbles comprising a lipid/galactose shell and an air core, Perflexane lipid microspheres comprising perfluorocarbon microbubbles, and Perflutren lipid microspheres comprising
octafluoropropane encapsulated in an outer lipid shell), magnetic resonance imaging (MRI) contrast agents (e.g., gadodi amide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid), and radiocontrast agents, such as for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, ioversol, iopentol, iodixanol, iomeprol, iobitridol, ioxilan, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, and calcium iopodate).
B. Production of Ligands
Ligands of the urokinase receptor (e.g., fusion proteins comprising a urokinase GFD linked to a vitronectin SMB domain) can be prepared in any suitable manner (e g., recombinant expression, purification from cell culture, chemical synthesis, etc.) and in various forms (e.g. tagged, labeled, li pi dated, ami dated, acetylated, etc.). Ligand fusion proteins may include naturally-occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing polypeptides are well understood in the art. Ligand fusion proteins are preferably prepared in substantially pure form (i.e. substantially free from other host cell or non-host cell proteins).
In one embodiment, the ligand fusion proteins are generated using recombinant techniques. One of skill in the art can readily determine nucleotide sequences that encode the desired fusion proteins using standard methodology and the teachings herein. Oligonucleotide probes can be devised based on the known sequences and used to probe genomic or cDNA libraries. The sequences can then be further isolated using standard techniques and, e.g., restriction enzymes employed to truncate the gene at desired portions of the full-length sequence. Similarly, sequences of interest can be isolated directly from cells and tissues containing the same, using known techniques, such as phenol extraction and the sequence further manipulated to produce the desired truncations. See, e.g., Sambrook et al., supra, for a description of techniques used to obtain and isolate DNA.
The sequences encoding fusion proteins can also be produced synthetically, for example, based on the known sequences. The nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired. The complete sequence is generally assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) Nature 292:756; Nambair ei al. (1984) Science 223 : 1299; Jay et al (1984) J. Biol Chem.
259:631 1; Stemmer et al. (1995) Gene 164:49-53.
Recombinant techniques are readily used to clone sequences encoding peptides or polypeptides that can then be mutagenized in vitro by the replacem ent of the appropriate
base pair(s) to result in the codon for the desired amino acid. Such a change can include as little as one base pair, effecting a change in a single amino acid, or can encompass several base pair changes. Alternatively, the mutations can be effected using a mismatched primer that hybridizes to the parent nucleotide sequence (generally cDNA corresponding to the RNA sequence), at a temperature below the melting temperature of the mismatched duplex. The primer can be made specific by keeping primer length and base composition within relatively narrow limits and by keeping the mutant base centrally located. See, e.g., Innis et al, (1990) PCR Applications: Protocols for
Functional Genomics; Zoller and Smith, Methods Enzymol. (1983) 100:468. Primer extension is effected using DNA polymerase, the product cloned and clones containing the mutated DNA, derived by segregation of the primer extended strand, selected.
Selection can be accomplished using the mutant primer as a hybridization probe. The technique is also applicable for generating multiple point mutations. See, e.g., Dalbie- McFarland et al. Proc. Natl Acad. Sci USA (1982) 79:6409.
Once coding sequences have been isolated and/or synthesized, they can be cloned into any suitable vector or replicon for expression. (See, also, Examples). As will be apparent from the teachings herein, a wide variety of vectors encoding modified polypeptides can be generated by creating expression constructs which operably link, in various combinations, polynucleotides encoding polypeptides having deletions or mutations therein.
Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage l (E. coli), pBR322 ( E . coli ), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFRl (gram -negative bacteria), pME290 (non-E. coli gram-negative bacteria), pH VI 4 (E. coli and Bacillus subtilis), pBD9 {Bacillus), pIJ61 {Streptomyces), pUC6 {Streptomyc.es), YIp5 ( Saccharomyces ), YCpl9
{Saccharomyces) and bovine papilloma virus (mammalian cells). See, generally, DNA Cloning: Vols. I & II, supra, Sambrook et al. , supra, B. Perbal, supra.
Insect cell expression systems, such as baculovirus systems, can also be used and are known to those of skill in the art and described in, e.g. , Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit).
Plant expression systems can also be used to produce the ligand fusion proteins described herein. Generally, such systems use virus-based vectors to transfect plant cells with heterologous genes. For a description of such systems, see, e.g., Porta et al., Mol. Biotech. (1996) 5:209-221; and Hackland et al., Arch. Virol. (1994) 139: 1-22.
Viral systems, such as a vaccinia-based infection/transfection system, as described in Tomei et al., J. Virol. (1993) 67:4017-4026 and Selby et al., J. Gen. Virol. (1993) 74: 1103-1 1 13, will also find use with the present invention. In this system, cells are first transfected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the DNA of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA that is then translated into protein by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation product(s).
The gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control " elements), so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the host cell transformed by a vector containing this expression construction. The coding sequence may or may not contain a signal peptide or leader sequence. With the present invention, both the naturally occurring signal peptides or heterologous sequences can be used. Leader sequences can be removed by the host in post-translational processing. See , e.g., U.S. Patent Nos. 4,431 ,739; 4,425,437;
4,338,397. Such sequences include, but are not limited to, the TP A leader, as well as the honey bee mellitin signal sequence.
Other regulatory sequences may also be desirable which allow for regulation of expression of the protein sequences relative to the growth of the host cell. Such regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.
In some cases, it may be necessary to modify the coding sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the proper reading frame. Mutants or analogs may be prepared by the deletion of a portion of the sequence encodi ng the protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et ah, supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.
The expression vector is then used to transform an appropriate host cell. A number of mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), Vero293 cells, as well as others. Similarly, bacterial hosts such as E. coli, Bacillus sub tilis, and Streptococcus spp., will find use with the present expression constructs.
Yeast hosts useful in the present invention include inter alia, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hamenula polymorpha, Kluyveromyces fragilis, Khtyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrow ia lipolytica. Insect cells for use with baculovirus expression vectors
include, inter alia, Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda , and Trichoplusia ni.
Depending on the expression system and host selected, the fusion proteins of the present invention are produced by growing host cells transformed by an expression vector described above under conditions whereby the protein of interest is expressed. The selection of the appropriate growth conditions is within the skill of the art.
In one embodiment, the transformed cells secrete the peptide or polypeptide product into the surrounding media. Certain regulatory sequences can be included in the vector to enhance secretion of the protein product, for example using a tissue
plasminogen activator (TPA) leader sequence, an interferon (g or a) signal sequence or other signal peptide sequences from known secretory proteins. The secreted peptide or polypeptide product can then be isolated by various techniques described herein, for example, using standard purification techniques such as but not limited to, hydroxyapatite resins, column chromatography, ion-exchange chromatography, size-exclusion chromatography, electrophoresis, HPLC, immunoadsorbent techniques, affinity chromatography, immunoprecipitation, and the like.
Alternatively, the transformed cells are disrupted, using chemical, physical or mechanical means, which lyse the cells yet keep the recombinant peptides or
polypeptides substantially intact. Intracellular proteins can also be obtained by removing components from the cell wall or membrane, e.g., by the use of detergents or organic solvents, such that leakage of the polypeptides occurs. Such methods are known to those of skill in the art and are described in, e.g., Protein Purification Applications: A Practical Approach, (Simon Roe, Ed., 2001).
For example, methods of disrupting cells for use with the present invention include but are not limited to: soni cation or ultrasonication; agitation; liquid or solid extrusion; heat treatment; freeze-thaw; desiccation; explosive decompression; osmotic shock; treatment with lytic enzymes including proteases such as trypsin, neuraminidase and lysozyme; alkali treatment; and the use of detergents and solvents such as bile salts, sodium dodecyl sulphate, Triton, NP40 and CHAPS. The particular technique used to
disrupt the cells is largely a matter of choice and will depend on the cell type in which the polypeptide is expressed, culture conditions and any pre-treatment used.
Following disruption of the cells, cellular debris is removed, generally by centrifugation, and the intracellularly produced peptides or polypeptides are further purified, using standard purification techniques such as but not limited to, column chromatography, ion-exchange chromatography, size-exclusion chromatography, electrophoresis, HPLC, immunoadsorbent techniques, affinity chromatography, immunoprecipitation, and the like.
For example, one method for obtaining the fusion proteins of the present invention involves affinity purification, such as by immunoaffinity chromatography using antibodies (e.g., previously generated antibodies), or by lectin affinity chromatography. Particularly preferred lectin resins are those that recognize mannose moieties such as but not limited to resins derived from Galanthns nivalis agglutinin (GNA), Lens culinaris agglutinin (LCA or lentil lectin), Pisum sativum agglutinin (PSA or pea lectin), Narcissus pseudonarcissus agglutinin (NPA) and Allium ursinum agglutinin (AUA). The choice of a suitable affinity resin is within the skill in the art. After affinity purification, the peptides or polypeptides can be further purified using conventional techniques well known in the art, such as by any of the techniques described above.
Ligand fusion proteins can also be conveniently synthesized chemically, for example by any of several techniques that are known to those skilled in the peptide art. See, e.g., Fmoc Solid Phase Peptide Synthesis: A Practical Approach (W. C. Chan and Peter D. White eds., Oxford University Press, 1st edition, 2000) ; N. Leo Benoiton, Chemistry of Peptide Synthesis (CRC Press; Ist edition, 2005); Peptide Synthesis and Applications (Methods in Molecular Biology, John Howl ed., Humana Press, 1st ed., 2005); and Pharmaceutical Formulation Development of Peptides and Proteins (The Taylor & Francis Series in Pharmaceutical Sciences, Lars Hovgaard, Sven Frokjaer, and Marco van de Weert eds., CRC Press; 1st edition, 1999); herein incorporated by reference.
In general, these methods employ the sequential addition of one or more amino acids to a growing peptide chain. Normal ly, either the amino or carboxyl group of the
first amino acid is protected by a suitable protecting group. The protected or derivatized amino acid can then be either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected, under conditions that allow for the formation of an amide linkage. The protecting group is then removed from the newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support, if solid phase synthesis techniques are used) are removed sequentially or concurrently, to render the final peptide or polypeptide. By simple modification of this general procedure, it is possible to add more than one amino acid at a time to a growing chain, for example, by coupling (under conditions which do not racemize chiral centers) a protected tripeptide with a properly protected dipeptide to form, after deprotection, a pentapeptide. See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis (Pierce Chemical Co., Rockford, IL 1984) and G. Bar any and R. B. Merrifield, The Peptides: Analysis Synthesis Biology editors E. Gross and J.
Meienhofer, Vol. 2, (Academic Press, New York, 1980), pp. 3-254, for solid phase peptide synthesis techniques; and M. Bodansky, Principles of Peptide Synthesis.
(Springer-V erlag, Berlin 1984) and E. Gross and J. Meienhofer, Eds., The Peptides: Analysis Synthesis Biology. Vol. 1, for classical solution synthesis. These methods are typically used for relatively small polypeptides, i.e , up to about 50-100 amino acids in length, but are also applicable to larger polypeptides.
Typical protecting groups include t-butyl oxy carb onyl (Boc), 9- fluorenylmethoxycarbonyl (Fmoc) benzyloxycarbonyl (Cbz); p -tol uenesul fonyl (Tx); 2,4-dinitrophenyl; benzyl (Bzl); biphenylisopropyloxycarboxy-carbonyl, t- amyl oxy carb onyl , isobornyloxycarbonyl, o-bromobenzyloxycarbonyl, cyclohexyl, isopropyl, acetyl, o-nitrophenyl sulfonyl and the like.
Typical solid supports are cross-linked polymeric supports. These can include divinylbenzene cross-linked-styrene-based polymers, for example, divinylbenzene- hy droxymethyl styrene copolymers, divinylbenzene-chloromethylstyrene copolymers and divinylbenzene-benzhydrylaminopolystyrene copolymers.
Ligand fusion proteins can also be chemically prepared by other methods such as by the method of simultaneous multiple peptide synthesis. See, e g., Houghten Proc.
Natl Acad. Sci. USA (1985) 82:5131-5135; U S. Patent No. 4,631 ,211.
C. Nucleic Acids Encoding Ligands
Nucleic acids encoding ligands of the urokinase receptor (e.g., fusion proteins comprising a urokinase GFD linked to a vitronectin SMB domain) can be used, for example, to treat cancer. Nucleic acids described herein can be inserted into an expression vector to create an expression cassette capable of producing the ligand fusion proteins in a suitable host cell. The ability of constructs to produce the ligand fusion proteins can be empirically determined (e.g., see Example 1 describing detection using immunofluorescent labeling).
Expression cassettes typically include control elements operably linked to the coding sequence, which allow for the expression of the gene in vivo in the subject species. For example, typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV immediate early promoter, the mouse mammary tu or virus LTR promoter, the adenovirus major late promoter (Ad MLP), and the herpes simplex vims promoter, among others. Other nonviral promoters, such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression. Typically, transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon. Preferably, a sequence for optimization of initiation of translation, located 5' to the coding sequence, is also present. Examples of transcription terminator/polyadenylati on signals include those derived from SV40, as described in Sambrook et al., supra , as well as a bovine growth hormone terminator sequence.
Enhancer elements ay also be used herein to increase expression levels of the mammalian constructs. Examples include the SV40 early gene enhancer, as described in Dijkema et al., EMPO J (1985) 4:761, the enhancer/ pro oter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., Proc. Natl. Acad. Sci. USA (l982b) 79:6777 and elements derived from human CMV, as
described in Boshart et al., Cell (1985) 41 :521, such as elements included in the CMV intron A sequence.
Once complete, the constructs encoding the ligand fusion proteins can be administered to a subject using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g, U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466. Genes can be delivered either directly to a vertebrate subject or, alternatively, delivered ex vivo, to cells derived from the subject and the cells reimplanted in the subject.
A number of viral based systems have been developed for gene transfer into mammalian cells. These include adenoviruses, retroviruses (g-retroviruses and lentiviruses), poxviruses, adeno-associated viruses, baculoviruses, and herpes simplex viruses (see e.g., Wamock et al. (2011) Methods Mol. Biol. 737: 1-25; Walther et al. (2000) Drugs 60(2):249-271; and Lundstrom (2003) Trends Biotechnol. 21 (3): 117-122; herein incorporated by reference).
For example, retroviruses provide a convenient platform for gene delivery systems. Selected sequences can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems have been described (U.S. Pat. No. 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A. D. (1990) Human Gene Therapy 1 :5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA
90:8033-8037; Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3: 102-109; and Ferry et al. (2011) Curr. Pharm. Des. 17(24):2516-2527). Lentiviruses are a class of retroviruses that are particularly useful for delivering polynucleotides to mammalian cells because they are able to infect both dividing and nondividing cells (see e.g., Lois et al (2002) Science 295:868-872; Durand et al. (2011) Viruses 3(2): 132-159; herein incorporated by reference).
A number of adenovirus vectors have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj -Ahmad and Graham, J. Virol. (1986) 57:267-274; Bett et al, J. Virol. (1993) 67:5911-5921; Mittereder et al.
Human Gene Therapy (1994) 5:717-729; Seth et al„ J. Virol. (1994) 68:933-940; Barr et al., Gene Therapy (1994) 1 :51-58; Berkner, K. L. BioTechniques (1988) 6:616-629; and Rich et al., Human Gene Therapy (1993) 4:461-476). Additionally, various adeno- associated virus (AAV) vector systems have been developed for gene delivery. AAV vectors can be readily constructed using techniques well known in the art.. See, e.g., U S. Pat. Nos. 5, 173,414 and 5, 139,941; International Publication Nos. WO 92/01070
(published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al., Molec. Cell. Biol. (1988) 8:3988-3996; Vincent et al., Vaccines 90 (1990) (Cold Spring Harbor Laboratory Press); Carter, B. J. Current Opinion in Biotechnology (1992) 3:533-539; Muzyczka, N. Current Topics in Microbiol and Immunol. (1992) 158:97-129; Kotin, R. M. Human Gene Therapy (1994) 5:793-801; Shelling and Smith, Gene Therapy (1994) 1 : 165-169; and Zhou et al., J. Exp. Med. (1994) 179: 1867-1875.
Another vector system useful for delivering the polynucleotides of the present invention is the enterically administered recombinant poxvirus vaccines described by Small, Jr., P. A., et al. (U.S. Pat. No. 5,676,950, issued Oct. 14, 1997, herein incorporated by reference).
Additional viral vectors which will find use for delivering the nucleic acid molecules encoding the ligand fusion proteins of interest include those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. By way of example, vaccinia vims recombinants expressing the ligand fusion proteins can be constructed as follows. The DNA encoding the particular ligand fusion protein coding sequence is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the coding sequences of interest into the viral genome. The resulting TK- recombinant can be selected by culturing the cells in the presence of 5- bromodeoxyuri dine and picking viral plaques resistant thereto.
Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the genes. Recombinant avipox viruses, expressing immunogens from
mammalian pathogens, are known to confer protective immunity when admini stered to non-avian species. The use of an avipox vector is particularly desirable in human and other mammalian species since members of the avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.
Molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al., J. Biol. Chem. (1993) 268:6866-6869 and Wagner et al., Proc. Natl. Acad. Sci. USA (1992) 89:6099-6103, can also be used for gene delivery.
Members of the Alphavirus genus, such as, but not limited to, vectors derived from the Sindbis virus (SIN), Semliki Forest virus (SFV), and Venezuelan Equine Encephalitis virus (VEE), will also find use as viral vectors for delivering the
polynucleotides of the present invention. For a description of Sindbis-virus derived vectors useful for the practice of the instant methods, see, Dubensky et al. (1996) J. Virol. 70:508-519; and International Publication Nos. WO 95/07995, WO 96/17072; as well as, Dubensky, Jr., T. W., et al., U.S. Pat. No. 5,843,723, issued Dec. 1, 1998, and Dubensky, Jr., T. W., U.S. Patent No. 5,789,245, issued Aug. 4, 1998, both herein incorporated by reference. Particularly preferred are chimeric alphavirus vectors comprised of sequences derived from Sindbis virus and Venezuelan equine encephalitis virus. See, e.g., Perri et al. (2003) J. Virol . 77: 10394-10403 and International Publication Nos. WO 02/099035, WO 02/080982, WO 01/81609, and WO 00/61772; herein incorporated by reference in their entireties.
A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression of the coding sequences of interest (for example, a ligand fusion protein expression cassette) in a host cell. In this system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the
bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide of interest, dri ven by a T7 promoter. The polymerase
expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into protein by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy- Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al., Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.
As an alternative approach to infection with vaccinia or avipox virus
recombinants, or to the delivery of genes using other viral vectors, an amplification system can be used that will lead to high level expression following introduction into host cells. Specifically, a T7 RNA polymerase promoter preceding the coding region for T7 RNA polymerase can be engineered. Translation of RNA derived from this template will generate T7 RNA polymerase which in turn will transcribe more template.
Concomitantly, there will be a cDNA whose expression is under the control of the T7 promoter. Thus, some of the T7 RNA polymerase generated from translati on of the amplification template RNA will lead to transcription of the desired gene. Because some T7 RNA polymerase is required to initiate the amplification, T7 RNA polymerase can be introduced into cells along with the template(s) to prime the transcription reaction. The polymerase can be introduced as a protein or on a plasmid encoding the RNA
polymerase. For a further discussion of T7 systems and their use for transforming cells, see, e.g., International Publication No. WO 94/26911; Studier and Moffatt, J. Mol. Biol. (1 86) 189: 113-130; Deng and Wolff, Gene (1994) 143 :245-249; Gao et al., Biochem. Biophys. Res. Commun. (1994) 200: 1201-1206; Gao and Huang, Nuc. Acids Res. (1993) 21 :2867-2872; Chen et al., Nuc. Acids Res (1994) 22:2114-2120; and U.S. Pat. No. 5, 135,855.
The synthetic expression cassette of interest can also be delivered without a viral vector. For example, the synthetic expression cassette can be packaged as DNA or RNA in liposomes prior to delivery' to the subject or to cells derived therefrom. Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed DNA to lipid preparation can vary but will generally be around 1 : 1 (mg DNA:micromoles lipid), or more of lipid. For a
review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight, Biochim Biophys Acta (1991.) 1097: 1-17; Straubinger et al., in Methods of Enzymology (1983), Vol. 101, pp. 512-527.
Liposomal preparations for use in the present invention include cationic
(positively charged), anionic (negatively charged) and neutral preparations, with cationic liposomes particularly preferred. Cationic liposomes have been shown to mediate intracellular deliver}' of plasmid DNA (Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077- 6081); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265: 10189- 10192), in functional form.
Cationic liposomes are readily available. For example, N-[l-(2,3- di ol eyl oxy)propyl ] -N,N,N -trimethyl ammonium chloride (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416). Other commercially available lipids include (DDAB/DOPE) and DOTAP/DOPE (Boerhinger). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g., Szoka et al., Proc. Natl. Acad. Sci. USA (1978) 75:4194-4198; PCT Publication No. WO 90/11092 for a description of the synthesis of DO TAP (l,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.
Similarly, anionic and neutral liposomes are readily available, such as, from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), di ol eoylphosphati dyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.
The liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See, e.g., Straubinger et al., in METHODS OF IMMUNOLOGY (1983), Vol. 101 , pp. 512-527; Szoka et al., Proc.
Natl. Acad. Sci. USA (1978) 75:4194-4198; Papahadjopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell (1979) 17:77); Deamer and Bangham, Biochim. Biophys. Acta (1976) 443 :629; Ostro et al., Biochem. Biophys. Res. Commun. (1977) 76:836; Fraley et al., Proc. Natl. Acad. Sci. USA (1979) 76:3348); Enoch and
Strittmatter, Proc. Natl. Acad. Sci. USA (1979) 76: 145); Fraley et al., J. Biol. Chem (1980) 255: 10431; Szoka and Papahadjopoulos, Proc. Natl. Acad. Sci. USA (1978) 75: 145; and Schaefer-Ridder et ah, Science (1982) 215: 166.
The DNA and/or peptide(s) can also be delivered in cochleate lipid compositions similar to those described by Papahadjopoulos et al., Biochem. Biophys. Acta (1975) 394:483-491. See, also, U S. Pat. Nos. 4,663,161 and 4,871,488.
The expression cassette of interest may also be encapsulated, adsorbed to, or associated with, particulate carriers. Examples of particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PEG. See, e.g., Jeffery et al., Pharm. Res. (1993) 10:362-368; McGee J. P., et al., J Microencapsul. 14(2): 197-210, 1997; O'Hagan D. T., et ai., Vaccine 11(2): 149-54, 1993.
Furthermore, other particulate systems and polymers can be used for the in vivo or ex vivo delivery of the nucleic acid of interest. For example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules, are useful for transferring a nucleic acid of interest. Similarly, DEAE dextran-mediated transfection, calcium phosphate precipitation or precipitation using other insoluble inorganic salts, such as strontium phosphate, aluminum silicates including bentonite and kaolin, chromic oxide, magnesium silicate, talc, and the like, will find use with the present methods. See, e.g., Felgner, P. L., Advanced Drug Delivery Reviews (1990) 5: 163-187, for a review of delivery systems useful for gene transfer. Peptoids (Zuckerman, R. N., et al., U.S. Pat. No. 5,831 ,005, issued Nov. 3, 1998, herein incorporated by reference) may also be used for delivery of a construct of the present invention.
Additionally, biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering synthetic expression cassettes of
the present invention. The particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun." For a description of such techniques, and apparatuses useful therefore, see, e.g., U.S. Pat. Nos. 4,945,050; 5,036,006;
5, 100,792; 5,179,022; 5,371,015; and 5,478,744. Also, needle-less injection systems can be used (Davis, H. L., et al, Vaccine 12: 1503-1509, 1994; Bioject, Inc., Portland, Oreg.). Recombinant vectors canying a synthetic expression cassette of the present invention are formulated into compositions for delivery' to a vertebrate subject. These compositions may either be prophylactic (e.g., to prevent cancer progression or metastasis) or therapeutic (e.g., to treat cancer). The compositions will comprise a "therapeutically effective amount" of the nucleic acid of interest such that an amount of the ligand (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) can be produced in vivo so that the urokinase receptor is inhibited in the individual to which it is administered. Preferably, the ligand is produced in a sufficient amount in the individual to have anti-tumor activity. The exact amount necessary will vary depending on the subject being treated; the age and general condition of the subject to be treated; the degree of protection desired; the severity of the condition being treated; the particular ligand fusion protein produced and its mode of administration, among other factors. An appropriate effective amount can be readily determined by one of skill in the art. Thus, a "therapeutically effective amount" will fall in a relatively broad range that can be determined through routine trials.
The compositions will generally include one or more "pharmaceutically acceptable excipients or vehicles" such as water, saline, glycerol, poly ethyleneglycol , hyaluronic acid, ethanol, etc. Additionally, auxiliary' substances, such as wetting or emulsifying agents, pH buffering substances, surfactants and the like, may be present in such vehicles. Certain facilitators of nucleic acid uptake and/or expression can also be included in the compositions or coadministered.
Once formulated, the compositions of the invention can be administered directly to the subject (e.g., as described above) or, alternatively, delivered ex vivo, to cells derived from the subject, using methods such as those described above. For example,
methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and can include, e.g., dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, lipofectamine and LT-l mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposom es, and direct microinjection of the DNA into nuclei.
Direct delivery of synthetic expression cassette compositions in vivo will generally be accomplished with or without viral vectors, as described above, by injection using either a conventional syringe, needless devices such as Bioject or a gene gun, such as the Accell gene delivery system (PowderMed Ltd, Oxford, England).
D. Pharmaceutical Compositions
Ligands of the urokinase receptor (e.g., fusion proteins comprising a urokinase GFD linked to a vitronectin SMB domain or nucleic acids encoding them) can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients. Exemplary excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof. Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants. A carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient. Specifi c carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cell obi ose, and the like; polysaccharides, such as raffmose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like. The excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof.
A composition of the invention can also include an antimicrobial agent for preventing or deterring microbial growth. Nonlimiting examples of antimicrobial agents
suitable for the present invention include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenyl ethyl alcohol, phenylmer curie nitrate, thimersol, and combinations thereof.
An antioxidant can be present in the composition as well. Antioxidants are used to prevent oxidation, thereby preventing the deterioration of the ligand fusi on proteins or nucleic acids or other components of the preparation. Suitable antioxidants for use in the present invention include, for example, ascorbyl palmitate, butyl ated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.
A surfactant can be present as an excipient. Exemplary surfactants include: polysorbates, such as "Tween 20" and "Tween 80," and pluronics such as F68 and F88 (BASF, Mount Olive, New Jersey); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanol amines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations.
Acids or bases can be present as an excipient in the composition. Nonlimiting examples of acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof. Examples of suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
The amount of the ligand (e.g., when contained in a drug delivery system) in the composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial). A therapeutically effective dose can be determined experimentally by
repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.
The amount of any individual excipient in the composition will vary depending on the nature and function of the excipient and particular needs of the composition.
Typically, the optimal amount of any indi vidual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of about 1 % to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred. These foregoing pharmaceutical excipients along with other excipients are described in "Remington: The Science & Practice of Pharmacy", 19th ed., Williams & Williams, (1995), the
"Physician’s Desk Reference", 52nd ed., Medical Economics, Montvale, NJ (1998), and Kibbe, A.H., Handbook of Pharmaceutical Excipients, 3rd Edition, American
Pharmaceutical Association, Washington, D C., 2000.
The compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emul sions and liquid concentrates for dilution prior to administration. Examples of suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof. With respect to liquid pharmaceutical compositions, solutions and suspensions are envisioned. Additional preferred compositions include those for oral, ocular, or localized delivery.
The pharmaceutical preparations herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use. Preferably, the compositions comprising one or more ligands of the urokinase receptor
(e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or nucleic acids encoding them) described herein are in unit dosage form, meaning an amount of a conjugate or composition of the invention appropriate for a single dose, in a premeasured or pre-packaged form.
The compositions herein may optionally include one or more additional agents, such as drugs for treating cancer or other medications used to treat a subject for a condition or disease. Compounded preparations may include a ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) and one or more drugs for treating cancer, such as, but not limited to, chemotherapy, immunotherapy, biologic or targeted therapy agents. Alternatively, such agents can be contained in a separate composition from the composition comprising a ligand of a urokinase receptor and co-administered concurrently, before, or after the composition comprising the ligand of the urokinase receptor.
E. Bioconjugation of Ligands of the Urokinase Receptor
Bioconjugates may comprise a ligand of the urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) conjugated to one or more diagnostic or therapeutic agents, or a combination thereof. A ligand of the urokinase receptor may be attached to diagnostic and/or therapeutic agents in a variety of manners. For example, an agent may be attached at the N-terminus, C -terminus, at both the N-terminus and C -terminus, and/or internally, for example, at a residue in the peptide linker between the GFD and SMB domains. Diagnostic and/or therapeutic agents may be connected directly to the ligand of the urokinase receptor or indirectly through an intervening linker or chelating agent (e.g., for metal labeling such as with a radionuclide or paramagnetic metal ion).
Conjugation of ligands can be performed using methods well-known in the art. For a discussion of bioconjugation techniques, see, e.g., Chemistry of Bioconjugates: Synthesis, Characterization, and Biomedical Applications (R. Narain ed., Wiley, 2014), G.T. Flermanson Bioconjugate Techniques (Academic Press, 3rd edition, 2013), and Bioconjugalion Protocols: Strategies and Methods (Methods in Molecular Biology, S.S.
Mark ed., Humana Press, 2nd edition, 201 1), van Vught et al. (2014) Comput Struct Biotechnol J. 9 :e201402001; Gao et al. (2016) Curr Cancer Drug Targets. May 12 [Epub ahead of print]; Massa et al. (2016) Expert Opin Drug Deliv 13: 1-15; Yeh et al. (2015) PLoS One 10(7):e0129681; Freise et al. (2015) Mol Immunol. 67(2 Pt A): l42-152; herein incorporated by reference in their entireties.
For example, imaging and/or therapeutic agents can be conjugated to the side chain e-amine of lysine residues or the free thiol of cysteine residues. In particular, reactions of cysteine thiols with maleimides are commonly used for bioconjugation of proteins. Maleimide-functionalized imaging probes and compounds to facilitate bioconjugation for various imaging modalities are commercially available from a number of companies (e.g., ThermoFisher Scientific (Waltham, MA), GE Healthcare Life Sciences (Pittsburgh, PA), SigmaAldrich (St. Louis, MO), and CF1EMATECH (Dijon, France)), including, for example, maleimide lipid derivatives and maleimide albumin derivatives, which can be incorporated into a microbubble shell for ultrasound imaging, maleimide fluorescent dye derivatives for fluorescence imaging, maleimide chelating agent derivatives for binding metals such as radionuclides and paramagnetic cations, and maleimide gold nanoparticle derivatives, which can be used in a variety of ways including as detection agents for electron microscopy and surface enhanced Raman spectroscopy, enhancement agents for radiotherapy, phototherm al agents for surface plasmon resonance, and delivery agents for attached drugs or other therapeutic agents.
In certain embodi m ents, the l igand of the urokin ase receptor is engineered to include an N-terminal or C-terminal cysteine residue providing a free thiol group to facilitate conjugation to a reagent comprising a functional group that is reactive with thiols. In other embodiments, a cysteine is incorporated into the linker peptide to allow attachment of reagents to the linker region between the VH and VL domains.
Alternatively, additional cysteine residues may be introduced into the single-chain antibody, for example, by site-directed mutagenesis to allow attachment at other sites. A site of attachment away from the urokinase receptor binding sites of the GFD and SMB domains should be chosen to avoid interfering with targeting of the bioconjugate to the urokinase receptor. In one embodiment, a diagnostic or therapeutic agent is conjugated
to a ligand of the urokinase receptor comprising a sequence selected from the group consisting of SEQ ID NOS: 12, 13, and 17-20.
An alternative bioconjugation method uses click chemistry. Click chemistry reactions include the Huisgen 1,3 -dipolar cycloaddition copper catalyzed reaction (Tornoe et al, 2002, 1 Organic Chem 67:3057-64), cycloaddition reactions such as Diels- Alder reactions, nucleophilic substitution reactions (especially to small strained rings like epoxy and aziridine compounds), reactions involving form ation of urea compounds, and reactions involving carbon-carbon double bonds, such as alkynes in thiol -yne
reactions. See, e.g., Kolb et al., 2004, Angew Chem Int Ed 40:3004-31; Evans, 2007, Aust J Chem 60:384-95; Millward et al. (2013) Integr Biol (Camb) 5(1 ): 87-95), Lai 1 ana et al. (2012) Pharm Res 29(1): 1-34, Gregoritza et al. (2015) Eur J Pharm Biopharm. 97(Pt B):438-453, Musumeci et al. (2015) Curr Med Chem. 22(17):2022-2050, McKay et al. (2014) Chem Biol21(9): 1075-1101, Ulrich et al. (2014) Chemistry 20(1):34-41, Pasini (2013) Molecules 18(8):9512-9530, and Wangler et al. (2010) Curr Med Chem.
17(11): 1092-1116; herein incorporated by reference in their entireties.
F. Urokinase Receptor-Targeted Imaging Agents
Ligands of the urokinase receptor can be conjugated to diagnostic agents (e.g., probes or detection agents) suitable for various imaging modalities, including, but not limited to, ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), or fluorescence imaging. Conjugation of a diagnostic agent comprising a detectable moiety or label to a ligand of the urokinase receptor localizes the diagnostic agent to tumors or cancerous cells expressing the urokinase receptor. Useful diagnostic agents that can be used in the practice of the invention include, but are not limited to, contrast agents, photoactive agents, radioisotopes, nonradioactive isotopes, dyes, fluorescent compounds or proteins, chemiluminescent compounds, bioluminescent proteins, enzymes, and enhancing agents (e.g., paramagnetic ions).
In certain embodiments, the ligand of the urokinase receptor is conjugated to a contrast agent. Exemplary contrast agents include ultrasound contrast agents (e.g.
SonoVue microbubbles comprising sulphur hexafluoride, Optison microbubbles comprising an albumin shell and octafluoropropane gas core, Levovist microbubbles comprising a lipi d/galactose shell and an air core, Perflexane lipid microspheres comprising perfluorocarbon microbubbles, and Perflutren lipid microspheres comprising octafl uoropropane encapsulated in an outer lipid shell), magnetic resonance imaging (MRI) contrast agents (e.g., gadodi mide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid), and radiocontrast agents, such as for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, ioversol, iopentol, iodixanol, iomeprol, iobitridol, ioxilan, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, and calcium iopodate).
In other embodiments, the diagnostic agent is a radioactive metal, paramagnetic ion, or other diagnostic cation. In this case, the ligand of the urokinase receptor can be conjugated to a chelating group for binding cations. Exemplary chelating agents include ethylenedi aminetetraaceti c acid (EDTA), di ethyl enetriaminepentaacetic acid (DTP A), l,4,7, 10-tetraazacyclododecane-l,4,7, 10-tetraacetic acid (DOT A), 1,4,7- triazacyclononane-N,N’,N”-triacetic acid (NOTA), NET A, p-bromoacetami do-benzyl - tetraethylaminetetraacetic acid (TETA), porphyrins, polyamines, crown ethers, bis- thiosemicarbazones, polyoximes, and like groups known to be useful for this purpose. Chelates are coupled to the single-chain antibodies using standard chemistries, which then can be used to bind diagnostic isotopes such as 125I, 131I, 123I, 1241, 62Cu, b4Cu, 18F, mIn, 67Ga, 68Ga, 99mTc, 223Ra, nC, 13N, !50, and 76Br for radioimaging. The same chelates, when complexed with non-radioactive metals, such as manganese, iron and gadolinium are useful for MRI, when used along with the ligands of the urokinase receptor.
Diagnostic agents comprising 18F or nC can be used in PET imaging. For example, a ligand of the urokinase receptor can be isotopically labeled with 1SF or UC or conjugated to 18F or uC-labeled compounds for use in PET imaging.
In certain embodiments, the ligand of the urokinase receptor is conjugated to a fluorescent label. Exemplar} fluorescent labels include fluorescein derivatives, rhodamine derivatives, coumarin derivatives, cyanine derivatives, acridine derivatives, squaraine derivatives, naphthalene derivatives, oxadiazol derivatives, anthracene derivatives, pyrene derivatives, oxazine derivatives, arylmethine derivatives, and tetrapyrrole derivatives. Alternatively, the fluorescent label may comprise a fluorescent protein, such as, but not limited to, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, rsCherry, and rsCherryRev.
In other embodiments, the ligand of the urokinase receptor is conjugated to a bioluminescent label such as a bioluminescent protein. Exemplary bioluminescent proteins, include, but are not limited to, firefly luciferase, bacterial luciferase, Renilla luciferase, and aequorin.
Fluorescence or bioluminescence images may be recorded by any suitable method. For example, a CCD image sensor (e.g., intensified CCD (ICCD) or electron multiplying CCD (EMCCD)), a CMOS image sensor, or a digital camera may be used to capture images. The image may be a still photo or a video in any format (e.g., bitmap, Graphics Interchange Format, JPEG file interchange format, TIFF, or mpeg).
Alternatively, images may be captured by an analog camera and converted into an electronic form. In addition, luminescence can be detected by a luminometer, and fluorescence can be detected by a fluorimeter, a fluorescence microscope, a fluorescence microplate reader, a fluorometric imaging plate reader, fluorescence-activated cell sorting, a fiber-optic fluorescence imaging system, or a medical fluorescence imaging device (e.g., a handheld fluorescence microscope, a laparoscope, an endoscope, or a microendoscope).
Various medical imaging systems have been developed for open surgery as well as for laparoscopic, thoracoscopic, and robot-assisted surgery and can be used in the practice of the invention. Conventional laparoscopes and endoscopes can be equipped with a photodetector (e.g., camera or CCD detector) to provide guidance during medical procedures. Fiber-optic imaging systems can also be used, which include portable handheld microscopes, flexible endoscopes, and microendoscopes. An illumination source can be added to such devices to allow fluorescence imaging. For fluorescence imaging, the excitation light source and photodetector can be integrated into a single medical imaging device or the excitation light source and/or photodetector may reside apart, in which case, imaging is performed with remote delivery of excitation light. Miniaturized imaging systems can be used that allow imaging inside small cavities and constricted spaces. In addition, miniaturized imaging devices (e.g., microendoscopes) may be implanted within a subject for long-term imaging studies. An imaging system that can simultaneously detect fluorescence or bioluminescence at multiple wavelengths can be used for detection of multiple fluorescent and/or bioluminescent agents that emit light at different wavelengths. In addition, a camera may be used to take both photographic images of a subject and to detect fluorescence and bioluminescence, so that photographic images and fluorescent or bioluminescent images can be superimposed to allow regions of fluorescence or bioluminescence to be mapped to the subject’s anatomy for identification of the source of light emissions. For a review of medical imaging devices and methods of using them in image-guided surgery and other medical procedures, see, e.g., Gray et al. (2012) Biomed. Opt. Express. 3(8): 1880-1890; Flusberg et al. (2005) Nat. Methods 2(12):941-950; Choyke et al. (2012) IEEE J. Sel. Top.
Quantum. Electron. 18(3): 1140-1146; Gray et al. (2012 ) Proc. SPIE February 3: 8207; Vahrmeijer et al. (2013) Nat. Rev. Clin. Oncol. 10:507-518; Braks et al. (2013) Methods Mol. Biol. 923 :353-368; Yong et al. (2011) Diabetes 60(5): 1383-1392; Wilson et al. (2008) J. Vis. Exp. May 2(14) pii: 740; Engel sm an et al. (2009) J. Biomed. Mater. Res B Appl Biomater. 88(1): 123-129; Franke-Fayard et al. (2006) Nat. Protoc. l(l):476-485; Rehemtulla et al. (2000) Neoplasia. 2(6):491-495; and Close et al. (2011) Sensors 11 : 180-206; herein incorporated by reference in their entireties.
Administration of Urokinase receptor-Targeted Imaging Agents
Preferably, a detectably effective amount of a urokinase receptor-targeted imaging agent (e.g., a ligand of the urokinase receptor conjugated to a diagnostic agent) is administered to a subject; that is, an amount that is sufficient to yield an acceptable image using the imaging equipment that is available for clinical use. A detectably effective am ount of the urokinase receptor-targeted imaging agent may be admini stered in more than one injection if needed. The detectably effective amount of the urokinase receptor- targeted imaging agent needed for an individual may vary according to factors such as the degree of binding of the imaging agent to cancerous tissue, the age, sex, and weight of the individual, and the particular medical imaging method used. Optimization of such factors is within the level of skill in the art.
Imaging with urokinase receptor-targeted imaging agents can be used in assessing efficacy of therapeutic drugs in treating cancer. For example, images can be acquired after treatment with an anti -cancer therapy to determine if the individual is responding to treatment. In a subject with cancer, imaging with a urokinase receptor-targeted imaging agent can be used to evaluate whether a tumor is shrinking or growing. Further, the extent of cancerous disease (stage of cancer progression) can be determined to aid in determining prognosis and evaluating optimal strategies for treatment (e.g., surgery, radiation, or chemotherapy).
Additionally, urokinase receptor-targeted imaging agents can be used in image- guided surgery. Cells or tissue of interest can be contacted with a urokinase receptor- targeted imaging agent, such that the urokinase receptor-targeted imaging agent binds to urokinase receptors present on the surface of cells or tissue (e.g., urokinase receptors overexpressed on tumors or cancerous cells). Imaging of tissues labeled with the urokinase receptor-targeted imaging agent in this way can be used, for example, for detection of pathology, tumor margin delineation, evaluation of the completeness of resection, and evaluation of the efficacy of treatment.
G. Tumor-Targeted Therapeutic Agents
The ligands of the invention localize specifically to uPAR-expressing tumors where they are internalized by cancerous cells (see Example 2). Thus, ligands can also be used to target therapeutic agents to the location of uPAR-expressing tumors or cancerous cells to directly treat cancer in a subject. A ligand of the invention (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain) can be conjugated to one or more therapeutic agents, such as, but not limited to, drugs, toxins, radioisotopes, immunomodulators, angiogenesis inhibitors, therapeutic enzymes, and cytotoxic or pro- apoptotic agents for treatment of cancer.
For example, a ligand can be conjugated to one or more chemotherapeutic agents such as, but not limited to, abitrexate, adriamycin, adrucil, amsacrine, asparaginase, anthracyclines, azacitidine, azathioprine, bicnu, blenoxane, busulfan, bleomycin, camptosar, camptothecins, carboplatin, carmustine, cerubidine, chlorambucil, cisplatin, cladribine, cosmegen, cytarabine, cytosar, cyclophosphamide, cytoxan, dactinomycin, docetaxel, doxorubicin, daunorubicin, ellence, el spar, epirubicin, etoposide, fludarabine, fluorouracil, fludara, gemcitabine, gemzar, hycamtin, hydroxyurea, hydrea, idamycin, idarubicin, ifosfamide, ifex, irinotecan, lanvis, leukeran, leustatin, matulane,
mechlorethamine, mercaptopurine, methotrexate, mitomycin, mitoxantrone, mithramycin, mutamycin, myleran, mylosar, navelbine, nipent, novantrone, oncovin, oxaliplatin, paclitaxel, paraplatin, pentostatin, platinol, plicamycin, procarbazine, purinethol, ralitrexed, taxotere, taxol, teniposide, thioguanine, tomudex, topotecan, valrubicin, velban, vepesid, vinblastine, vindesine, vincristine, vinorelbine, VP- 16, and vumon.
Alternatively or additionally, a ligand can be conjugated to, one or more tyrosine- kinase inhibitors, such as Imatinib mesylate (Gleevec, also known as STI-571), Gefitinib (Iressa, also known as ZD 1839), Erlotinib (marketed as Tarceva), Sorafenib (Nexavar), Sunitinib (Sutent), Dasatinib (Sprycel), Lapatinib (Tykerb), Nilotinib (Tasigna), and Bortezomib (Velcade); Janus kinase inhibitors, such as tofacitinib; ALK inhibitors, such as crizotinib; Bel -2 inhibitors, such as obatoclax and gossypol; PARP inhibitors, such as Iniparib and Olaparib; PI3K inhibitors, such as perifosine; VEGF Receptor 2 inhibitors, such as Apatinib; AN-152 (AEZS-108) doxorubicin linked to [D -Ly s(6)] - LHRF1 ; Braf
inhibitors, such as vemurafenib, dabrafenib, and LGX818; MEK inhibitors, such as trametinib; CDK inhibitors, such as PD-0332991 and LEE011; Hsp90 inhibitors, such as salinomycin; and/or small molecule drug conjugates, such as Vintafolide;
serine/threonine kinase inhibitors, such as Temsirolimus (Torisel), Everolimus (Afmitor), Vemurafenib (Zelboraf), Trametinib (Mekinist), and Dabrafenib (Tafinlar).
In another example, a ligand is conjugated to a hormonal blocking therapeutic agent for treatment of a cancer depending on estrogen for growth (e.g., cancer expressing estrogen receptors (ER+ cancer)). For example, the anti-B7-H3 antibody can be conjugated to a drug that blocks ER receptors (e.g. tamoxifen) or a drug that blocks the production of estrogen, such as an aromatase inhibitor (e.g. anastrozole, or letrozole).
In another example, the ligand is conjugated to a toxin. The toxin can be of animal, plant or microbial origin. Exemplary toxins include Pseudomonas exotoxin, ricin, abrin, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, and Pseudomonas endotoxin.
In a further example, the ligand is conjugated to an immunomodulator, such as a cytokine, a lymphokine, a monoline, a stem cell growth factor, a lymphotoxin (LT), a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, a transforming growth factor (TGF), such as TGF-oc or TGF-b, insulin-like growth factor (IGF), erythropoietin, thrombopoietin, a tumor necrosis factor (TNF) such as TNF-ct or TNF-b, a mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM- CSF), an interferon such as interferon-a, interferon-b, or interferon-v, SI factor, an interleukin (IL) such as IL-l, IL-lcc, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-l l, IL-l 2, IL-13, IL-l 4, IL-15, IL-l 6, IL-l 7, IL-l 8 IL-21 or IL-25, LIF, kit-ligand, FLT-3, angiostatin, thrombospondin, endostatin, and LT.
In another embodiment, the ligand is conjugated to a radioactive isotope.
In certain embodiments, the therapeutic radionuclide has a decay energy in the range of 20 to 6,000 keV (e.g., 60 to 200 keV for an Auger emitter, 100-2,500 keV for a beta emitter, and 4,000-6,000 keV for an alpha emitter). In one embodiment, the radionuclide is an Auger-emitter (e.g., Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt- 109, In-111, Sb- 1 19, 1-125, Ho-161 , Os-189m and Ir-192). In another embodiment, the radionuclide is an alpha-emitter (e.g., Dy-152, At-21 1, Bi-212, Ra-223, Rn-219, Po-215,
Bi-21 1, Ac-225, Fr-221, At-217, Bi-213 and Fm-255).
225AC, /bBr, 169Yb, and the like.
Ligands may also be conjugated to a boron addend-loaded carrier for thermal neutron activation therapy. For example, boron addends such as carboranes, can be attached to B7-H3-targeting agents. Carboranes can be prepared with carboxyl functions on pendant side chains, as is well-known in the art. Attachment of carboranes to a carrier, such as aminodextran, can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier. The intermediate conjugate is then conjugated to the B7-H3-targeting agent. After administration of the B7-H3- targeting agent conjugate, a boron addend is activated by thermal neutron irradiation and converted to radioactive atoms which decay by alpha-emission to produce highly toxic, short-range effects.
H. Administration
The methods of the invention can be used for treating a subj ect for cancer. For example, ligands of the urokinase receptor (or bioconjugates thereof) can be used for
treating a subject for a tumor, cancer, or metastasis that is progressing, worsening, stabilized or in remission as well as precancerous lesions.
At least one therapeutically effective cycle of treatment with a ligand of the urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or a bioconjugate thereof) will be admini stered to a subject for treatment of cancer. By "therapeutically effective dose or amount" of a ligand of the urokinase receptor is intended an amount that when administered brings about a positive therapeutic response with respect to treatment of an individual for cancer. Of particular interest is an amount of a ligand of the urokinase receptor that provides an anti-tumor effect, as defined herein. By "positive therapeutic response" is intended the individual undergoing the treatment according to the invention exhibits an improvement in one or more symptoms of the cancer for which the individual is undergoing therapy.
Thus, for example, a "positive therapeutic response" would be an improvement in the disease in association with the therapy, and/or an improvement in one or more symptoms of the disease in association with the therapy. Therefore, for example, a positive therapeutic response would refer to one or more of the following improvements in the disease: (1) reduction in tumor size; (2) reduction in the number of cancer cells;
(3) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (4) inhibition (i.e., slowing to some extent, preferably halting) of cancer cell infiltration into peripheral organs; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor metastasi s; and (6) some extent of relief from one or more symptoms associated with the cancer. Such therapeutic responses may be further characterized as to degree of improvement. Thus, for example, an improvement may be characterized as a complete response. By "complete response" is documentation of the disappearance of all symptoms and signs of all measurable or evaluable disease confirmed by physical examination, laboratory, ultrasound, nuclear, radiographic studies (i.e., CT (computer tomography), and/or MRI (magnetic resonance imaging)), and other non-invasive procedures repeated for all initial abnormalities or sites positive at the time of entry into the study. Alternatively, an improvement in the disease may be categorized as being a partial response. By "partial response" is intended a reduction of greater than 50% in the
sum of the products of the perpendicular diameters of all measurable lesions when compared with pretreatment measurements.
In certain embodiments, multiple therapeutically effective doses of compositions comprising a ligand of the urokinase receptor (e g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain or a bioconjugate thereof) and/or one or more other therapeutic agents, such as other drugs for treating cancer, or other medications will be administered according to a daily dosing regimen, or intermittently. For example, a therapeutically effective dose can be administered, one day a week, two days a week, three days a week, four days a week, or five days a week, and so forth. By "intermittent" administration is intended the therapeutically effective dose can be administered, for example, every other day, every two days, every three days, and so forth. For example, in some embodiments, a ligand will be administered twice-weekly or thrice-weekly for an extended period of time, such as for 1, 2, 3, 4, 5, 6, 7, 8...10...15...24 weeks, and so forth. By "twice-weekly" or "two times per week" is intended that two therapeutically effective doses of the agent in question is administered to the subject within a 7-day period, beginning on day 1 of the first week of administration, with a minimum of 72 hours, between doses and a maximum of 96 hours between doses. By "thrice weekly" or "three times per week" is intended that three therapeutically effective doses are administered to the subject within a 7-day period, allowing for a minimum of 48 hours between doses and a maximum of 72 hours between doses. For purposes of the present invention, this type of dosing is referred to as "intermittent" therapy. In accordance with the methods of the present invention, a subject can receive intermittent therapy (i.e., twice-weekly or thrice-weekly administration of a therapeutically effective dose) for one or more weekly cycles until the desired therapeutic response is achieved. The agents can be administered by any acceptable route of administration as noted herein below.
The compositions of the present invention are typically, although not necessarily, administered orally, via injection (subcutaneously, intravenously, or intramuscularly), by infusion, or locally. Additional modes of administration are also contemplated, such as intra-arterial, intraperitoneal, pulmonary, nasal, topical, transderm al, intralesion,
intrapleural, intraparenchymatous, rectal, transdermal, transmucosal, intrathecal, pericardial, intra-arterial, intraocular, and so forth. When administering the ligand of the urokinase receptor by injection, the administration ay be by continuous infusion or by single or multiple boluses.
The preparati ons according to the invention are also suitable for local treatment.
In a particular embodiment, a composition of the invention is used for localized delivery of a ligand of the urokinase receptor for the treatment of cancer. For exampl e, compositions may be administered directly into a tumor or cancerous cells.
Administration may be by perfusion through a regional catheter or direct intralesional injection.
The pharmaceutical preparation can be in the form of a liquid solution or suspension immediately prior to administration, but may also take another form such as a syrup, cream, ointment, tablet, capsule, powder, gel, matrix, suppository, or the like. The pharmaceutical compositions comprising a ligand of the urokinase receptor and other agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
In another embodiment, the pharmaceutical compositions comprising a ligand of the urokinase receptor and/or other agents are administered prophylactically, e.g., to prevent cancer progression or metastasis in tissue. Such prophylactic uses will be of particular value for subjects with a potentially precancerous or premalignant condition (e.g., precancerous lesions, dysplasia or benign neoplasia), or who have a genetic predisposition to developing cancer.
In another embodiment of the invention, the pharmaceutical compositions comprising a ligand of the urokinase receptor and/or other agents are in a sustained- release formulation, or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.
The invention also provides a method for administering a conjugate comprising a ligand of the urokinase receptor (e.g., conjugated to a diagnostic or therapeutic agent) as provided herein to a patient suffering from cancer. The method comprises administering, via any of the herein described modes, a therapeutically effective amount of the conjugate or drug delivery system, preferably provided as part of a pharmaceutical composition.
The method of administering may be used to treat any cancer that is responsive to treatment with a ligand of the urokinase receptor. More specifically, the compositions herein are effective in treating cancer.
Those of ordinary skill in the art will appreciate which conditions a ligand of the urokinase receptor can effectively treat. The actual dose to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered. Therapeutically effective amounts can be determined by those skilled in the art, and will be adjusted to the particular requirements of each particular case.
Generally, a therapeutically effective amount will range from about 0.50 mg to 5 grams of a ligand of the urokinase receptor daily, more preferably from about 5 mg to 2 grams daily, even more preferably from about 7 mg to 1.5 grams daily. Preferably, such doses are in the range of 10-600 mg four times a day (QID), 200-500 mg QID, 25 - 600 mg three times a day (TID), 25-50 mg TID, 50-100 mg TID, 50-200 mg TID, 300-600 mg TID, 200-400 mg TID, 200-600 mg TID, 100 to 700 mg twice daily (BID), 100-600 mg BID, 200-500 mg BID, or 200-300 mg BID. The amount of compound administered will depend on the potency of the specific ligand of the urokinase receptor and the magnitude or effect desired and the route of administration.
A purified ligand of the urokinase receptor (again, preferably provided as part of a pharmaceutical preparation) can be administered alone or in combination with one or more other therapeutic agents, such as chemotherapy, immunotherapy, biologic or targeted therapy agents, or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth. The specific dosing schedule will be known
by those of ordinary skill in the art or can be determined experimentally using routine methods Exemplary dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof Preferred compositions are those requiring dosing no more than once a day.
A ligand of the urokinase receptor can be administered prior to, concurrent with, or subsequent to other agents. If provided at the same time as other agents, the ligand of the urokinase receptor can be provided in the same or in a different composition. Thus, the ligand of the urokinase receptor and other agents can be presented to the individual by way of concurrent therapy. By "concurrent therapy" is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering a dose of a pharmaceutical composition comprising a ligand of the urokinase receptor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating cancer, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen. Similarly, the ligand of the urokinase receptor and one or more other therapeutic agents can be administered in at least one therapeutic dose. Administration of the separate
pharmaceutical compositions can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
Where a subject undergoing therapy in accordance with the previously mentioned dosing regimens exhibits a partial response or a relapse following a prolonged period of remission, subsequent courses of concurrent therapy may be needed to achieve complete remission of the disease. Thus, subsequent to a period of time off from a first treatment period, a subject may receive one or more additional treatment periods with the ligand of the urokinase receptor. Such a period of time off between treatment periods is referred to herein as a time period of discontinuance. It is recognized that the length of the time peri od of discontinuance is dependent upon the degree of tumor response (i.e., complete
versus partial) achieved with any prior treatment periods of concurrent therapy with these therapeutic agents
Additionally, treatment with a ligand of the urokinase receptor may be combined with any other medical treatment for cancer, such as, but not limited to, surgery, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or molecularly targeted or biologic therapy. Any combination of these other medical treatment methods with a ligand of the urokinase receptor may be used to effectively treat cancer in a subject.
For example, treatment with a ligand of the urokinase receptor may be combined with chemotherapy with one or more chemotherapeutic agents such as, but not limited to, abitrexate, adriamycin, adrucil, amsacrine, asparaginase, anthracyclines, azacitidine, azathioprine, bicnu, blenoxane, busulfan, bleomycin, camptosar, camptothecins, carboplatin, carmustine, cerubidine, chlorambucil, cisplatin, cladribine, cosmegen, cytarabine, cytosar, cyclophosphamide, cytoxan, dactinomycin, docetaxel, doxorubicin, daunorubicin, ellence, el spar, epirubicin, etoposide, fludarabine, fluorouracil, fludara, gemcitabine, gemzar, hycamtin, hydroxyurea, hydrea, idamycin, idarubicin, ifosfamide, ifex, irinotecan, lanvis, leukeran, leustatin, matulane, mechlorethamine, mercaptopurine, methotrexate, mitomycin, mitoxantrone, mithramycin, mutamycin, myleran, mylosar, navelbine, nipent, novantrone, oncovin, oxaliplatin, paclitaxel, paraplatin, pentostatin, platinol, plicamycin, procarbazine, purinethol, ralitrexed, taxotere, taxol, teniposide, thioguanine, tomudex, topotecan, valrubicin, velban, vepesid, vinblastine, vindesine, vincri stine, vinorelbine, VP- 16, and vumon.
In another example, treatment with a ligand of the urokinase receptor may be combined with targeted therapy with one or more small molecule inhibitors or monoclonal antibodies such as, but not limited to, tyrosine-kinase inhibitors, such as Imatinib mesylate (Gleevec, also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as Tarceva), Sorafenib (Nexavar), Sunitinib (Sutent), Dasatinib (Sprycel), Lapatinib (Tykerb), Nilotinib (Tasigna), and Bortezomib (Velcade); Janus kinase inhibitors, such as tofacitinib; ALK inhibitors, such as crizotinib; Bcl-2 inhibitors, such as obatoclax and gossypol; PARP inhibitors, such as Iniparib and Olaparib; PI3K inhibitors, such as perifosine; VEGF receptor 2 inhibitors, such as
Apatinib; AN-152 (AEZS-108) doxorubicin linked to [D-Lys(6)]-LHRH; Braf inhibitors, such as vemurafenib, dabrafenib, and LGX818; MEK inhibitors, such as trametinib; CDK inhibitors, such as PD-0332991 and LEE011 ; Hsp90 inhibitors, such as salinomycin; small molecule drag conjugates, such as Vintafolide; serine/threonine kinase inhibitors, such as Temsirolimus (Torisel), Everolimus (Afmitor), Vemurafenib (Zelboraf),
Trametinib (Mekinist), and Dabrafenib (Tafmlar); and monoclonal antibodies, such as Rituximab (marketed as MabThera or Rituxan), Trastuzumab (Herceptin), Alemtuzumab, Cetuximab (marketed as Erbitux), Panitumumab, Bevacizumab (marketed as Avastin), and Ipilimumab (Yervoy).
In a further example, treatment with a ligand of the urokinase receptor may be combined with immunotherapy, including, but not limited to, using any of the following: a cancer vaccine (e.g., E75 HER2-derived peptide vaccine, nelipepimut-S (NeuVax), Sipuleucel-T), antibody therapy (e.g., Trastuzumab, Ado-trastuzumab emtansine, Alemtuzumab, Ipilimumab, Ofatumumab, Nivolumab, Pembrolizumab, or Rituximab), cytokine therapy (e.g., interferons, including type I (IFNa and PTNGb), type II (LFNy) and type III (ITNl) and interleukins, including interleukin-2 (IL-2)), adjuvant
im unochemotherapy (e.g., polysaccharide-K), adoptive T-cell therapy, and immune checkpoint blockade therapy. I. Kits
The invention also provides kits comprising one or more containers holding compositions comprising at least one ligand of a urokinase receptor (e.g., a fusion protein comprising a urokinase GFD linked to a vitronectin SMB domain), or a bioconjugate thereof (e.g. conjugated to a therapeutic and/or diagnostic agent), or a nucleic acid encoding such a ligand and optionally one or more other drugs for treating cancer.
Compositions can be in liquid form or can be lyophilized, as can individual peptides, polypeptides, or nucleic acids. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for
example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
The kit can further comprise a second container comprising a pharmaceutically- acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices. The delivery device may be pre-filled with the compositions.
The kit can also comprise a package insert containing written instructions for methods of treating cancer. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
In certain embodiments, the kit comprises a ligand comprising a fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NOS: 17-20, or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the ligand is capable of binding to and/or inhibiting the urokinase receptor.
III. Experimental
Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
Example 1
Engineering High-Affinity Ligands of The Urokinase Receptor
INTRODUCTION
Over the last 30 years the data implicating uPAR in cancer metastasis has continued to grow, with over 5,000 research articles and reviews published on the topic to date. In addition to uncovering uPAR’s role in metastasis, a tremendous effort has been made to develop molecules that block uPAR activity as a means of combating the spread of cancer in patients. Although numerous molecules targeting uPAR have shown promising efficacy in animal models of cancer, surprisingly, none have been further developed and made available in the clinic for treating patients. One molecule that inhibits uPA activity did complete two separate phase II clinical trials in 2008 and 2012 and was well tolerated1 2, suggesting toxicity is not impeding progress. However, further developm ent of this molecule has not been published, likely due to the underwhelming efficacy of only extending median progression free survival from 49 to 100 days in patients with epithelial ovarian cancer1, and having no positive effect on patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma2. Nevertheless, the significant, although low, efficacy demonstrated by this first-in-class molecule and the absence of toxic side effects confirms uPA and uPAR as viable clinical targets for cancer treatment. Our hypothesis is the lack of efficacy delivered by previous molecules is due to their inadequate inhibition of uPAR activity. The goal of this thesis is to apply lessons learned from these previous attempts toward engineering a next-generation uPAR antagonist capable of more completely inhibiting uPAR activity in aggressive and metastatic cancers.
Previously developed uPAR antagonists can be categorized by the specific uPAR functions they inhibit. For example, there are inhibitors of uPAR’s interaction with its soluble ligand urokinase, and with an assortment of integrins, FPRL1, vitronectin, and P AI- 1 , and there are direct inhibitors of urokinase catalytic activity. A close evaluation of these antagonists reveals key shared characteristics between them, 1) they each
effectively reduce cancer establishment, growth, and/or metastasis in vivo, even though 2) they bind uPAR with similar or weaker affinity compared to the competing wild-type uPAR ligands, and 3) each antagonist alone only partially inhibits uPAR activity.
Targeting the uPAR receptor with an antagonist engineered to: a) have orders-of- magnitude higher binding affinity than uPAR’s native ligands, and thus more effectively outcompete native ligand binding in vivo, and b) simultaneously block multiple cancer- associated uPAR interactions is therefore an attractive strategy for developing a next- generation uPAR antagonist. Such an antagonist would overcome the limitations of previously developed molecules, and potentially have a more dramatic effect on cancer metastasis in vivo.
Towards this goal, we sought to engineer a bispecific protein that simultaneously binds to two distinct functional uPAR epitopes with an affinity superior to the native ligands. Possible strategies for engineering said protein include 1) developing and fusing together two antibodies that each bind a separate functional uPAR epitope, such that both simultaneously bind uPAR, 2) developing two antibodies that each bind a separate functional uPAR epitope, and then creating a "knob-in-hole" heterodimer3 6 composed of one arm from each antibody that simultaneously bind uPAR, 3) engineering non-antibody scaffold proteins de novo to bind two distinct uPAR epitopes, and then chemically or genetically fusing them such that each simultaneously bind uPAR, or 4) Re-engineering two natural uPAR ligands that already simultaneously bind uPAR to function as antagonists, and fusing them together such that they simultaneously bind the receptor. There are two key challenges inherent in the first three strategies mentioned; the first challenge is developing a high-throughput assay capable of separating off-target uPAR binders from binders of the desired epitope, and the second is engineering de novo ligand with binding affinities superior to the wild-type ligands. The latter challenge is particularly difficult in the case of interrupting the uPA-uPAR interaction, which has an affinity of approximately 230 pM'. The fourth strategy mentioned - re-engineering uPAR’s native ligands as antagonists, avoids both of these challenges. Specifically, starting with the native ligands preserves the mechanism of binding, ensuring specific inhibition of only the target uPAR epitopes. Additionally, each ligand starts with a
binding affinity equal to the wild-type interaction; any further improvement in affinity from engineering efforts would result in ligands already more capable of outcompeting the natural ligands for binding. Therefore, we focused our efforts on re-engineering uPAR’s natural ligands to form a bispecific ligand.
Our first step toward engineering a ligand-based bi specific uPAR antagonist was to select two ligands that simultaneously bind uPAR, and when re-engineered, are capable of blocking multiple cancer-associated uPAR interaction s. Domains of uPA and the ECM component vitronectin meet these criteria. uPA contains a growth factor domain, a kringle domain, and a protease domain. The growth factor domain (GFD, amino acids 1 -48) binds uPAR with an affinity equal to that of full-length uPA (KD =
0.23 nM)7, and has no other known binding partner. Additionally, GFD lacks both the protease domain and kringle domain that are required for focalizing ECM degradation at the cell surface, and for uPAR interactions with anb3 integrin8’9, gp 130 (ref 10) and PAI- 1 (ref u) that play roles in cancer metastasis (FIG. 1 A, FIG. IB, i). Furthermore, GFD by itself already has a baseline level of anti -cancer activity; treating mice with GFD fused to the Fc domain of an antibody (GFD-Fc) has been shown to reduce tumor growth in vivo12’13. However, the GFD-uPAR complex also binds vitronectin14, which induces cell migration. Additionally, GFD is predicted to be the only urokinase domain required to induce EGFR activation via formation of "the proliferasome"15, and downstream signaling for cell proliferation, migration, and angiogenesis. Therefore, GFD alone is a sub optimal uPAR antagonist; it inhibits a subset of uPAR functions, but activates others that facilitate cancer metastasis. The somatomedin B domain (SMB, amino acids 1 -44) of vitronectin binds the urokinase-uP AR complex with a cooperative affinity of 300 nM, or binds uPAR alone with a Kd of ~ 2 pM7. SMB blocks uPAR from binding vitronectin7 and FPR1/27, and is predicted to block EGFR activation by binding the same domain required for uRAII/aίbi integrin/EGFR complex formation16 17 (FIG. IB, ii). Thus, a bispecific ligand comprising GFD linked to SMB is expected to simultaneously block multiple uPAR interactions that coordinate cancer metastasis (FIG. I B, iii). Furthermore, fusing the wild-type GFD and SMB proteins is expected to create a bispecific ligand with substantially higher affinity compared to native uPA and vitronectin due to the avidity
effect of GFD and SMB simultaneously binding uPAR We therefore chose to develop a bispecific uPAR ligand comprised of GFD genetically fused to SMB
In addition to engineering the human uPAR (huPAR) ligand, we also followed the same strategy to engineer a mouse uPAR (muPAR) ligand in parallel, which will be required to demonstrate the full potential of a uPAR-targeted therapy in mouse model s of cancer. This is because human uPA/GFD does not bind mouse uPAR, and mouse uPA/GFD does not bind human uPAR18. Therefore, when testing huPAR ligands in a xenograft model, the cancer cell-surface huPAR will not be stimulated by endogenous mouse uPA, and thus antagonizing the receptor is expected to produce a lower, less physiologically accurate response. Furthermore, the huPAR ligand will not inhibit mouse uPAR present on the vasculature that facilitates tumor-associated angiogenesis and tumor growth. Inhibiting muPAR in a syngeneic mouse model avoids these issues. In this case, the murine cancer cell-surface muPAR would be stimulated by endogenous mouse uPA, which when inhibited is expected to result in a more substantial and accurate response. In addition, the muPAR on endothelial cells facilitating tumor-associated angiogenesis will also be inhibited. Targeting muPAR activity in a syngeneic mouse model is thus expected to more accurately represent the full potential of a uPAR antagonist.
We used yeast surface display technology and directed evolution to engineer the bi specific uPAR ligands. First, the individual domains and various GFD-SMB fusion designs were displayed on the surface of yeast and their binding affinities for uPAR were measured. As predicted, fusing GFD and SMB resulted in an 8.3 -fold and 8.7-fold improvement in binding affinity for the mouse and human proteins, respectively, compared to indivi dual GFD. This improvement is due to the avidity effect of the domains simultaneously binding uPAR. Subsequently, libraries of GFD and SMB mutants were generated and screened by FACS to identify amino acid mutations that confer enhanced binding affinity for uPAR This yielded mutants with additional 6-to- 235 -fold improvements in binding affinity. To our knowledge, these are the highest affinity uPAR ligands reported to date, and represent significant progress towards developing a more effective uPAR-targeted therapy.
3.3 RESULTS
3.3.1 ENGINEERING BISPECIFIC UPAR LIGANDS.
To design a ligand-based bispecific uPAR ligand it was critical to engineer the peptide linker connecting the termini of GFD and SMB such that both ligands can simultaneously bind uPAR, while avoiding excess conformational entropy in the linker that would otherwise hinder the overall affinity of the fusion protein. We optimized two parameters to achieve this goal: 1) linker length, and 2) linker amino acid composition.
To first approximate the minimum and maximum boundaries of the linker length to explore, we used data from the crystal structure of the solved uPA-uPAR-SMB complex19 (PDB 3BT1) to model various linker lengths connecting the COOH-terminus of GFD to the NH2 -terminus of SMB. Specifically, we wrote amino acid coordinates into the PDB text file bridging the GFD and SMB domains, and then loaded the edited text file into UCSF chimera software20 to assign possible structures to the added linker sequence. We started by modeling two different linker lengths comprising repeating GGGGS (GlyrSer) sequences, a [Gly4Ser]4 and [Gly4Ser]s linker, predicted to have total lengths of 40 and 50 angstroms, respectively. Linkers composed of Gly4Ser repeats are commonly used due to their favorable solubility and inherent flexibility18, allowing the fused proteins to sample a vast landscape of orientations, including, ideally, the orientation required for both to simultaneously engage the target.
Fusing GFD and SMB with a [Gly4Ser]4 linker appears to allow both ligands to simultaneously bind uP AR (FIG. 2), with backbone dihedral angles in the linker predicted to be energetically allowed by Ramachandran plots (not shown). However, the linker has a limited set of conformations that bridge GFD and SMB, as one of the three possibilities shown clashes sterically with the receptor. This suggests a longer linker may be more optimal. Indeed, the [Gly4Ser]s linker appears long enough to orient around all angles of the receptor without causing steric clash (FIG. 3), also with backbone dihedral angles predicted to be favorable by Ramachandran plots (not shown). We therefore generated and tested three different GFD -SMB fusion proteins containing a [Gly4Ser]3, [Gly4Ser]4, or [Gly4Ser]s linker. The [Gly4Ser]3 linker was included as a negative control, as modeling predicts it is too short to allow GFD and SMB to simultaneously bind uPAR.
To test the different linker designs, the mouse GFD-SMB proteins were first displayed on the surface of yeast as N-terminal fusions to the aga2p yeast coat protein, and their binding affinities for soluble muPAR were measured. In addition, mouse GFD (mGFD) and SMB (mSMB) were also displayed and their binding affinities were measured for comparison. This is a rapid method for generating proteins and measuring their affinities for a soluble target, as it does not require the laborious soluble expression and purification of each individual protein. The three mGFD-mSMB designs with varying linker lengths all expressed well on the surface of yeast and showed significant binding to soluble recombinant muPAR (FIG. 4). The mGFD-mSMB proteins with 3x, 4x, and 5x Gly4Ser linkers had Kd values of 2 34 nM, 0.83 nM, and 0.55 nM, respectively, indicating the fusion protein with the 5x(Gly4Ser) linker is the most optimal of the three as predicted by our modeling results. When compared head-to-head with mGFD, mGFD-mSMB bound muPAR with 8.3 -fold higher affinity (Kd = 0.22 nM, FIG. 5), indicating the GFD and SMB domains are simultaneously binding muPAR. To further confirm the enhanced affinity observed for mGFD-mSMB compared to mGFD alone is due to the added SMB domain specifically and simultaneously binding muPAR, we made two amino acid mutations in the SMB domain of mGFD-mSMB (Y27A and Y28A) that are known to abolish SMB-uPAR binding21 23. As expected, the mutant mGFD- mSMB Y2 /A ’ Y28A protein bound muPAR with the same affinity as mGFD (FIG. 6). The affinity of mSMB alone is too low (~ 2 mM)7 to detect binding to muPAR using this assay, and therefore those data are not included here. These results indicate the bi specific mGFD-mSMB protein binds with superior affinity compared to the wild-type mGFD protein, and simultaneously engages both the uPA (GFD) and vitronectin (SMB) binding sites on muPAR.
Given the [Gly4Ser]5 linker was optimal in the mGFD-mSMB design and the high structural similarity between the hGFD-huPAR and mGFD-muPAR complexes (FIG. 7) we also used this linker to generate the bispecific human uPAR ligand comprising human GFD (hGFD) linked to SMB (hSMB), hereafter called "hGFD- hSMB". As before, this protein was displayed on the surface of yeast and its binding affinity for soluble huPAR was measured and compared with the individual hGFD and hSMB domains. All three
proteins expressed well on the surface of yeast and showed significant binding so soluble recombinant huPAR (FIG. 8), except hSMB which again has too low of an affinity (~2 mM)7 to detect binding to huPAR using this assay (data not shown). Similar to the hGFD- hSMB protein, hGFD-hSMB bound huPAR with an 8.7-fold higher affinity (Kd = 0.12 nM) compared to hGFD alone (Kd = 1.04 nM). To again confirm the enhanced affinity observed for hGFD-hSMB compared to hGFD is due to the added hSMB domain specifically and simultaneously binding huPAR, we made the same two amino acid mutations in the SMB domain of hGFD-hSMB (Y27A and Y28A) that abolish its affinity for uPAR21 23. As expected, the mutant hGFD-hSMB Y27A,Y28A protein bound uPAR with the same affinity as hGFD (FIG. 9).
Without further engineering, the hGFD-hSMB and hGFD-hSMB proteins already block multiple functions of uPAR with superior affinities compared to the wild-type ligands. However, that is assuming both epitopes of uPAR are available for mGFD- mSMB to bind, which will not always be the case in vivo. For example, if cancer cell- surface muPAR is already bound to vitronectin, the mGFD-mSMB protein affinity will be effectively reduced to that of wild-type mouse uPA. Likewise, if muPAR is already bound to mouse uPA, the mGFD-mSMB affinity will be effectively reduced to that of wild-type vitronectin. In these cases, mGFD-mSMB will be less capable of outcompeting uPAR’ s natural ligands for binding. To solve this problem, we next used directed evolution to identify amino acid mutations in the GFD and SMB domains that enhance their individual affinities for uPAR, thus making them more effective competitors. We also evolved the [Gly4Ser]5 linkers in parallel to search for amino acid mutations that reduce excess linker entropy and favor simultaneous binding of each ligand.
3.3.2 RECOMBINANT SOLUBLE UPAR EXPRESSION AND
PURIFICATION
Directed evolution and characterization of the uPAR ligands was expected to require significant amounts of recombinant uPAR protein. Therefore, we established methods for producing and purifying these proteins. The cDNA sequences coding for soluble human and mouse uPAR were cloned into the mammalian expression vector
pCEP4, and the proteins were expressed in suspension Freestyle 293 -F cells using transient transfection. The recombinant proteins lack amino acid G305 (huPAR) or G298 (muPAR) required for lipidation, and are thus released from the cell as soluble proteins after being exported to the extracellular space. Two versions of huPAR and muPAR were expressed, one with an NH2-terminal FLAG tag as a handle for detection in vitro by a fluorescent anti -FLAG antibody, and one without. All proteins were expressed with C- terminal 6x -histidine tags as handles for purification. The 6x-histidine tagged huPAR and muPAR (henceforth simply called "huPAR" and "muPAR") and the FLAG-tagged muPAR (henceforth called muPAR-FLAG") were expressed and purified by nickel-NTA affinity chromatography followed by size exclusion chromatography (FIG. 10A). The final products were > 95-99% pure (FIG. 10B), and the yields were 1.8 mg/L, 12 mg/L, and 1.1 mg/L for huPAR, muPAR, muPAR-FLAG, respectively. Unfortunately, we were unable to separate the desired FLAG-tagged huPAR protein from expression byproducts using size-exclusion chromatography. Therefore, we used the 6x -histidine-tagged huPAR to evolve high-affinity hGFD and hSMB ligands. To our knowledge, this is the first documented method of producing these proteins using FIEK 293 cells as an expression host.
3.3.3 MOUSE GFD LIBRARY 1 GENERATION, SORT PROGRESSION, AND VARIANT CHARACTERIZATION
Amino acids 19 - 31 in the mouse GFD protein are primarily responsible for forming the interaction between muPA and muPAR, with additional potential interactions between amino acids 39-42. Exhaustively testing every possibl e combination of amino acids in these regions using saturation mutagenesis would require a library of 1.3 c IQ22 variants, which is far larger than the ~108 variant limit that can be practically screened using FACS. Therefore, we instead used error-prone PCR to make random mutations across the entire 46 amino acid sequence. In addition to exploring mutations at the binding interface, this approach also has the potential to identify mutations distal from the binding interface that have a positive allosteric effect on binding affinity, and/or that enhance the stability and expression of the protein24. Five separate DNA librari es were
generated using varying concentrations of dNTP analogs that induce A-to-C, G-to-T, A- to-G, and G-to-A mutations. The DNA libraries were sequenced to identify which contained the desired frequency of mutation (FIG. 11). Two libraries were pooled that had amino acid mutations ranging from 0-to-3 and 0-to-5 per gene, with averages of 1 and 2 mutations per gene. The pooled DNA library was transformed into yeast resulting in a protein library of approximately 5.9 x 10 ' variants. Preliminary analysis indicated ~ 20% of the library retained significant binding affinity to soluble muPAR (data not shown), indicating the level of mutation produced the desired stratification of binding affinities (i.e. within 20 - 80% of variants retaining binding).
The mGFD library was sorted using equilibrium binding conditions to separate variants with improved binding affinities from those with weaker affinities. For the first sort, the library was incubated with 1 nM muPAR-FLAG and approximately 50% of the binding population (10% of the library) was collected (FIG. 12). The purpose of the first sort round is primarily to remove the non-binding and low-binding variants and reduce the library size to a level that can be sorted at higher coverage (e.g., lOx) in the next sort. For the second sort, the library was again incubated with 1 nM muPAR-FLAG, but only 1% of the binding population was collected to increase the rate of enrichment of high- affinity variants. Finally, for sort 3 and 4 the concentration of muPAR-FLAG was reduced to 200 pM to increase the selective pressure for improved variants, and only the top 0.5-to-l% of binders were collected in each round. There was a noticeable increase in binding from sort 3 to 4 (FIG. 12), indicating the sorting strategy successfully isolated superior variants in the library.
DNA from the variants remaining after the 4th sort was isolated and sequenced to identify consensus mutations that may confer enhanced affinity for muPAR. Of the 20 sequences obtained, 6 unique variants had an E41K mutation (FIG. 13 A), suggesting this mutation may be responsible for the increase in muPAR binding observed between sorts 3 and 4. Indeed, when analyzed in bulk, the library after sort 4 had a 2.5-fold
improvement in apparent Kd compared to wild-type mGFD (FIG. 13B). Our goal was to improve the affinity of mGFD by a minimum of 10-fold, so we submitted the remaining vari ants to another round of directed evolution.
3.3,4 MOUSE GFD LIBRARY 2 GENERATION, SORT PROGRESSION,
AND VARIANT CHARACTERIZATION
A similar strategy was used to generate the second mGFD library. DNA isolated after the 4th sort of the first library was mutagenized again using error-prone PCR. Five separate DNA libraries were generated using a range of dNTP analog concentrations and sequenced to determine which had the desired mutation frequency (FIG. 14). DNA from three of the libraries with averages of 3.4, 2.5, and 1.5 amino acid mutations per gene were pooled and transformed into yeast resulting in a protein library of approximately 2 x 10' variants. Preliminary analysis indicated ~ 20% of the library retained binding to soluble muPAR (data not shown).
The library was sorted first using equilibrium binding conditions to reduce the library to an amenable size, and then using a kinetic off-rate screen to isolate variants with slower off-rates and thus improved binding affinities for muPAR. For the first sort, the library was incubated with 1 nM muPAR-FLAG and approximately 50% of the binding population (10% of the l ibrary) was collected (FIG. 15). The concentration of muPAR-FLAG was reduced to 500 pM in the next sort to increase the selective pressure for binding, and only the top 1% of the binding population was collected to further enrich for higher-affinity variants.
After the second sort, the remaining library was estimated to contain around 4.5 x 105 unique variants, which is an amenable size to sort using a kinetic off-rate screen. This type of screen is used when the average affinity of the library approaches the 1 x 10 10 - to - 1 x 10 11 M range, whereafter issues with ligand depletion and the incubation times required for binding to go to completion in an equilibrium binding screen become impractical to manage. Using a kinetic off-rate screen avoids these challenges, and allows the application of a more stringent selection pressure for variants with lower off-rates, and thus improved binding affinities (Kd = kon/kon). In this strategy, the library is completely saturated with muPAR-FLAG such that all surface-displayed variants are bound, and then the unbound muPAR-FLAG is thoroughly washed away and replaced with a molar excess of a "competitor" protein that renders dissociation of muP AR-FLAG
from displayed variants irreversible. In this case, a 1, 000-fold molar excess of muPAR without a FLAG tag was used as the competitor. When muPAR-FLAG dissociates from a displayed variant, its place is rapidly taken by the competing muPAR protein.
Subsequently, the library is sorted for yeast cells expressing variants that remain bound to FLAG-muPAR by using an anti-FLAG fluorescent antibody.
For the first off-rate sort (3rd library sort), the library was incubated with 50 nM muPAR-FLAG to saturate the displayed variants. The excess unbound muPAR-FLAG was then removed and replaced with 2 mM muPAR and the library was incubated for an additional 2 hours (here called "2 hour off). Subsequently, the library was sorted for cells that had the highest percentage of displayed variants still bound to muPAR-FLAG. The incubation time with 2 mM muPAR was successively increased from 2 hours in the 3rd sort to 3 hours in the 4th and 5th sorts, and finally to 12 hours in the 6th sort to increase the selective pressure for variants with improved off-rates. In each sort, 0.5 - to - 1% of the top binding variants were collected. There was a noticeable increase in the amount of muPAR bound to the library between sort 4 and 5, and sort 5 and 6 (FIG. 15), indicating the kinetic screen successfully enriched for superior variants in the library.
35 clones and 10 clones were isolated from the library after the 5th and 6th sorts, respectively, and their DNA were sequenced to identify consensus amino acid mutations responsible for the improved binding properties. There was a strong consensus for 4 amino acid mutations (K37G, Q39R, E41R, and F142Y) after the 5th sort, with variants containing all 4 making up 46% of the 35 cl ones sequenced (FIG. 16 A). After the 6th sort the library converged on a single variant, with 100% of the 10 clones isolated having identical sequences (FIG. 16B). Surprisingly, the remaining variant was missing consensus mutations identified after the previous sort, and had a new mutation, R30W, that was yet to be detected in previous sequences. Judging by the sort plots, it appears this new R30W mutation is responsible for the substantially superior binding population that emerged in the 6th sort. We therefore suspected adding the R30W mutation to the dominant variant remaining after sort 5 would generate a superior variant. Indeed, the variant with all 5 mutations (henceforth referred to as *mGFD, FIG. 45) had
approximately 2-fold higher affinity for muPAR compared to the final variant isolated
after sort 6 (data not shown). When compared head-to-head with wild-type mGFD, the *mGFD protein bound muPAR with 235 -fold higher affinity (Kd = 9 pM, FIG. 17A). As would be expected, 4 out of the 5 mutations in *mSMB are at the interface of the *mGFD-muPAR complex (FIG. 17B), suggesting they may be contributing additional binding interactions with the receptor. To our knowledge, this is the highest affinity uPAR-binding protein reported to date, and represents a noteworthy protein engineering achievement and a significant step towards developing a next generation uPAR ligand.
3.3.5 HUMAN GFD LIBRARY 1 GENERATION, SORT PROGRESSION,
AND VARIANT CHARACTERIZATION
Although there is no cross-reactivity between human urokinase and mouse uPAR, or mouse urokinase and human uPAR, an alignment of the uPA-uPAR complexes from both species reveals high structural similarity between the two (FIG. 7). Therefore, hGFD was engineered in parallel with mGFD using the same strategy Error-prone PCR was used to generate 5 separate DNA libraries of hGFD variants, and the libraries were sequenced to identify those with the desirable level of mutation (FIG 18). Two libraries that had an average of 1 -2 mutations per gene were pooled and transformed into yeast resulting in a protein library of - 3 c 10 ' variants. Preliminary analysis indicated approximately 30% of the library retained significant binding to soluble huPAR (data not shown).
The hGFD library was sorted using equilibrium binding conditions to isolate variants with improved affinities for huPAR. For the first sort, the library was incubated with 1 nM huPAR and approximately 40% of the binding population (-10% of the library) was collected (FIG. 19). There was an interesting characteristic of this library not observed in others - the binding population was separated into two distinct groups with different levels of expression. It’s still not clear what caused this, but we decided to continue sorting the library' nonetheless. Two gates were drawn to collect variants from both binding populations. The same conditions were used for the second sort, and approximately 5% of the top binding populations were collected. The concentration of huPAR was reduced to 500 pM and 400 pM in the 3rd and 4th sorts, respectively, and only
the top 1% of binders were collected to increase the selective pressure and further enrich for higher-affinity variants. By the third sort the two distinct binding populations converged and it was only possible to gate cells from the left-most population.
DNA from the variants remaining after the 4th sort was isolated and sequenced to identify consensus mutations that may confer enhanced affinity for huPAR. Of the 20 sequences obtained, 6 unique variants had a D12G mutation, and three had a K46R mutation (FIG. 20A). To parse the benefits of each mutation, variants with all combinations of the two mutations were compared with wild-type hGFD for their huPAR binding affinity (FIG. 20B). The variant containing both mutations had the highest improvement in affinity (3.3 -fold, ¾ = 130 pM), indicating the sorting strategy successfully enriched for improved mGFD variants. However, as with mGFD, our goal was to improve the affinity of hGFD by a minimum of 10-fold. We therefore submitted the variants isolated after the 4th sort to a subsequent round of directed evolution. 3.3.6 HUMAN GFD LIBRARY 2 GENERATION, SORT PROGRESSION,
AND VARIANT CHARACTERIZATION
A new strategy was explored to generate the second hGFD library. DNA isolated after the 4th sort of the first library was "shuffled" using the PCR-based staggered extension process (StEP)25. Rather than adding additional mutation to the library, this process combines, or shuffles, mutations from different variants to generate a library of new variants. As a result, favorable mutations present in the enriched pool of binders are combined to create variants with potentially further enhanced binding affinities. To increase the probability of identifying improved binders, we generated two separate libraries, one using the StEP method and the other using the standard error-prone PCR method. The DNA libraries were transformed into yeast resulting in two protein libraries with approximately 2 5 x lO7 variants each. Approximately 50% of the library generated by error-prone PCR retained binding to soluble huPAR, and interestingly, over 95% of the library generated by the StEP method retained binding to huPAR. The higher percentage of binders in the library generated by StEP is likely due to the mutations
already being selected for in the previous round; shuffling neutral or beneficial mutations is not expected to dramatically reduce binding affinity.
Both hGFD libraries were first sorted separately using an equilibrium binding screen to reduce them to a size amenable to sorting using an off-rate screen. Each library was incubated with 1 nM huPAR and approximately 5 - 15% of the top binders were collected and combined. For sorts 2-4 the concentration of huPAR incubated with the library was reduced to 0.5 nM, 0.25 nM, and 0.15 nM respectively, and the top 0.5 - 1% of binders were collected. In the following sorts the remaining variants were subjected to an off-rate screen to further increase the selective pressure for binding. After saturating the displayed variants with huPAR, the remaining unbound uPAR was removed and replaced with a 100-fold molar excess of soluble hGFD fused to the Fc domain of an antibody (hGFD-Fc). The hGFD-Fc competitor effectively renders dissociation of huPAR irreversible, as unbound uPAR is rapidly bound by the excess hGFD-Fc. The library was then incubated with hGFD-Fc for an additional 24 hours and sorted for cells displaying the highest percentage of variants that remained bound to huPAR. In each sort, 0.5 - to - 1% of the top binding variants were collected. There was a noticeable increase in the amount of huPAR bound to the library between sort 5 and 6 (FIG. 21), indicating the kinetic screen successfully enriched for superior variants in the library.
10 clones and 40 clones were isolated from the library after the 4th and 6th sorts, respectively, and their DNA were sequenced to reveal amino acid mutations driving their enhanced affinity for huPAR (FIG. 22). Consensus mutations already emerged after the 4th sort with only minor changes after two additional sorts. Six mutations (L4W, Q6R, K36G, Q40R, 1141R, and K46R) were present in over 60% of the 40 clones sequenced after the 6th sort. Interestingly, the library didn’t converge on a single dominant variant after the 6th sort, with the most frequent variant only making up 22% of the sequences.
We therefore screened seven unique variants of interest (FIG 23 A) to identify which had the slowest off-rate, and thus the highest affinity for muPAR. Of the seven tested, one variant (L2.S6.15) stood out from the others as having a slower kinetic dissociation rate (FIG. 23B). When compared directly with wild-type hGFD, the L2.S6.15 mutant (henceforth referred to as *hGFD, FIG. 45) had a 30-fold higher affinity for huPAR (Kd ==
28 pM, FIG. 24A). Four out of seven mutations in *hGFD are at the interface of the *hGFD-muPAR complex (FIG. 24B), and may thus be contributing additional binding interactions with the receptor.
3.3.7 MOUSE LINKER-SMB LIBRARY GENERATION, SORT
PROGRESSION, AND VARIANT CHARACTERIZATION
Our next goals were to 1) enhance the affinity of mSMB for muPAR, and 2) search for mutations in the [Gly+Serjs linker joining mGFD and mSMB that further facilitate simultaneous binding of both ligands to muPAR, resulting in an overall increase in binding affinity of the mGFD-mSMB protein. We developed a strategy to accomplish both goals in parallel. Error-prone PCR was used to make random mutations across only the linker and mSMB domain of the mGFD-mSMB gene. As described previously, 5 DNA libraries were generated and sequenced (FIG. 25), and two were pooled that had the desired frequency of amino acid mutations ranging from of 3 to 4.8 per gene. The pooled DNA library was transformed into yeast resulting in a protein library of approximately 7 x 107 variants, of which approximately 35% retained binding to soluble muPAR (data not shown).
The linker-mSMB library was first sorted using an equilibrium binding screen, followed by a kinetic off-rate screen to isolate high-affinity variants. In the first two sorts, the library was incubated with 500 pM and 100 pM muPAR-FLAG, and the top 10% and 1% of binders were collected, respectively (FIG. 26). From the 3rd sort onward, the variants were sorted based on their off-rates as previously described for the mGFD library- in Section 3.3.4. The library was incubated with 50 nM muPAR-FLAG to saturate all displayed variants. Then, unbound muPAR-FLAG was removed and replaced with a molar excess of muPAR without a FLAG tag, and the library was incubated for an additional 2, 5, 12, and 16 hours for sorts 3-6, respectively, to increase the selective pressure for variants with slower dissociation rates. In each sort, 0.5 - to - 1% of the top binding variants were collected. There was a noticeable increase in the amount of muPAR remaining bound between sort 3 and 4, and sort 5 and 6 (FIG. 26), indicating the kinetic screen successfully enriched for superior variants in the library. 10 clones were
isolated after the 6th sort and their DNA were sequenced to identify consensus mutations behind the observed improvement in binding affinity. All 10 sequences were identical (FIG. 27), indicating the library had converged on a single superior variant. The variant contains a total of seven mutations, three in the linker region, and four in the SMB domain. When compared with the parent mGFD-mSMB fusion protein, the variant (henceforth referred to as mGFD-*mSMB, FIG. 45) bound muPAR with a 6-fold higher affinity (Kd = 125 pM, (FIG. 28), indicating the engineering strategy successfully evolved improved muPAR binding. Unfortunately, however, none of the mutations in the SMB domain are at the binding interface of the mSMB-muPAR interaction (FIG. 29), suggesting the affinity for the individual SMB-muPAR interaction was not improved.
The enhanced affinity is thus likely a result of the mutations improving the linker’s proficiency to coordinate simultaneous binding of the GFD and SMB domains to muPAR. Whereas mutations that add additional binding interactions reduce the off-rate of the interaction, these mutations are effectively increasing the on-rate of the second ligand after the first has bound muPAR.
3.3.8 HUMAN LINKER-SMB LIBRARY GEN ERATION, SORT
PROGRESSION, AND VARIANT CHARACTERIZATION
A slightly different strategy was used to improve the linker-SMB region of the hGFD-hSMB fusion protein. Given the high affinity interaction between hGFD-hSMB and huPAR (Kd = 115 pM), we postulated yeast display may not offer a large margin for improvement, as it becomes challenging to isolate variants with improved affinity when the general Kd of the library approaches the femtomolar range. To avoid this potential problem, we searched for mutations in the GFD region that reduced the overall affinity of the fusion protein. Three mutants were tested, each with a single amino acid change in the main binding loop of hGFD: F25A, W30A, and I28A. Of the three tested, the hGFDF25A-hSMB mutant had the desired reduction in affinity (Kd = 15 nM), while still maintaining a characteristic binding interaction with huPAR (FIG. 30). We therefore engineered the linker-hSMB domain in the context of the hGFDF25A-hSMB mutant. Error-prone PCR was used to generate ten separate DNA libraries with varying levels of
mutation. The libraries were sequenced (FIG. 31), and seven were pooled to form an overall library with an average of 3-4 amino acid mutations per gene. The pooled DNA library was transformed into yeast resulting in a protein library of approximately 5 x 106 variants, of which only approximately 5% retained binding to soluble huPAR (data not shown). Both the library size and the percent of variants retaining huPAR binding were about 10-fold lower than desired. However, due to limited time we decided to sort the library regardless.
Given the higher starting affinity of this library (Kd - 15 nM), equilibrium binding screens were sufficient for creating selective pressure in all sorts. The library was first incubated with 250 nM huPAR and a generous gate was drawn to collect the small fraction of variants retaining binding to huPAR (FIG. 32). In sorts 2 through 5, the huPAR concentration was reduced sequentially from 5 nM to 0.025 nM to increase the selective pressure for improved variants. The top 0.17 - 0.34 % of binders were collected after each sort. There was a noticeable increase in huPAR binding between sorts 3 and 4 even though the huPAR concentration was reduced by 10-fold (FIG. 32), indicating the sorting successfully enriched for superior variants.
10 clones were isolated after the 5th sort and their DNA were sequenced to identify consensus mutations responsible for improving binding. Only two unique variants were present, with one making up 80% of the 10 sequences (FIG. 33A). Both variants had approximately the same affinity for huPAR (0.44 nM and 0.37 nM, FIG. 33B). When compared to the parent hGFDF25A-h SMB protein, the slightly superior variant (henceforth referred to as hGFDF2'A-*hSMB, FIG. 45) had a 10-fold improvement in binding affinity (FIG. 34), indicating the engineering strategy successfully evolved improved huPAR binding. The hGFDF25A-*hSMB protein contains 5 amino acid mutations total, 1 in the linker region and 4 in the SMB domain. Just as with the mGFD- *mSMB variant, none of the mutations in the hSMB domain are at the binding interface of the h SMB -huPAR interaction (FIG. 35). This suggests the amino acid mutations in hGFD-*hSMB are instead increasing the capability of both ligands to simultaneously engage huPAR.
3.4 DISCUSSION
Since the discovery of uPAR’s role in cancer growth and metastasis, considerable progress has been made toward developing uPAR-targeted therapeutics for clinical use. The most noteworthy was the significant in vivo efficacy demonstrated by a first-in-class molecule targeting uPA in patients with epithelial ovarian cancer1 Although a promi sing proof of concept, the underwhelming efficacy of this molecule is suspected to have impeded further development toward the clinic, as is also the case for other previously developed uPAR ligands. The lack of efficacy delivered by these molecules can be attributed to their inability to completely and effectively antagonize uPAR, as they only block a subset of uPAR interactions with affinities equal to or weaker than the native binding interactions they target.
Our hypothesis is a ligand capable of blocking multiple uPAR interactions with superior affinity may deliver more significant efficacy in vivo. Towards this goal, we have generated a bispecific uPAR ligand that simultaneously blocks both the urokinase and vitronectin binding sites with orders-of-magnitude higher affinity compared to the native uPAR ligands. This was accomplished by genetically fusing the GFD domain of uPA to the SMB domain of vitronectin using a 25-amino acid [Gly4Ser]5 linker, which resulted in an 8.3 and 8.7-fold improvement in apparent binding affinity for the mouse and human uPAR ligands, respectively, due to the avidity effects of multivalent binding. Yeast display was then used to enhance the individual affinities of GFD and SMB, and improve the linkers abili ty to coordinate simultaneous binding of both ligands to uPAR. The affinities of the human and mouse GFD proteins were improved by 30-fold, and 235- fold, respectively. The linker and SMB regions were then engineered as a single unit, and additional 10-fold and 6-fold improvements in affinity were achieved for the bispecific human and mouse uPAR ligands, respectively. Since the mutations driving the enhanced affinity for the linker-SMB regions are not at the binding interface of the SMB-uPAR interaction, we suspect these mutations are improving the overall affinity of the fusion proteins by increasing the ability of both ligands to simultaneously bind uPAR, or more specifically, by increasing the on-rate of the second ligand after the first ligand has bound. The bispecific proteins comprising the improved human and mouse GFD and
linker-SMB domains (henceforth referred to as hGS and mGS, respectively, Table 1 and FIG 36) are thus expected to have over 1, 000-fold higher affinity for uPAR relative to the wild-type ligands, representing the highest affinity uPAR ligand developed to date that also simultaneously block multiple functions of uPAR involved in cancer metastasis.
We suspected amino acid mutations improving the mouse uPAR ligand affinities would not be transferable to the human ligands due to the absence of species cross reactivity between hGFD and muPAR, and mGFD and huPAR Therefore, the human and mouse ligands were both engineered separately. Indeed, unique mutations were identified in each ligand, suggesting this strategy was appropriate. Interestingly, however, 2 of the 5 mutations in the engineered *mGFD protein were also present in the *hGFD protein, (K37G and E41R in *mGFD corresponding to K36G and Q40R in *hGFD protein). The numbers designating amino acid position are offset by 1 between the mouse and human proteins due to mGFD having an additional amino acid at the Fb-termimus. These mutations are located outside of the growth factor-like binding loop (amino acids 19 - 31) that is primarily responsible for the high-affinity interaction with uPAR. Therefore, although the interaction between the primary binding loop of uPA and uPAR has diverged significantly between the human and mouse proteins (eliminating cross reactivity between them) it appears the region in human and mouse uPAR that interacts with amino acids 37 and 41 in mGFD, and 36 and 40 in hGFD, has not. It is still possible other mutations identified in *mGFD may benefit *hGFD, and vice versa. Of particular interest i s the R30W mutation found in *mGFD that appears to dramatically improve binding affinity. Although we did not add this mutation to *hGFD, it may be worth investigating if future improvement of *hGFD is desired.
In summary, we used insights from previous structural analysis of the uPA-uPAR- SMB binding interaction to develop an engineering strategy focused on producing an improved uPAR ligand. Using yeast display as a platform for engineering, we generated bispecific ligands that simultaneously engage two functional uPAR epitopes with orders- of-magnitude higher affinity than the wild-type uPAR ligands.
3.6 MATERIALS AND METHODS
3.6.1 MEDIA AND REAGENTS
SD-CAA media was composed of 20 g/L dextrose, 6.7 g/L yeast nitrogenous based without amino acids, 5.4 g/L Na2HP04, 8.6 g/L NatLPQ^ILO, and 5 g/L Bacto casamino acid, pH 4.5. SG-CAA media was identical except for galactose replacing the dextrose, and was titrated to pH 6.0. YPD media contained 20 g/L dextrose, 20 g/L peptone, and 10 g/L yeast extract. SD-CAA plates contained 182 g/L sorbitol and 15 g/L agar in addition to the media components. PBS A was lx phosphate buffered saline with 1 g/L bovine serum albumin added and sterile filtered using a 0.22-micron filter
(Millipore). Chicken anti-c-myc (A21281) was purchased from Invitrogen, Goat anti chi cken-PE (ab72482) was from Abeam, goat anti-chicken-488 (A11039) and rabbit anti- 6histidine-488 (NC0585792) were from Fisher Scientific, and anti-FLAG-PE (PJ315) was from PROzyme. The yeast-display pCTcon2 vector and EBY100 yeast cells were a gift from Professor Dane Wittrup’s research group at MIT.
3.6.2 SOLUBLE RECOMBINANT PROTEIN EXPRESSION AND
PURIFICATION
Human and murine uPAR were expressed in Freestyle 29 -F cells (Thermo Fisher Scientific) suspension cells, and purified by nickel -NT A metal affinity chromatography followed by size exclusion chromatography. cDNA encoding amino acids 1-303 for huPAR and 1-296 for muPAR were cloned into the mammalian expression vector pCEP4 (Thermo Fisher Scientific) between the Hindlll and Xhol (huPAR) and Hindlll and BamHI (muPAR) restriction sites. The human signal peptide was used in place of the murine signal peptide for the muPAR gene. Each gene was immediately preceded by a Kozak sequence (GCCACC), and followed by a C -terminal 6x-histidine tag. A separate version of the muPAR protein was expressed that contained a GGGS linker (SEQ ID NO: 16) and FLAG tag (GGGGSDYKDDDDK, SEQ ID NO: 10) between the signal peptide and L-terminus of the receptor. Freestyle 293F cells were transiently transfected with the expression vectors following the manufacturers protocols. Briefly,
cells were grown in suspension culture at 37°C in a humidified atmosphere with 5% CO2 in Freestyle 293 -F culture medium (Thermo Fisher Scientific) to density of
approximately 1-3 million cells/mL, after which they were passaged in fresh medium to 0.3 million cells/mL. Cells were passaged a minimum of 5 times prior to transfection.
The day before transfection, cells were diluted to 0.5 million/mL in fresh medium, cultured overnight to a density of 1 million cells/mL, and then transfected with a DNA/polyethyleneimine mixture. For example, for a 0.5 L culture, 0.5 mg plasmid DNA and 1 01L of 1 g/L linear polyethyl eneimine (MW 25 kDa, Polysciences), pH 7.0 were separately diluted in 10 mL OptiPro SFM (Thermo Fisher Scientific) and incubated for 15 minutes. The DNA and PEI dilutions were then gently mixed and incubated for an additional 15 minutes, and finally added dropwise to the cell culture while mixing.
Cultures were incubated for 5-6 days, after which the cells were removed by
centrifugation and the desired protein in the supernatant was purified by nickel -NT A (Quigen) affinity chromatography followed by size exclusion chromatography (Superdex 75, 10/300 GL, GE Healthcare) following the manufacturers protocols. The eluted protein was kept in storage buffer (lx PBS, pH 7.4, 0.1% BSA, and 10% glycerol) at concentrations of 10 mM (huPAR and muP AR-F LAG) or 100 mM (muPAR) at -80°C.
3.6.3 LIBRARY CREATION
The genes encoding human and murine GFD, SMB, and the GFD-SMB fusion proteins were generated by PCR-diiven overlap extension and used as templates for error-prone PCR. Mutations were introduced by PCR amplification of the genes in the presence of the dNTP analogs 8-oxo-dGTP and dPTP (TriLink Biotech) using low- fidelity Taq polymerase (New England Biolabs). Five separate PCR reactions were used with varying analog concentrations and PCR cycles to generate a range of mutation frequency: ten cycles with (400 pM, 200 pM, 100 pM), and twenty cycles with (80 pM, 40 pM). The DNA libraries were sequenced and those with the desired level of mutation (-2-5%) were combined and used to generate yeast-displayed protein libraries. The combined DNA libraries were PCR amplified absent dNTP analogs using primers that generate 50-base pair overlapping regions upstream and downstream of the Nhel and
BamHI cloning sites in the yeast display pCTcon2 vector. The pCTcon2 vector was linearized by double digestion with Nhel and BamHI-HF (New England Biolabs), and the PCR amplification and double digestion products were purified by agarose gel electrophoreses on a 1% gel, extracted using a Gene Jet kit (Fisher Scientific), ethanol precipitated, and resuspended in sterile nuclease-free water. Purified mutant DNA "insert" and linear plasmid were mixed at a 4: 1 weight ratio (12 pg insert: 4 pg plasmid) and electroporated into EBY100 yeast following the protocol by Benetuil L. ei a/.26 Four separate electroporations were performed for per library, and each were recovered in 8 mL of a 1 : 1 mixture of 1 M sorbitol :YPD shaking in an incubator at 225 RPM and 30°C for 1 hour. The library was then propagated in selective SD-CAA medium to dilute out untransfected cells, and expression of surface-displayed protein variants was induced by switching to SG-CAA medium. Library sizes were estimated by dilution plating on selective SD-CAA plates.
3.6.4 LIBRARY SCREENING
Yeast cells displaying variants with a range of affinities for uPAR were stratified by their equilibrium dissociation constants (Kd) or their kinetic off-rate constants (koff) and then sorted by FACS to isolate variants with superior affinities. For equilibrium binding sorts, yeast libraries were incubated at room temperature gently mixing with the indicated concentrations of uPAR in PBS A buffer for the necessary time required to reach 95-99% equilibrium that was calculated using the formula t = (£on[L]o + / f) 1, where t is the equilibrium time constant; koa and k0t F are the on and off rates of binding, respectively, and [L]o is the initial concentration of ligand in solution27 At 3t and 4.6t the reactions have reached approximately 95% and 99% equilibrium, respectively. The binding reaction volumes were adjusted to prevent [L]o from changing significantly throughout the reaction (i.e. to prevent ligand depletion). After reaching > 95% equilibrium, cells were pelleted by centrifugation, excess supernatant was removed, and a chicken anti-cMyc antibody was added at a dilution of 1 :250 and mixed with the cells for 1 hour at room temperature. The concentration of uPAR remained relatively unchanged during this step. Yeast cells were then washed with cold PBS A and kept on ice for the
remainder of the procedure. Cells were pelleted and resuspended with secondary antibodies (anti -chi cken-PE and anti-6histidine-488 for reactions with huPAR, and anti chicken-488 and anti-FLAG-PE for reactions with muPAR) at a 1 : 100 dilution in PBS A and mixed for 30 minutes at 4°C, washed with cold PBS A, pelleted, and immediately sorted by FACS.
For kinetic off-rate sorts, cells were incubated with the indicated concentrations of uPAR required to saturate high-affmity variants for 3 hours at room temperature, after which cells were washed 3 times to remove unbound uPAR, resuspended in PBS A containing a molar excess of either muPAR or hGFD-Fc for the mouse or human uPAR ligand libraries, respectively, and incubated for the indicated times at room temperature. During the last hour, a 1 :250 dilution of chicken anti-c-myc was added to the reaction. Cells were then pelleted, washed, and labeled with secondary antibodies as described for the equilibrium binding sorts.
The labeled yeast libraries were sorted using a BD Aria FACS instrument (Stanford FACS Core Facility) and FACSDiva software (BD biosciences). For the first sort, the number of cells sorted was between l-10x the estimated library diversity, depending on the library size and available instrument time. After the first sort, the number of cells sorted was at least lOx the estimated library diversity to ensure adequate sampling of the library diversity. Collected cells were propagated in SD-CAA and induced in SG-CAA as previously described, and subjected to additional rounds of sorting. Following sorts 4, 5, and/or 6 of each library, plasmid DNA was extracted from the library using a Zymoprep kit (Zymo Research Corp.), transformed into DHlOb electrocompetent cells, isolated using a plasmid miniprep kit (Qiagen), and sequenced by MC Lab.
3.6.5 EQUILIBRIUM BINDING TITRATIONS OF YEAST-DISPLAYED
PROTEINS
Clonal cultures of yeast cells expressing a single protein variant were grown and induced following the same procedure used for the protein libraries. Approximately 50,000 cells were incubated in PBSA with varying concentrations of uPAR ranging from
500 fM to 200 nM for the required time to reach > 95% binding equilibrium (see section 3.6.4) in volumes sufficient to avoid >10% ligand depletion Immunofluorescent labeling was performed as described for library sorting, and cell fluorescence was analyzed using a C6 Accuri flow cytometer (BD Biosciences). Data were analyzed using Flow Jo software (Tree star Inc.) or BD Accuri C6 software (BD Biosciences) Binding data from triplicate experiments were fit to a four-parameter variable slope sigmoidal curve using Prism 7 software (GraphPad) to calculate equilibrium dissociation constants.
Table 1 Assembled sequences for the engineered *mGFD-*mSMB (mGS) and *hGFD-*hSMB (hGS) bispecific uPAR ligands
3.9 REFERENCES
1. Ghamande, S. A. et al. A phase 2, randomized, double-blind, placebo- controlled trial of clinical activity and safety of subcutaneous Aό in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol. Il l, 89-94 (2008).
2. Gold, M. A. et al. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fal lopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 125, 635-9 (2012).
3. Byrne, H., Conroy, P. J., Whisstock, J. C. & O’Kennedy, R. J. A tale of two specificities: bi specific antibodies for therapeutic and diagnostic applications Trends Biotechnol. 31, 621-632 (2013).
4. May, C., Sapra, P. & Gerber, H.-P. Advances in bi specific biotherapeutics for the treatment of cancer. Biochem. Pharmacol. 84, 1 105-1112 (2012).
5. Klein, C. et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 4, 653-663 (2012).
6. Kontermann, R. Dual targeting strategies with bispecific antibodies. MAbs 4, 182-197 (2012).
7. Gardsvoll, H & Ploug, M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 282, 13561-72 (2007).
8. Taaii, T. et al Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost. 95, 524- 34 (2006).
9. Kwak, S .-H. et al. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with (alpha}V(beta)3 integrins. Leukoc. Biol. 78, 937-45 (2005).
10. Liang, O. D . et al. Binding of urokinase plasminogen activator to gpl30 via a putative urokinase-binding consensus sequence. Biol. Chem. 384, 229-36 (2003).
1 1. Degryse, B., Sier, C. F., Resnati, M , Conese, M. & Blasi, F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBSLett. 505, 249-54 (2001).
12. Bu, X et al. Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an anti angiogenesis mechanism. Lab. Invest. 84, 667-78 (2004).
13. Min, H. Y. et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56, 2428-33 (1996).
14. Gardsvoll, H et al. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lameliipodia induction. J. Biol. Chem. 286, 33544-56 (201 1).
15. Eden, G., Archinti, M., Furlan, F , Murphy, R. & Degryse, B. The urokinase receptor interactome. Curr. Pharm. Des. 17, 1874-89 (2011).
16. Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-57 (2002).
17. Sidenius, N. & Blasi, F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEES Lett. 470, 40-6 (2000).
18. Quax, P. H. et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler . Thromb. Vase. Biol. 18, 693-701 (1998).
19. Huai, Q et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat. Struct. Mol. Biol. 15, 422-3 (2008).
20. Pettersen, E. F. et al UCSF Chimera— a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-12 (2004).
21. Deng, G., Royle, G., Wang, S., Crain, K. & Loskutoff, D. J Structural and functional analysis of the plasminogen activator inhibitor- 1 binding motif in the somatomedin B domain of vitronectin. J. Biol. Chem. 271, 12716-23 (1996).
22. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. & Loskutoff, D. J. Is plasminogen activator inhibitor- 1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-71 (1996).
23. Okumura, Y. et al. Kinetic Analysis of the Interaction between Vitronectin and the Urokinase Receptor. J. Biol. Chem. 277, 9395-9404 (2002)
24. Traxlmayr, M. W. & Obinger, C. Directed evolution of proteins for increased stability and expression using yeast display. Arch. Biochem. Biophys. 526, 174- 80 (2012).
25. Zhao, H. & Zha, W. In vitro‘sexual’ evolution through the PCR-based staggered extension process (StEP). Nat. Protoc. 1, 1865-1871 (2006).
26. Benatuil, L., Perez, J. M., Bel , J. & FIsieh, C.-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 23, 155-159 (2010).
27. Van Deventer, J. A. & Wittrup, K. D Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. Methods Mol. Biol. 1131, 151-81 (2014).
28. Lin, L., Gardsvoll, H., Huai, Q., Huang, M. & Ploug, M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J. Biol. Chem. 285, 10982- 92 (2010).
Example 2
Evaluating the Urokinase Receptor Ligands in Vitro and in Vivo in Animal Models
of Cancer
4.2 INTRODUCTION
The urokinase receptor has been a target for therapeutic intervention of cancer metastasis since its discovery in 19881. To date, countless molecules have been developed to antagonize the cancer-promoting functions of the receptor, including small molecules, linear peptides, cyclic peptides, proteins, and antibodies, though these have failed to reach the clinic because of their insufficient efficacy in vivo, owing to their inability to effectively antagonize the urokinase receptor. In Example 1, we outlined a strategy for creating an improved uPAR ligand that has the potential to overcome these shortfalls. Using yeast display, we generated bispecific ligands of murine and human uPAR comprising the GFD domain of urokinase and the SMB domain of vitronectin genetically fused by a 25 -amino acid [Gly- Serjs linker (mGFD-mSMB and hGFD-hSMB, respectively). The bi specific ligands simultaneously engage the urokinase and vitronectin
binding sites of uPAR with an apparent affinity approximately 8 -fold higher than wild- type urokinase due to the avidity effects of multivalent binding. Subsequently, the affinities of the individual GFD and linker-SMB domains were enhanced using directed evolution; mGFD, and the linker-mSMB domains were improved 235 -fold and 6-fold, respectively, and the hGFD and linker-hSMB regions were improved 30-fold and 10- fold, respectively. Combining the evolved domains is expected to generate bispecific ligands with over 1,000-fold higher affinity for uPAR relative to the native ligands. The high affinity and multi -functionality of the engineered proteins thus have the potential to overcome the limitations of previously developed ligands.
Here we describe further work with the engineered uPAR ligands, which were expressed, purified, and characterized in vitro and in vivo for their ability to localize to tumors and inhibit growth and experimental metastasis. Given their small size (~12 kDa), these proteins are expected to have a serum half-life of only 10-20 minutes in vivo, leaving a limited window of therapeutic efficacy. Therefore, we expressed the affinity matured *mGFD-*mSMB and *hGFD-*hSMB proteins as fusions to the Fc domain of an antibody (henceforth referred to as hGS-Fc and mGS-Fc, respectively) to increase their molecular weight above the renal clearance cutoff of 60 kDa, and as a result extend serum half-life to approximately 24 hours in vivo. The human and murine GFD domains were also expressed as Fc fusion proteins (hGFD-Fc and mGFD-Fc, respectively) to include as positive controls and for comparison in these studies. We show the hGS-Fc and mGS-Fc proteins bind to multiple uPAR-expressing cancer cell lines and inhibit the uPA-uPAR binding interaction. Additionally, the hGS-Fc protein demonstrates increased tumor targeting and localization in vivo compared to the hGFD-Fc control, and is also shown to internalize into cancer cells in vitro via a uPAR-dependent mechanism, thus offering exciting potential for delivery of cytotoxic agents specifically to cancer cells.
4.3 RESULTS
4.3.1 REFORMATTING THE UPAR LIGANDS INTO FC FUSIONS
For the bispecific uPAR ligands to be effective in vivo, their concentration in the blood must be maintained at or above the level required to sufficiently inhibit uPAR function. This is problematic given the 12 kDa proteins will rapidly filter out of the blood through the kidneys with a circulating half-life of only 10-20 minutes, necessitating frequent and/or high doses to be effective. Furthermore, the proteins must be delivered intravenously or subcutaneously due to their instability in the denaturing and proteolytic environment of the gastrointestinal tract. Therefore, to avoid expensive and impractical dosing requirements, we reformatted the bi specific ligands as fusions to the fragment crystal lizable (Fc) region of the mouse IgG2a antibody. The resulting cysteine-linked dimers have molecular weights of 77 kDa for the hGS-Fc and mGS-Fc proteins, and 64 kDa for hGFD-Fc and mGFD-Fc, which are above the 60 kDa renal clearance cutoff and thus have extended serum half-lives of approximately 24 hours in vivo.
The Fc-fusion proteins were recombinantly expressed by transient transfection of suspension Freestyle 293 cells and purified by protein A affinity chromatography, followed by size exclusion chromatography to remove undesired oligomers of the Fc domain (FIG. 37). The purified products were subsequently analyzed by polyacrylamide gel electrophoresis; they were of high purity and ran at the expected homodimer mol ecular weights of approximately 64 kDa and 77 kDa for the GFD-Fc and GS-Fc proteins, respectively (FIG. 38). The final protein yields from cell culture were 11.5 mg/L, 7.5 mg/1,, 7 mg/L and 4 mg/L for hGFD-Fc, hGS-Fc, mGFD-Fc, and mGS-Fc, respectively.
4.3.2 INHIBITION OF UPA-UPAR BINDING IN VITRO BY THE HGS-FC
AND MGS-FC
We next verified the engineered hGS-Fc and mGS-Fc proteins are capable of inhibiting the uPA-uPAR binding interaction. Since uPA-uPAR binding is coordinated by the growth factor domain (GFD) of uPA, we displayed GFD on the surface of yeast cells
as a fusion to the aga2p coat protein and measured its binding to soluble uPAR in the presence of the hGS-Fc and mGS-Fc proteins. The wild-type hGFD-Fc and mGFD-Fc proteins were also included as a positive control. All Fc fusion proteins successfully inhibited tire GFD-uPAR interaction in a typical dose-dependent manner (FIG. 39). The assay used required a minimum of 2 nM uPAR to obtain a signal with sufficient dynamic range to measure inhibition of uPAR binding. Since 2 nM uPAR is orders of magnitude above the Kd of the engineered proteins, the binding reaction between hGS-Fc and huPAR, and mGS-Fc and muPAR were concentration-driven, rather than Kd-driven, and thus accurate values for the half-maximal inhibitory concentrations (ICso) could not be determined. Regardless, these results qualitatively indicate the engineered bispecific uPAR ligands hGS-Fc and mGS-Fc inhibit the uPA-uPAR binding interaction.
4.3.3 BINDING OF MGS-FC AND HGS-FC TO UPAR EXPRESSED ON
THE SURFACE OF VARIOUS CANCER CELL LINES
In preparation for testing the ability of the bispecific uPAR ligands to localize to tumors and inhibit growth and metastasis in vivo, we first confirmed the proteins bind to uPAR expressed on the surface of multiple types of cancer cells. Adherent cancer cells were grown in tissue culture flasks, harvested by non-enzymatic dissociation to maintain the integrity of the surface proteins, and incubated with 100 nM of the hGS-Fc and mGS- Fc proteins. Binding was detected by flow cytometry following immunostaining with a fluorophore-labeled anti-Fc antibody. The hGS-Fc protein bound to uPAR on the surface of all cell lines tested, including the human breast (MDA-MB-231), brain (U-87-MG), and ovarian (SKOV-3) cancer cell lines (data not shown). Additionally, the hGS-Fc protein also bound to huPAR on the surface of human umbilical vein endothelial cells (HUVEC), which is expected given the pivotal role uPAR plays in angiogenesis2,3. The mGS-Fc protein bound to two of the three murine cancer cell lines tested: murine breast cancer (4T1) and colon adenocarcinoma (MC-38) cell lines, but not the murine skin melanoma (B16-F10) cell line (data not shown). These data are consistent with the finding that uPAR is overexpressed in numerous types of cancer4, and validate use of the uP AR-positive lines to assess the efficacy of mGS-Fc and hGS-Fc in vivo.
4.3,4 LOCALIZATION OF HGS-FC AND HGFD-FC TO HUMAN
BREAST CANCER TUMOR XENOGRAFTS IN VIVO
We first verified the engineered uPAR ligands localize specifically to uPAR- expressing tumors in vivo. Aggressive human breast (MDA-MB-231) tumors that express high levels of uPAR were implanted into the left shoulders of athymic nude mice.
Additionally, human embryonic kidney (HEK 293T) tumors that do not express uPAR were implanted into the right shoulder as a negative control for uPAR-specific tumor localization. After tumors reached ~10 mm in diameter, mice were injected with 1.5 nmol of either Alex a 680 fluorophore-labeled hGFD-Fc (hGFD-Fc-680) or hGS-Fc (hGS-Fc- 680), and localization of the labeled proteins was tracked via whole-body fluorescence imaging using an IVIS Lumina III in vivo imaging system. Compared to the wild-type hGFD-Fc-680 control, the hGS-Fc-680 protein demonstrated enhanced tumor localization that persisted for over 3 weeks after injection (FIG. 40). To quantify uPAR-specific tumor localization, the fluorescence signal from the uPAR-positive breast cancer tumor was divided by the signal from the uPAR-negative tumor and plotted over the course of the experiment (FIG. 41). The hGS-Fc-680 protein exhibited substantially higher uPAR- positive tumor specificity. These results were consistent when the experiment was repeated in two additional pairs of mice (FIG. 42). The engineered hGS-Fc fusion protein thus demonstrates enhanced tumor targeting and localization in vivo compared to the wild-type hGFD-Fc control. Given GFD-Fc has been shown to effectively inhibit cancer growth and metastasis in vivo5 7, these results suggest the engineered hGS-Fc protein may demonstrate more significant efficacy in vivo.
In addition to testing uPAR-specific tumor localization of the Fc-fusion proteins in vivo, we also tested localization of the monomeric hGFD and hGS proteins. Given their small size of 6 and 12 kDa, respectively, the injected proteins that remained unbound to cell-surface uPAR were expected to rapidly clear from the blood though the kidneys with a circulating serum half-life of only 10-to-20 minutes. Although longer serum half-lives are typically desired for cell -surface receptor ligands to be effective, the rapid clearance of these molecules may be advantageous for other applicati ons such as
cancer diagnostics or cancer-specific cytotoxic drug delivery, where clearance of unbound protein increases contrast for tumor detection, or reduces side effects from off- target toxicity. As with the Fc-fusion proteins, 1.5 nmol of Alexa 680-1 abeled hGFD (hGFD-680) and hGS (hGS-680) were injected into mice with uPAR-positive MDA-MB- 231 and uPAR-negative HEK 293T tumors in their left and right shoulders, respectively. As expected, both proteins rapidly cleared from circulation through the kidneys (FIG.
43). However, to our surprise, neither hGFD-680 nor hGS-680 showed detectable uPAR- specific tumor localization. The 680-1 abeled proteins showed potent inhibition of uPA- uPAR binding in vitro (data not shown), indicating their activity was not compromised prior to injection. These results suggest the increased circulating serum half-life afforded by fusion to the Fc domain of an antibody is required for detectable levels of uPAR- specific tumor accumulation lndeed, the hGFD-Fc-680 and hGS-Fc-680 proteins only show uPAR-specific tumor accumulation higher than background signal between four and five days after injection (FIG. 40).
4.3.4 UPAR-DEPENDENT INTERNALIZATION OF HGFD-FC AND HGS-
FC INTO CANCER CELLS
Given the prolonged tumor accumulation of hGS-Fc-680 observed in vivo , we suspected the protein may be internalizing into cancer cells following uPAR binding. The hGS-Fc protein was actually designed to inhibit active uPAR internalization; after formation of the uPA-uPAR complex, pl asminogen activator inhibitor 1 (P AI- 1 ) binds to the protease domain of uPA, and PAI-1 is then bound by the low-density lipoprotein receptor-related protein (LRP1)8, which drives internalization of the entire protein assembly9,10, degradation of PAI-1 -uP A in the lysosome9, and recycling of uPAR back to the cell surface11. The absence of the uPA protease domain in the hGS-Fc protein should therefore inhibit this process of internalization, which has been shown to contribute to cancer migration and metastasis12. However, the hGS-Fc-uPAR complex may still be internalized passively given uPAR’s localization at focal adhesion sites13, where various adhesion receptors such as integrins are constantly internalized and recycled to the cell surface14.
Intemalization of the hGFD-Fc and hGS-Fc proteins was confirmed in vitro. Human breast cancer (MDA-MB-231) cells were incubated with Alexa 488-labeled hGS- Fc (hGS-Fc -488) and hGFD-Fc (hGFD-Fc-488) for 15 hours, harvested by non- enzymatic cell dissociation, and incubated with an anti -Alexa 488 antibody that quenches extracellular Alexa 488 fluorescence (FIG. 44 A). The cells were then analyzed by flow cytometry to detect the presence of intracellular hGFD-Fc-488 or hGS-Fc-488. Both proteins internalized into the cancer cells (FIG. 44B). Interestingly, the fluorescent signal for internalization of 0.2 nM and 2 nM hGFD-Fc-488 was 3.79 ± 0.17 and 19.74 ± 0.27 a.u., respectively, whereas the signal for internalization of hGS-Fc-488 was significantly higher at both concentrations (Mean ± SEM = 10 84 ± 0.35, p value < 0.0001, and 41.88 ± 1.11 a.u., p value = 0.0016, respectively). Given both proteins were conjugated with equal amounts of fluorophore (approximately 0.5 Alexa 488 fluorophores per protein), this suggests the hGS-Fc protein binds uPAR and/or internalizes more effectively than the wild-type hGFD-Fc protein. Internalization was dependent on incubation time (FIG. 44C), and on uPAR binding (FIG. 44B), as a 100-fold molar excess of unlabeled hGFD-
Fc or hGS-Fc protein blocked internalization of hGFD-Fc-488 and hGS-Fc-488, respectively. The results from this assay and the uPAR-specificity of hGS-Fc in vivo suggest the engineered protein may also be an effective vehicle for intracellular delivery of cytotoxic agents specifically to cancer cells in vivo, which may further increase the efficacy of the hGS-Fc protein for inhibiting cancer growth and metastasis.
Table 2 Amino acid sequences of the engineered uPAR ligands fused to the Fc domain of the mouse IgG2a antibody or human IgGl antibody (bold). The human and murine GFD sequences are preceded by the native 20-amino acid signal peptide for human and murine uPA, respectively (underlined).
4.8 REFERENCES
1. Nielsen, L. S. el al. A 55,000-60,000 Mr receptor protein for urokinase- type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem. 263, 2358-63 (1988).
2. Montuori, N. & Ragno, P in Chemical immunology and allergy 99, 1 OS- 122 (2013).
3. Herkenne, S. et al. The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Sci. Signal. 8, ral l7-ral l7 (2015).
4. de Bock, C. E & Wang, Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24, 13-39 (2004).
5. Hu, X.-W. et al. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol. Ther. 7, 651-9
(2008).
6. Ignar, D. M. et al. Inhibition of establishment of primary and
micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp. Metastasis 16, 9-20 (1998).
7. Zhou, H. et al. Synergistic inhibitory' effects of an engineered antibody like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model. Oncol. Lett. (2017).
doi: 10.3892/ol.2017.6896
8. Nykjaer, A. et al. Purified alpha 2-macroglobulin receptor/LDL receptor- related protein binds urokinase plasminogen activator inhibitor type-l complex Evidence that the alpha 2 -macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 267, 14543-6 (1992).
9. Cubeilis, M. V, Wun, T. C. & Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO ,/. 9, 1079-85 (1990).
10. Olson, D. et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. Biol. Chem.
267, 9129- 33 (1992).
11. Nykjar, A. et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16, 2610-2620 (1997).
12. Chazaud, B. et al. Promigratory Effect of Plasminogen Activator
Inhibitor-! on Invasive Breast Cancer Cell Populations. Am. J. Pathol. 160, 237- 246 (2002).
13. Salasznyk, R. M. et al. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells. Matrix Biol. 26, 359-370 (2007).
14. Hiilsbusch, N., Solis, G. P., Katanaev, V. L. & Stuermer, C. A. O. Reggie- l/Flotillin-2 regulates integrin trafficking and focal adhesion turnover via Rabl la. Eur. J. Cell Biol 94, 531-545 (2015).
While the preferred embodiments of the invention have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.
Claims
1. A ligand of a urokinase receptor (uPAR) comprising a fusion protein comprising a growth factor domain (GFD) of urokinase (uPA) linked to a somatomedin B (SMB) domain of vitronectin.
2. The ligand of claim 1, further comprising a linker connecting the GFD to the SMB domain.
3. The ligand of claim 2, wherein the linker is about 40 to about 50 angstroms in length.
4. The ligand of claim 2 or 3, wherein the linker is selected from the group consisting of:
a) a linker comprising a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 14, and SEQ ID NO: 15; and
b) a linker comprising a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NO: l 1, SEQ ID NO: 14, and SEQ ID
NO: 15, wherein the ligand is capable of binding to or inhibiting the urokinase receptor.
5. The ligand of claim 4, wherein the linker comprises at least one amino acid substitution selected from the group consisting of S5N, S10G, G12R, and G19S, and wherein positions of the amino acids are numbered relative to the reference linker sequence of SEQ 1D NO: 11.
6. The ligand of any of claims 1 -5, wherein the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of R30W,
K37G, K37R, Q39R, E41K, E41 R, and H42Y, and wherein positions of the amino acids are numbered relative to the reference murine GFD sequence of SEQ ID NO: 1.
7. The ligand of claim 6, wherein the GFD comprises the R30W, K37R, Q39R, E41R, and H42Y amino acid substitutions.
8. The ligand of claim 6 or 7, wherein the ligand comprises:
a) a fusion protein comprising an amino acid sequence of SEQ ID NO: 12; or b) a fusion protein comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 12, wherein the ligand is capable of binding to or inhibiting the urokinase receptor.
9. The ligand of any of claims 1-8, wherein the GFD comprises at least one mutation comprising an amino acid substitution selected from the group consisting of L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R, and wherein positions of the amino acids are numbered relative to the reference human GFD sequence of SEQ ID NO:3.
10. The ligand of claim 9, wherein the GFD comprises the L4W, Q6R, H29Q, K36G, Q40R, H41R, and K46R amino acid substitutions.
1 1. The ligand of claim 9 or 10, wherein the ligand comprises:
a) a fusion protein comprising an amino acid sequence of SEQ ID NO: 13; or b) a fusion protein compri sing an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 13, wherein the ligand is capable of binding to or inhibiting the urokinase receptor.
12. The ligand of any of claims 1-11, wherein the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DIN, E3G, M14V, and KITE, and wherein positions of the amino acids are numbered relative to the reference murine SMB domain sequence of SEQ ID NO:5.
13 The ligand of claim 12, wherein the SMB domain comprises the D IN, E3G, M44V, and K17E amino acid substitutions.
14. The ligand of claim any of claims 1-11, wherein the SMB domain comprises at least one mutation comprising an amino acid substitution selected from the group consisting of DI G, E3G, K18E, and P41 S, and wherein positions of the amino acids are numbered relative to the reference human SMB domain sequence of SEQ ID NO:7.
15. The ligand of claim 14, wherein the SMB domain comprises the DI G, E3G, K18E, and P41S amino acid substitutions.
16. The ligand of any of claims 1-15, wherein the fusion protein further comprises a tag.
17. The ligand of any of claims 1-16, wherein the fusion protein further comprises an immunoglobulin Fc domain.
18. The ligand of claim 17, wherein the immunoglobulin Fc domain is linked to an N- terminal or C -terminal end of the fusion protein.
19. The ligand of claim 17 or 18, wherein the immunoglobulin Fc domain is from an immunoglobulin G (IgG) selected from the group consisting of IgGl, IgG2, IgG3, and IgG4.
20. The ligand of claim 19, wherein the IgGl is a human IgGl isotype.
21. The ligand of any of claims 17-20, wherein the ligand comprises:
a) a fusion protein comprising an amino acid sequence selected from the group
consisting of SEQ FD NOS: 17-20; or
b) a fusion protein comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 17- 20, wherein the ligand is capable of binding to or inhibiting the urokinase receptor.
22. The ligand of any of claims 1-21, further comprising an anti-cancer therapeutic agent conjugated to the fusion protein.
23. The method of claim 22, wherein the anti -cancer therapeutic agent is selected from the group consisting of a cytotoxic agent, a drug, a toxin, a nuclease, a hormone, an immunomodulator, a pro-apoptotic agent, an anti-angiogenic agent, a boron compound, a photoactive agent, and a radioisotope.
24. The ligand of any of claims 1-23, wherein the fusion protein further comprises a signal peptide.
25. The ligand of claim 24, wherein the signal peptide is a urokinase signal peptide.
26. The ligand of any of claims 1 -25, wherein the ligand binds to the urokinase receptor with a dissociation constant (KD) of less than 100 pM.
27. The ligand of claim 26, wherein the ligand binds to the urokinase receptor with a dissociation constant (KD) of less than 10 pM.
28. A composition for use in the treatment of cancer comprising the ligand of any of claims 1 -27
29. The composition of claim 28, further comprising a pharmaceutically acceptable excipient.
30. The composition of claim 28 or 29, further comprising one or more other anti- cancer therapeutic agents.
31. The composition of claim 30, wherein the one or more other anti-cancer therapeutic agents are selected from the group consisting of chemotherapeutic agents, immunotherapeutic agents, or biologic therapeutic agents.
32. A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the composition of any of claims 28-31.
33. The method of claim 32, wherein the cancer overexpresses the urokinase receptor.
34. The method of claim 32 or 33, wherein the cancer has metastasized.
35. The method of any of claims 32-34, wherein the cancer is breast cancer, colon cancer, brain cancer, or ovarian cancer.
36. The method of any of claims 32-35, wherein multiple cycles of treatment are administered to the subject.
37. The method of claim 36, wherein the compound is administered intermittently or according to a daily dosing regimen.
38. The method of claim 36 or 37, wherein multiple cycles of treatment are administered to the subject for a time period sufficient to effect at least a partial tumor response.
39. The method of claim 38, wherein multiple cycles of treatment are administered to the subject for a time period sufficient to effect a complete tumor response.
40. The method of anyof claims 32-39, wherein the ligand comprises:
a) a fusion protein comprising an amino acid sequence selected from the group
consisting of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NOS: 17-20; or b) a fusion protein comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NOS: 17-20, wherein the ligand is capable of binding to or inhibiting the urokinase receptor.
41. The method of any of claims 32-40, wherein the composition is administered intravenously, subcutaneously, or intralesionally to a subject.
42. The method of any of claims 32-40, wherein the composition is administered locally into a tumor of the subject.
43. The method of any of claims 32-42, wherein the subj ect is human.
44. The method of any of claims 32-43, further comprising performing one or more of surgery, radiation therapy, chemotherapy, immunotherapy, or biologic therapy.
45. A kit comprising the composition of any of claims 28-31 and instructions for treating cancer.
46. The kit of claim 45, further comprising means for delivering said composition to a subject.
47. A polynucleotide encoding the ligand of any of claims 1-27.
48. A recombinant polynucleotide comprising the polynucleotide of claim 47 operably linked to a promoter.
49. A vector comprising the recombinant polynucleotide of claim 48.
50. A host cell comprising the recombinant polynucleotide of claim 48.
51. A method for producing the ligand of any of claims 1 -27, the method comprising: a) transforming a host cell with a recombinant polynucleotide comprising a promoter operably linked to a polynucleotide encoding the ligand of any of claims 1-27; b) culturing the transformed host cell under conditions whereby the ligand is
expressed; and
c) isolating the ligand from the host cell .
52. A urokinase receptor-targeted imaging agent comprising the ligand of any of claims 1-27 conjugated to a diagnostic agent.
53. The urokinase receptor-targeted imaging agent of claim 52, wherein the diagnostic agent is a contrast agent or a photoactive agent.
54. The urokinase receptor-targeted imaging agent of claim 53, wherein the contrast agent is an ultrasound contrast agent, a magnetic resonance imaging (MRI) contrast agent, or a radiocontrast agent.
55. The urokinase receptor-targeted imaging agent of claim 54, wherein the ultrasound contrast agent is a microbubble.
56. The urokinase receptor-targeted imaging agent of any of claim 52, wherein the diagnostic agent comprises a detectable label.
57. The urokinase receptor-targeted imaging agent of claim 56, wherein the detectable label is a fluorescent label, a radioactive isotopic label, a non-radioactive
isotopic label, a chemiluminescent label, a bioluminescent label, a paramagnetic ion, or an enzyme.
58. The urokinase receptor-targeted imaging agent of claim 57, wherein the fluorescent label is selected from the group consisting of a fluorescein derivative, a rhodamine derivative, a coumarin derivative, a cyanine derivative, an acridine derivative, a squaraine derivative, a naphthalene derivative, an oxadiazol derivative, an anthracene derivative, a pyrene derivative, an oxazine derivative, an arylmethine derivative, a tetrapyrrole derivative, and a fluorescent protein.
59. The urokinase receptor-targeted imaging agent of claim 58, wherein the fluorescent protein is selected from the group consisting of green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, rsCherry, and rsCherryRev.
60. The urokinase receptor-targeted imaging agent of claim 52, wherein the isotopic label is selected from the group consisting of 3H,
35S, UC, !3C, 14C, 32P , 15N, 13N, 110In, luIn, 177Lu, 18F, 52Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 86Y, 90Y, 89Zr, 94mTc, 94Tc, 99mTc, 154Gd, 155Gd, 156Gd, 157Gd, 158Gd, 150, 186Re, 188Re, 51M, 52mMn, 55Co, 72 As, 7¾r, 76Br, 82mRb, and 83 Sr.
61. The urokinase receptor-targeted imaging agent of claim 57, wherein the detectable label comprises a radionuclide selected from the group consisting of a gamma- emitter, a beta-emitter, and a positron-emitter.
62. The urokinase receptor-targeted imaging agent of claim 57, wherein the paramagnetic ion is selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III),
ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (IP).
63. The urokinase receptor-targeted imaging agent of any of claims 52-62, wherein the ligand of the urokinase receptor is further conjugated to an anti-cancer therapeutic agent.
64. The urokinase receptor-targeted imaging agent of claim 63, wherein the anti cancer therapeutic agent is selected from the group consisting of a cytotoxic agent, a drug, a toxin, a nuclease, a hormone, an immunomoduiator, a pro-apoptotic agent, an anti-angiogenic agent, a boron compound, a photoactive agent, and a radioisotope.
65. The urokinase receptor-targeted imaging agent of any of claims 52-64, wherein the diagnostic agent is conjugated to an N-terminal or C -terminal end of the ligand of the urokinase receptor.
66. A method of detecting cancer, the method comprising:
a) administering a detectably effective amount of the urokinase receptor-targeted imaging agent of any of claims 52-65 to a patient suspected of having cancer, under conditions wherein the urokinase receptor-targeted imaging agent localizes to urokinase receptors present on tumors or cancerous cells, if present, in the patient; and
b) detecting the urokinase receptor-targeted imaging agent that localizes to the tumors or cancerous cells, if present, by imaging tissue of the patient.
67. The method of claim 66, wherein said imaging is performed using ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), or fluorescence imaging.
68 The method of claim 66 or 67, wherein the patient is human.
69. A method of imaging tissue of a patient suspected of having cancer, the method comprising:
a) contacting tissue of the patient with a detectably effective amount of the urokinase receptor-targeted imaging agent of any of claims 52-65 under conditions wherein the urokinase receptor-targeted imaging agent binds to urokinase receptors present on tumors or cancerous cells, if present, in the tissue; and
b) imaging tissue of the patient, wherein detection of increased binding of the
urokinase receptor-targeted imaging agent to the tissue of the patient compared to a control indicates that the patient has cancer.
70. The method of claim 69, wherein the tissue is contacted with the urokinase receptor-targeted imaging agent in vivo or in vitro.
71. The method of claim 69 or 70, wherein said imaging is performed using ultrasound imaging (UI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging (OI), photoacoustic imaging (PI), or fluorescence imaging.
72. A method of monitoring progression of cancer in a patient, the method comprising: imaging cancerous tissue of the patient according to the method of claim 69, wherein a first image is obtained at a first time point and a second image is obtained later at a second time point, wherein detection of increased binding of the urokinase receptor- targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is worsening, and detection of decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient at the second time point compared to the first time point indicates that the patient is improving.
73. The method of claim 72, wherein increased binding of the urokinase receptor- targeted imaging agent to the tissue of the patient is associated with growth of a tumor or presence of more tumors or cancerous cells at the second time point.
74. A method for evaluating the effect of an agent for treating cancer in a patient, the method comprising: imaging tissue of the patient according to the method of claim 69 before and after the patient is treated with said agent, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient after the patient is treated with said agent compared to before the patient is treated with said agent indicates that the patient is worsening, and decreased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient after the subject is treated with said agent compared to before the patient is treated with said agent indicates that the patient is improving.
75. A method for monitoring the efficacy of a therapy for treating cancer in a patient, the method comprising: imaging tissue of the patient according to the method of cl aim 69 before and after the subject undergoes said therapy, wherein detection of increased binding of the urokinase receptor-targeted imaging agent to the tissue of the patient after the patient undergoes said therapy compared to before the patient undergoes said therapy indicates that the patient is worsening, and decreased binding of the urokinase receptor- targeted imaging agent to the tissue of the patient after the patient undergoes sai d therapy compared to before the patient undergoes said therapy indicates that the patient is improving.
76. A method of using the urokinase receptor-targeted imaging agent of claim 57 for fluorescence imaging of cancerous cells, the method comprising:
a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the fluorescent label of claim 57, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor-targeted imaging agent;
b) illuminating the cell with light at a fluorescence excitation wavelength of the fluorescent label; and
c) recording a fluorescence image of the cancerous cells by detecting fluorescence emitted by the fluorescent label of the urokinase receptor-targeted imaging agent.
77. The method of claim 76, wherein a fluorescence image is visualized with a fluorescence microscope, a fiber-optic fluorescence imaging system, or a medical fluorescence imaging device.
78. The method of claim 77, wherein the medical imaging system is a miniaturized medical imaging system.
79. The method of claim 78, wherein the miniaturized imaging system is a handheld microscope, a laparoscope, an endoscope, or a microendoscope.
80. A method of using the urokinase receptor-targeted imaging agent of claim 57 for bioluminescence imaging of cancerous cells, the method comprising:
a) contacting the cancerous cells with the urokinase receptor-targeted imaging agent comprising the bioluminescent label of claim 57, wherein cancerous cells expressing the urokinase receptor uptake the urokinase receptor-targeted imaging agent;
b) contacting the cancerous cells with a chemiluminescent substrate; and c) recording a biol uminescen ce image of the cancerous cells by detecting
bioluminescence emitted from the bioluminescent label of the urokinase receptor- targeted imaging agent.
81. The method of claim 80, wherein a bioluminescence image is visualized with an optical microscope, a digital microscope, a charged coupled device (CCD) image sensor, a complementary metal-oxide-semiconductor (CMOS) image sensor, a digital camera, a fiber-optic imaging system, or a medical imaging system.
82 The method of claim 81, wherein the medical imaging system is a miniaturized medical imaging system. 83. The method of claim 82, wherein the miniaturized imaging system is a handheld microscope, a laparoscope, an endoscope, or a microendoscope.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862635509P | 2018-02-26 | 2018-02-26 | |
US62/635,509 | 2018-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019165105A1 true WO2019165105A1 (en) | 2019-08-29 |
Family
ID=67687882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/019003 WO2019165105A1 (en) | 2018-02-26 | 2019-02-21 | Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019165105A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115501337A (en) * | 2022-09-22 | 2022-12-23 | 广州医科大学附属第二医院 | Liposome nano-particles and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035969A2 (en) * | 1996-03-28 | 1997-10-02 | Chiron Corporation | Peptide ligands of the urokinase receptor |
WO2006122786A2 (en) * | 2005-05-18 | 2006-11-23 | Ablynx Nv | Improved nanobodies™ against tumor necrosis factor-alpha |
WO2008125116A2 (en) * | 2007-03-31 | 2008-10-23 | Aarhus Universitet | Upar inhibition |
WO2012085076A1 (en) * | 2010-12-22 | 2012-06-28 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | uPAR-ANTAGONISTS AND USES THEREOF |
US20140161803A1 (en) * | 2011-08-05 | 2014-06-12 | IFOM Fondazione Istituo FIRC di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
-
2019
- 2019-02-21 WO PCT/US2019/019003 patent/WO2019165105A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035969A2 (en) * | 1996-03-28 | 1997-10-02 | Chiron Corporation | Peptide ligands of the urokinase receptor |
WO2006122786A2 (en) * | 2005-05-18 | 2006-11-23 | Ablynx Nv | Improved nanobodies™ against tumor necrosis factor-alpha |
WO2008125116A2 (en) * | 2007-03-31 | 2008-10-23 | Aarhus Universitet | Upar inhibition |
WO2012085076A1 (en) * | 2010-12-22 | 2012-06-28 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | uPAR-ANTAGONISTS AND USES THEREOF |
US20140161803A1 (en) * | 2011-08-05 | 2014-06-12 | IFOM Fondazione Istituo FIRC di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
Non-Patent Citations (1)
Title |
---|
FABBRINI ET AL.: "The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated", FASEB JOURNAL, vol. 11, no. 13, 1 November 1997 (1997-11-01), pages 1169 - 1176, XP002979024 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115501337A (en) * | 2022-09-22 | 2022-12-23 | 广州医科大学附属第二医院 | Liposome nano-particles and preparation method and application thereof |
CN115501337B (en) * | 2022-09-22 | 2024-01-26 | 广州医科大学附属第二医院 | Liposome nano-particle and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7252278B2 (en) | ACTIVATABLE BINDING POLYPEPTIDES AND METHODS FOR IDENTIFICATION AND USES THEREOF | |
CA2861307C (en) | High affinity sirp-alpha reagents | |
US20180127480A1 (en) | High affinity cd47 analogs | |
AU2007246144B2 (en) | Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK | |
KR20190140943A (en) | Anti-CD33 Antibody Formulations | |
JP2015193653A (en) | Proproteins and methods of use thereof | |
JP7186940B2 (en) | Antibody variants that cross the blood-brain barrier and uses thereof | |
KR20150036700A (en) | Antibody specific for cd22 and methods of use thereof | |
EP4028417A1 (en) | Anti-oncolytic virus antigen antibodies and methods of using same | |
JP2010085108A (en) | Probe for imaging biolight | |
US20160312207A1 (en) | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling | |
US20190022244A1 (en) | Blood-brain barrier vector compounds and conjugates thereof | |
WO2017214050A1 (en) | Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody | |
US11939609B2 (en) | Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system | |
WO2019165105A1 (en) | Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer | |
CN110885377B (en) | anti-CD 47/VEGF bispecific antibody and application thereof | |
US20190024070A1 (en) | Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system | |
KR20210020006A (en) | Compositions and methods for diagnosing and treating cancer | |
WO2023020551A1 (en) | Anti-ptk7 single-domain antibody and application thereof | |
KR20240026182A (en) | Novel single domain antigen binding molecules and uses thereof | |
WO2024105116A1 (en) | NANOCONJUGATES CONTAINING PDGFR-β LIGANDS AND USES THEREOF | |
CA3173137A1 (en) | Designed antibody-bound nanoparticles | |
JP5661148B2 (en) | Bio-optical imaging probe | |
CN113795501A (en) | Peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19758038 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19758038 Country of ref document: EP Kind code of ref document: A1 |